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ABSTRACT 
PW1
+
/Pax7
–
 skeletal muscle-derived interstitial progenitor cells (PICs) are 
myogenic in vitro, efficiently contribute to skeletal muscle regeneration in vivo, 
and are self-renewing in vivo whilst also giving rise to satellite cells (Mitchell et al. 
2010). They have previously been identified in the mouse and pig and are bi-
potent forming both smooth and skeletal muscle (Mitchell et al. 2010, Lewis et al. 
2014). This study characterised murine PICs for stem cell properties of self-
renewal, clonogenicity and multipotency. Furthermore, PW1 expression was 
assessed in cardiac tissue, and in an isolated Sca1
+
 cardiac stem cell population. 
Satellite cells and PICs were identified and quantified in hind limb skeletal muscle 
of 3, 10 and 21 day, and 2 year old mice: there was a decline in abundance of both 
SC and PICs with age. PICs were isolated by MACS technology from hind limb 
murine skeletal muscle of 21 day old mice, and their phenotype characterised. 
Isolated PICs expressed markers of pluripotency; Oct3/4, Sox2 and Nanog, were 
clonogenic and self- renewing over >60 population doublings in vitro, with a 
population doubling time of 15.8±2.9 hours.  Furthermore, PICs demonstrated 
multipotency both in vitro and in vivo giving rise to cell types from the 3 germ 
layers. 
PW1
+
 cells were identified and quantified with respect to location in the heart on 
3, 10 day, 21 day and 2 year old mice with the majority of cells found within the 
epicardium. There was rapid decline in abundance during postnatal development. 
CD45
-
/Sca-1
+
 CSCs were isolated from 6 week old mice via MACS technology 
and assessed for PW1 expression (83%). 
In summary, this study showed PICs have broad developmental plasticity both in 
vitro and in vivo, and can be propagated and maintained in a primitive state in 
culture. Furthermore, PW1 also marks a stem cell population within the heart. 
These data opens new avenues for solid tissue engineering and regeneration 
utilising a single multi-potent stem cell type, isolated from an easily accessible 
source such as skeletal muscle.   
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1. INTRODUCTION 
1.1 Muscular Dystrophy and Heart Disease 
1.1.1 Muscular Dystrophies 
Muscular dystrophy is a term used to describe a range of genetic muscle diseases 
which result in progressive skeletal muscle weakness and wastage (Pearson 1963). 
The condition predominantly affects males and is inherited genetically, although 
roughly 1/3 of cases occur without any family history due to prenatal mutations 
(Bakker et al. 1989).  The phenotypic manifestation of muscle wastage/weakness 
is mainly due to defects and/or the inability to make the protein dystrophin and 
other associated protein complexes. Dystrophin is a cytoplasmic protein located in 
the sarcolemma which forms part of a membrane spanning protein complex to 
connect the cytoskeleton to the basal lamina (Blake et al. 2002). 
There are approximately 70,000 babies, children and adults in the UK suffering 
from some form of muscular disease (Table 1.1), with 12.6% of these being 
dystrophic disorders such as Duchenne’s Muscular Dystrophy (DMD). DMD is a 
progressive muscle wasting disease which affects approximately 1:3500 boys and 
often results in death due to respiratory failure before 25 years of age (Blake et al. 
2002).  Current treatments include physiotherapy and corticosteroids to improve 
muscle strength, along with surgery to correct associated spinal curvature, these 
treatments however, are not a cure and only serve to manage the condition.  Using 
stem cells as a regenerative therapy may be the key to providing a definitive cure 
for such genetic conditions. 
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To date there have been 6 clinical trials looking at the benefits of stem cell 
transplantation therapies in treating Duchene’s muscular dystrophy 
(NCT01834040, NCT01834066, NCT02241434, NCT01610440, NCT02235844, 
NCT02285673), however results have not yet been published.  
Table 1.1  Prevalence of muscular diseases within the UK (Muscular 
Dystrophy Campaign stats 2012). 
Group of conditions  Patient number in UK Percentage of total (%) 
Muscular dystrophies 8,000-10,000 12.6 
Myotonic disorders 9,500 13.3 
Congenital myopathies 1,000 1.4 
Distal myopathies 300 0.4 
Mitochondrial myopathies 3,500 4.9 
Metabolic myopathies 700 1.0 
Periodic paralysis 900 1.3 
Myositis 5,000-6,000 7.7 
Spinal muscular atrophies  1,200 1.7 
Hereditary neuropathies 23,000 32.0 
Inflammatory and autoimmune 
neuropathies 
6,400 8.9 
Disorders of the neuromuscular 
junction 
10,500 14.7 
Myositis ossificans progressiva  60 0.1 
Total number (prevalence) 70,060-73,060 100 
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1.1.2 Heart Failure and Disease 
Heart failure occurs when the heart can no longer efficiently pump blood around 
the body resulting in a variety of symptoms including shortness of breath, 
dizziness, angina, weakness, nausea and eventually death. Caused by damage 
from an ischemic event such as a myocardial infarction (MI), cardiomyopathies of 
the muscle or disease of associated vessels and valves, heart failure is a chronic 
disease which gradually gets worse over time. 
In 2011 there were 71,837 reported deaths from heart disease within the UK with 
more than 750,000 patients living with the condition (British Heart Foundation 
statistics 2012). Available treatments are currently highly ineffective, mainly 
given to reduce symptoms and slow down the progression of the disease, with the 
only ‘cure’ being organ transplantation (Jessup and Brozena 2003). A goal of 
cardiovascular research is to find a way to replace cardiomyocytes to prevent or 
reverse heart disease and failure, with many people looking promisingly to stem 
cell therapies as the solution (Nadal-Ginard et al. 2006).  
In 2001 bone marrow derived stem cells (BMDCs) were found to give rise to new 
cardiomyocytes and vasculature (Orlic et al. 2001). A flurry of studies and clinical 
trials were conducted as a result of this paper, injecting BMDC’s into patients 
after myocardial infarction (MI). Subsequent meta-analysis of the results showed 
a modest improvement in ventricular ejection fraction of 3 % (Lipinski et al. 2007, 
Kang et al. 2008, Abdel-Latif et al. 2007), however in 2004 two separate papers 
gave evidence that BMDCs do not form cardiac tissue (Murry et al. 2004, Balsam 
et al. 2004). Current clinical trials are mainly using bone marrow derived cells 
(BMDCs) of different origins in the hope of a positive paracrine effect (Nadal-
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Ginard et al. 2006) and the hunt is still on to find the ‘best’ type of cell which will 
yield the most functional myocardial regeneration. 
The discovery of an endogenous small cell population with the phenotype, 
behaviour and regenerative potential of bona fide cardiac stem cells (eCSCs) in 
adult mammalian myocardium, including in the human (Beltrami et al. 2003, 
Moretti et al. 2006) and their ability to regenerate contractile myocytes and 
microvascular both in vitro and in vivo (Ellison et al. 2007, Beltrami et al. 2003) 
may hold the key to producing functional regeneration of the myocardium 
damaged by an ischemic event. 
Recently 2 clinical trials utilising cardiac stem/progenitor cells, (SCIPIO - 
NCT00474461) and CDC’s (CADUCEUS - NCT00893360) have shown 
improvements in cardiac function in ischemic heart failure patients. The 
CADUCEUS trial looked at a total of 25 patients, of which with 17 received stem 
cell treatment. There was an 11% reduction in scar tissue compared to controls 
after 1 year, however this did not result in any improvement in global cardiac 
function (Makkar et al. 2012; Malliaras et al. 2014). The SCIPIO trial looked at 
33 patients, 20 of which received stem cell treatment. They reported a higher 
reduction in scar tissue of 30%, and an increase in ejection fraction of 13.6 EF 
units after 1 year (Bolli et al. 2011; Chugh et al. 2012). 
1.2 Stem Cells as Regenerative Medicines. 
Stem cells are self-renewing cells capable of differentiation into a variety of cell 
types within the body. They can be unipotent or bipotent in that they can only 
make one or two cell types, or be multipotent being able to make a wider range of 
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cell types including those from other germ layers. Pluripotent stem cells are those 
with the highest level of potency and are able to give rise to any type of cell 
within the body. Due to these capabilities stem cells  are currently at the forefront 
of research for regenerative medicines. Understanding the mechanisms by which 
these cells activate, proliferate and differentiate is fundamental in designing 
treatments for degenerative diseases and tissue repair. By utilising stem cell 
therapies we have the potential to save and improve lives of patients suffering 
from a wide array of medical conditions whether they are, acute, chronic, 
congenital or acquired. They may also be used to treat less ‘life saving’ but 
certainly ‘life changing’ conditions such as baldness or infertility (Ogawa et al. 
2000; Yang et al. 2011). 
To date there have been over 4500 registered stem cell related clinical trials of 
which around 1800 are currently in process, 500 of these being within Europe 
(www.clinicaltrials.gov). One of the most successful and best known stem cell 
therapies is bone marrow transplantation (BMT) which was first conducted in 
humans in 1968 and it still regularly used to treat blood and bone marrow diseases 
such as cancers and immune disorders, with approximately 60,000 BMT’s taking 
place worldwide annually (Syed and Evans 2013).  
It is hoped that the development of further cellular therapies may eventually 
reduce the need for invasive surgery and oversubscribed organ/tissue 
transplantations, as well as providing effective treatments for conditions for which 
there is currently none. Not only will this provide massive health benefits to the 
population but it will also reduce the economic burden of on-going illness and 
disease. 
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Unfortunately the reality of most stem cell trials to date (bar a few successful ones 
such as in BMT) have not yet shown striking results, mainly due to poorly 
controlled and commercially driven trials where results are inconclusive. 
Stem cells can be used in regenerative therapies and treatments via a variety of 
avenues; the easiest and most commonly used is a direct infusion of cells either 
into the circulatory system or directly to the site of interest, this is the method of 
transfer used in BMTs and cellular based therapies and can be either autologous, 
where the donor and recipient are the same person, or allogeneic, when the donor 
is someone other than the recipient. 
More recently stem cells have been used in tissue engineering to provide 
biologically functional grafts such as skin, bone and cartilage where the grafts 
main purpose is structural; this involves either growing the tissue in vitro before 
transplant, or using an artificial scaffold with incorporated stem cells for 
integration of the graft in vivo. However, the challenge lies in creating integrative 
tissues with a higher level of function such as the heart, liver or pancreas. 
Promisingly, recent research has shown the generation functional human liver in a 
mouse model when liver buds generated from human iPSCs were transplanted 
into non-obese diabetic/severe combined immunodeficient (NOD/SCID) Mice 
(Takebe et al. 2013). A similar study transplanting human stem-cell-derived β 
cells into NOD/SCID mice found that they went on to produce insulin, however 
insulin levels were lower than seen in cadaveric islet cell transplantation (Pagliuca 
et al. 2014). 
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In conditions such as muscular dystrophy or multiple sclerosis, where the 
condition affects the whole or a large area of the body, tissue grafts may not be a 
viable solution and therefore it is imperative that we develop cellular therapies 
that can repair damage and restore function in situ (Cossu and Sampaolesi 2007) 
One avenue for achieving this in genetic conditions may be gene therapy, where 
the genetic content of a patient’s own cells is altered by the insertion/replacement 
or removal of genes using a vector. Examples of Vectors used include 
adenoviruses, retroviruses, adeno-associated viruses and plasmids (Chamberlain 
et al. 2002). Such therapies can be targeted at mature myofibres, however to 
ensure long-lasting results they must also be targeted at muscle stem-progenitor 
cells (Bertoni 2014). 
In non-genetic conditions or injury such as a myocardial infarction (MI), it may be 
possible to activate patients’ functional endogenous stem cells using stimuli such 
as growth factors and cytokines to encourage and/or increase in situ regeneration. 
Such a therapy has previously been shown to improve ventricular function in pigs 
that have received intracoronary insulin-like growth factor (IGF-1) and hepatocyte 
growth factor (HGF) after an induced MI (Ellison et al. 2011). A more recent 
study found that sustained delivery of IGF-1, delivered via a hydrogel had a 
similar effect in a pig chronic MI model, with a 4 fold increase in the number of 
cardiac stem cells, increased ventricular function, new myocyte formation and 
increased capillarization (Koudstall et al. 2014). 
Furthermore, stem cells may be used as a stepping stone between animal studies 
and clinical trials; cultivated and differentiated in vitro they can be utilised to test 
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and help in the development of new drugs and medicines, allowing us to see cell 
responses and possible side effects before testing on patients. One example of this 
is cholangiocytes derived from human induced pluripotent stem cells, which were 
found to have a similar reaction in vitro as seen in patients, to two drugs used to 
treat cystic fibrosis associated cholangiopathy: verapamil and octreotide 
(Sampaziotis et al. 2015). 
Stem cells can be acquired from a number of sources which are generally divided 
into 3 categories. Embryonic stem cells (ESCs), induced pluripotent stem cells 
(iPSCs) and adult stem cells (ASCs), with each type having its own benefits, 
drawbacks and relevant applications.  
1.2.1 Embryonic Stem Cells 
ESCs are pluripotent stem cells found within the epiblast tissue of the inner cell 
mass of a blastocyst; in humans this is 5-6 days post fertilization (Hardy et al. 
1989). They are universally recognised as the most pluripotent of all stem cells 
due to their indefinite self-renewal capacity and differentiation efficacy into 
derivatives of the 3 primary germ layers; endoderm, mesoderm and ectoderm 
(Thomson et al. 1998; Amit et al. 2000). ESCs have been successfully isolated 
from numerous mammalian species including the mouse (Evans and Kaufman 
1981), primate (Müller at al. 2009) and human (Thomson et al. 1998) and 
although initially hailed as a new tool for tissue engineering and regenerative 
therapies, they have since proved to be problematic. The production, harvest and 
subsequent use of human ESCs is highly controversial and raises many ethical, 
religious and moral questions, these however are not the only limitations. 
Autologous cell transplantations are not possible; indeed there are problems with 
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histocompatibility and immunological response within the recipient (Taylor et al. 
2011). Furthermore, the sheer attribute of their assured pluripotency may also be 
their downfall with reports of malignant teratoma formation (Shih et al. 2007; 
Knoepfler  2009). Whilst much research has been conducted on ESCs from a 
number of sources, the first approved human clinical trial using human ESC-
derived (hESC) oligodendrocyte progenitor cells to treat spinal cord injuries was 
halted due to financial issues (NCT01217008), affirming that ESC research still 
needs to overcome many hurdles before it can be supported and translated to a 
clinical setting. 
1.2.2 Induced Pluripotent Stem Cells  
iPSCs are artificially derived from non-pluripotent adult somatic cells, such as 
skin fibroblasts, via forced expression of pluripotency genes. The most commonly 
used are Oct3/4, Sox2, c-Myc and Klf4 (Takahashi and Yamanaka 2006; 
Takahashi et al. 2007) although transfection of Nanog and LIN28 alongside Oct4 
and Sox2, has also been shown to induce pluripotency (Yu et al. 2007). iPSCs 
produce morphologically similar colonies to ESCs and contribute to a variety of 
tissues within the developing embryo when injected into the blastocyst (Takahashi 
and Yamanaka 2006). Since their initial production in 2006 in the mouse, they 
have since also been produced in rats (Li et al. 2009), rhesus monkeys (Lui et al. 
2008), Pigs (Ezashi et al. 2009) and importantly in humans (Yu et al. 2007; 
Takahashi et al. 2007). Initially iPSCs were hailed as the new saviour of stem cell 
research, allowing a patient’s own cells to be utilized for autologous 
transplantation. While it was thought this would eliminate problems associated 
with allogeneic transplants it seems that some immunological responses still occur, 
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possibly due to epigenetic alterations within the cells during ex vivo processing 
(Zhao et al. 2011). 
As with ESCs, iPSCs form teratomas, one suggested reason being the use of 
oncogenic factors such as c-Myc to induce these cells (Kneopler 2009), However 
it should be noted that teratoma forming ESC’s do not over express c-Myc and 
therefore the exact reason behind this is still unknown. Initially most iPSCs were 
induced using retroviral transfection, which carried risks associated with using 
any viral vector (Cornetta et al. 1991), however more recently safer integration 
free methods have been devised. 
1.2.3 Adult Stem Cells 
ASCs are tissue-specific stem-progenitor cells found throughout the tissues and 
organs of the body after embryonic development, usually residing within a 
specific cellular niche (Snippert and Clevers 2011). They are self-renewing 
through mitotic cell division and multipotent; giving rise to mature, differentiated 
cell types of the tissue from which they are derived. It is generally accepted that 
they are responsible for maintaining homeostasis of the wear-and-tear renewal and 
repair of aged or damaged tissue and have been identified in most adult tissue 
types (Table 1.2), including skeletal muscle (Tedesco et al. 2010), heart (Beltrami 
et al. 2003), brain (Paspala et al. 2011), liver (Kordes and Häussinger 2013), 
kidneys (Gupta et al. 2006), skin (Fuchs 2008), gut (Wang et al. 2013), lung (Liu 
et al. 2006) and eyes (Secker and Daniels 2009). 
One of the most well documented and clinically successful ASC is the 
hematopoietic stem cell (HSC), capable of giving rise to cells of myeloid and 
lymphoid lineages (Osawa et al. 1996; Iwasaki and Akashi 2007). HSCs are found 
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in the bone marrow, peripheral blood and cord blood. First identified in 1961 in 
the mouse (Till and McCulloch 1961), HSCs have since been used to treat over 50 
diseases including leukaemia, inflammatory bowel disease and osteogenesis 
imperfecta (Thomas 1999).  
Each of the above ASC population has a distinctive marker profile on which they 
can be identified (Table 1.2). 
 
Table 1.2  Tissue specific ASC populations and their phenotype 
throughout the mammalian body. 
Organ/Tissue Stem/Progenitor Cell Phenotype 
Muscle Satellite Cell  CD45
-
/Pax7
+
 
Heart Cardiac Stem Cell  CD45
-
/c-kit
+
/Sca-1
+
 
Brain Neural Stem Cell  
CD45
-
/CD34
-
CD133
+
/Nestin
+
/Sox2
+
 
Liver Hepatic Progenitor Cells  EpCAM
+
 
Kidneys 
Multipotent Renal Progenitor 
Cell  
CD45
-
/CD133
-
/CD106
-
/CD31
-
 
CD56
-
/CD90
+
/CD44
+
 
Skin 
Keratinocyte Stem Cell (Bulge, 
SG and epidermal) 
Ck5
+
/Ck14
+
/p63
+
/α6β4+ 
Gut Intestinal Stem Cell  CD44
+
/CD24
low
/CD166
+
 
Lung 
Basal Stem cell 
Clara Stem Cell 
Ck5
+
/Ck14
+
 
CCSP
+
/Cyp2f2
+
 
Eyes Limbal Epithelial Stem Cell  Ck3
-
/Ck12
-
/Cn43
-
/p63
+
 
Blood/Bone Marrow Hematopoietic Stem Cell  Lin
-
/CD34
+
/c-kit
+
/Sca-1
+
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1.2.4 Adult Stem Cells vs Embryonic Stem Cells and Induced Pluripotent 
Stem Cells  
Interestingly, unlike ESCs and iPSCs, pluripotent ASCs such as cCFUs do not 
independently form teratomas (Chong et al. 2011). Whilst many consider teratoma 
formation a measure of pluripotency, a stem cell capable of trans-germ layer 
differentiation without teratoma formation is surely ideal in the formation of 
viable, safe clinical therapies. As with iPSCs, ASCs provide us with a source for 
autologous therapies, and with minimal manipulation these cells may not incite 
any undesirable immunological response, as demonstrated by HSC therapies used 
to date. Finally, ASCs do not carry the same ethical issues associated with ESCs, 
with both host and donor able to give informed consent. 
Current human trails aimed at muscle regeneration of both skeletal and cardiac 
muscle primarily use either cord blood or adult stem cells of multiple origins, 
however some studies using iPSCs have recently begun. Much of this research is 
still on-going and the best cell type is yet to be determined. 
1.3 Stem Cell Properties and Characteristics  
1.3.1 Pluripotency  
ESCs and iPSCs are pluripotent, with the ability to differentiate into cell types 
from the three primary germ layers; the mesoderm, ectoderm and endoderm, 
which appear during early embryonic development in vivo. Pluripotency and self-
renewal in stem cells is usually associated with phenotypic expression of three 
important markers, Sox2, Oct3/4 and Nanog, which act together and individually 
to maintain stem cells in a pluripotent state. They are thought to function as 
molecular rheostats in inhibiting stem cell differentiation and promoting self-
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renewal and pluripotency, although the exact mechanisms by which they do this 
are very complex and not yet fully understood (Rizzino 2009). The presence of 
these markers in ESCs, alongside forced expression in iPSCs, is well documented; 
however their function within ASC populations needs to be further fortified. 
Together these three factors have become somewhat of a proxy for stemness.  
SRY-high mobility group box 2 (Sox2) is a transcription factor concomitant to the 
maintenance of self-renewal and pluripotency. Indeed, down regulation of Sox2 
has been shown to promote differentiation in murine ESCs (Avilion et al. 2003).  
Initially expressed in blastomeres it continues to persist in the epiblast, with 
further expression reported in some multipotential and precursor cells (Avilion et 
al. 2003). Sox2 deletion during embryonic development proves lethal with murine 
embryos unable to develop an epiblast (Avilion et al. 2003), thus showing the 
importance of Sox2 during embryogenesis and development. It is surmised that 
Sox2 acts in synergy with Oct3/4 to activate Oct-Sox enhancers capable of 
regulating pluripotency genes such as Nanog, Oct4 and Sox2 itself (Bosnali et al. 
2009).  
Octomer binding transcription factor 4, also commonly known as Oct3, Oct4 or 
Oct3/4, belongs to the Pit-Oct-Unc (POU) transcription factor family (Schöler et 
al. 1990). It is attributed to the maintenance of pluripotency and is almost 
exclusively expressed in ESC and germ line cells (Schöler et al. 1990; Nichols et 
al. 1998). Oct3/4 knockout embryos are incapable of development beyond the 
blastocyst stage exhibiting irregular inner cell mass formation; subsequently ESCs 
cannot be derived from Oct3/4 deficient blastocysts (Nichols et al. 1998). While a 
50% reduction in Oct3/4 seems to promote trophectodermal differentiation within 
INTRODUCTION 
 
14 
 
ESCs, a two fold increase in Oct3/4 similarly results in primitive endoderm and 
mesoderm differentiation (Niwa et al. 2000) suggesting that a precise expression 
level of Oct3/4 is needed to maintain pluripotency of ESCs and the functionality 
of Oct3/4 does not operate in an on/off mechanism.  
The transcription factor Nanog is a homeobox protein and the third key player in 
pluripotency, it is expressed in the inner cell mass of blastocysts, the epiblast and 
germ cells (Chambers et al. 2003; Hart et al. 2004). Unlike Oct3/4 and Sox2, 
Nanog is not homogeneously distributed in ESCs with cells being a mix of Nanog 
high or Nanog low. Overexpression of Nanog can alleviate LIF (leukaemia 
inhibitory factor) dependence of mouse ESCs (Chambers et al. 2003; Mitsui et al. 
2003) which neither Oct3/4 nor Sox2 have been shown to do. Furthermore, Nanog 
ablation results in decelerated cell growth of murine ESCs (Mitsui et al. 2003). 
This correlates with the reported enhanced proliferation of Nanog expressing cells 
via promotion of cells into s-phase (Zhang et al. 2005). 
1.3.2 Self-renewal  
Stem cells can self-renew by either symmetrical or asymmetric division, 
dependant on intrinsic and extrinsic influences (Morrison and Kimble 2006) 
Stem cell self-renewal capability can be assessed by a number of methods in vitro: 
Clonogenicity is the ability of a single cell to clone itself and subsequently form a 
colony, generally shown as a percentage or number of colonies per initial cell 
population, it is assessed via colony scoring (Preisler et al. 1975), where cells are 
plated at a very low density and later assessed via microscopy for colony 
formation. Alternatively single cells are seeded, usually within individual wells of 
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a 96-well plate, and the percentage of single cells that go on to form colonies is 
counted, with the benefit of generating 100% pure single cell derived colonies 
which can be used for further experimentation.  
The total number of possible population doublings (PDs) can also be an indicator 
of stemness, with true stem cells capable of indefinite self-renewal and therefore 
infinite population doublings.  It should however be noted that non-optimum 
culture conditions can severely affect proliferation in vitro with cells displaying a 
PD below their intrinsic potential.   
Hayflick and Moorhead (1961) first described that human cells derived from 
embryonic tissues are only capable of between 40-60 PDs in culture before 
growth arrest or replicative senescence occurs. This data has subsequently been 
used to define ‘Hayflicks limit’ (Hayflick 1979), which is the number of times any 
normal cell can divide. These initial studies were conducted using human 
fibroblasts but have since been conducted in many other tissues and a variety 
species. Further research by Hayflick (1973) suggested that this ‘limit’ is in fact 
correlated to the maximum lifespan of a species, with a PD limit of 14-28 in mice 
which can live to 3.5 years of age, and 15-35 in chickens which can reach 30 
years old . In agreement with this, in longer-living species such as the Galapagos 
tortoise the limit extends to 90-130 doublings (Goldstein 1974).  
As well as passing the species specific ‘limit’ of PDs, to demonstrate true ‘self-
renewal’ the phenotype of the cell after long-term culture should be the same as 
the starting cell population.   
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1.3.3 Trans-germ Layer Differentiation  
Some purported ASCs share more characteristics with progenitor cells than bona 
fide stem cells, whilst they may be multipotent and have self-renewal capability 
most are incapable of trans-germ layer differentiation (Figure 1.1). Promisingly 
however, an increasing number of ASCs have shown such capability indicating 
that there may be a pool or several populations of pluripotent ASCs residing 
within the adult mammalian body.  
 
 
Figure 1.1  Plutipotent potential of ESCs and proposed pluripotency of 
ASCs (Adapted from O’Connor and Crystal 2006). 
 
In 1997, Eglitis and Mezey transplanted labelled HSCs (of mesoderm origin) into 
sub lethally irradiated mice which were then seen to be widely distributed 
throughout multiple regions of the brain at 3 days post-transplant, with the 
number of cells detected rising over several weeks. 10% of the HSC derived cells 
found in the brain regions went on to express astroglial marker GFAP suggesting 
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that HSCs are capable of trans-germ layer differentiation. Further to this, human 
derived HSCs implanted into lesions of the developing spinal cord of chick 
embryos differentiate into neurons with neuronal expressing neuronal markers 
NeuN and MAP2 (Sigurjonsson et al. 2005). 
More recently, Neural stem cells taken from the adult mouse brain have been 
shown to contribute in the formation of chimeric chick and mouse embryos, 
concurrently giving rise to cells of all germ layers (Clarke et al. 2000). Similarly 
cardiac derived colony forming units (cCFUs) from mouse hearts also show 
differentiation into mesodermal, endodermal and ectodermal cells when injected 
alongside ESCs in teratoma formation assays (Chong et al. 2011). These data 
support the hypothesis that like ESCs and iPSCs, some adult stem cells may be 
pluripotent. It should be noted that these few studies have not yet been replicated 
and therefore their conclusions should be treated with caution. 
1.4 Stem Cell Aging  
There are two main types of stem cell aging: replicative and chronological aging 
(Figure 1.2). Replicative aging is related to the number of cell divisions a cell has 
been through, whilst chronological aging is the actual age of the cell. Stem cells 
that undergo more cycles (e.g intestinal stem cells) due to a higher cell turnover, 
show both replicative and chronological aging. Those which undergo fewer 
divisions because of a lower cell turnover (e.g CSC’s) are chronologically aged 
but not necessarily replicative senescent.  
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Figure 1.2 Replicative and Chronological aging of Stem Cells. (Rando. 
2006). 
The reason why stem cells become dysfunctional or senescent during replicative 
aging may be linked to telomere shortening, genetic mutations or other changes 
that occur with each cell division (Rando 2006). Telomeres are nucleotide 
sequences at the end of chromosomes which act like a buffer to prevent changes 
to the functional section. They can become shortened during replication as DNA 
polymerase does not start at the beginning of the strand, however they can also 
become shortened following oxidative stress (von Zglinicki et al. 1995) 
In contrast, chronologically aged cells may become dysfunctional due to changes 
in their niche or systemic environment which can cause epigenetic changes and 
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effect intrinsic cell processes, such as Notch signaling which controls satellite cell 
activation  (Conboy and Rando 2002; Rando. 2006; Liu and Rando 2011).   
1.5 Skeletal Muscle  
Skeletal muscle is comprised of striated multinucleated myofibers, formed by the 
fusion of mononucleated myoblasts during development (Hawke and Garry 2001) 
and is capable of contraction, controlled by  the somatic nervous system. Each 
myofiber is composed of myofibrils, which contain sarcomeres made up of actin 
and myosin heavy chain (MHC) filaments. MHC exists in a number of isoforms 
which dictates the physiological properties of individual fibres via ATPase 
activity (Jones and Round 1990). Fibres can be divided into Type I, Type IIa or 
Type IIb fibres dependent on the MHC isoform present, with Type I fibres classed 
as slow-twitch due to their slow speed of contraction, whilst Types IIa and IIb are 
fast-twitch fibres. Skeletal muscles throughout the body use a combination of 
these fibres in different proportions to achieve the desired physiology required for 
the function of that individual muscle.  
1.5.1 Skeletal Muscle Regeneration 
In the normal healthy adult, homeostasis of skeletal muscle is mediated by 
resident stem-progenitor cells called satellite cells (SCs), however as we age our 
body’s ability to replace muscle fibres decreases and there is a progressive loss of 
muscle mass called sarcopenia, with a reduction in the cross sectional area of 
muscle fibres (Faulkner et al. 1995). Indeed, 20% of all 60-70 year olds have 
sarcopenia, this figure rises to 50% in those over 75 (Berger and Doherty 2010). 
One explanation for this may be that the SCs have a maximum proliferative 
capacity so as we age and our SCs are activated to repair wear and tear over our 
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lifetime, the pool of competent SCs becomes depleted.  In agreement with this, 
Renault et al. (2002) reported a significant reduction in the number of satellite 
cells between young (23±1 years) and old (74±4 years) individuals in both bicep 
and masseter muscle. Furthermore it has been demonstrated that SCs isolated 
from aged muscle display a lag time before proliferation suggesting compromised 
activation (Schultz and Lipton 1982). 
SCs are small round mononuclear ASCs located between the basal lamina and 
sarcolemma of individual muscle fibres accounting for 2-7% of the nuclei 
associated with a fibre (Péault et al. 2007; Mauro. 1961). They are universally 
identified by their expression of Pax7 (Seale et al. 2000).  
Pax7 (paired box-7) is a transcription factor that is involved in the specification of 
SCs during development (Relaix et al. 2005), with Pax7 germline mutant mice 
having few SCs (Seale et al. 2000) and reduced muscle regeneration (Oustanina et 
al. 2004). 
SCs are also known to express other markers such as CD56, M-Cadherin, CXCR4, 
c-met and CD34 (Beauchamp et al. 2000; Tedesco et al. 2010) and are mitotically 
quiescent until stimulated following acute/chronic injury or stress (Figure 1.3). 
Upon activation they initiate MyoD and Myf5 expression, losing CD34 before 
becoming myoblasts (Zammit et al. 2006; Tedesco et al. 2010). During this 
process they also undergo asymmetric division and are capable of rounds of 
pronounced stem cell proliferation (Zammit et al. 2006) allowing the SC pool to 
be replenished (Figure 1.3). 
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Figure 1.3  Muscle fibre anatomy and SC activation (Tedesco et al. 2010). 
 
Whilst SCs are capable of myogenic differentiation  in vitro and in vivo and 
extensively contribute to new muscle fibre formation (Collins et al. 2005), 
transplanted SCs have limited migration capacity with an inability to cross the 
endothelial wall (Price et al. 2007; Tedesco et al. 2010). SCs that have undergone 
culture ex vivo also have decreased proliferative capacity and a reduction in 
myofiber production when transplanted in vivo (Shadrach and Wagers 2011; 
Montarras et al. 2005); therefore SCs are not currently regarded as a viable source 
for systemic regenerative cellular therapies until at least part of these problems are 
solved. 
1.5.2 Muscle-resident Stem Cell Populations 
Since the first discovery of SCs 50 years ago (Mauro. 1961), a variety of other 
muscle-resident stem cells have been identified and described with varied 
differential and clinical potentials. These include vessel-associated cells such as 
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mesoangioblasts (Cossu and Bianco. 2003) and pericytes (Dellavalle et al. 2007, 
2011), alongside interstitial cells such as; side population cells (Asakura et al. 
2002), fibro/adipogenic progenitors (Joe et al. 2010) and PW1 positive interstitial 
cells (Mitchell et al. 2010). Whilst we may not know the exact role of each cell 
type in the normal healthy individual, many appear to interact with satellite cells 
to regulate myogenisis, adipogenisis and fibrogenisis during regeneration (Joe at 
al. 2010; Murphy et al. 2011; Uezumi et al. 2010). Understanding these 
mechanisms may allow us to utilise these cell types in developing therapies for 
damaged or diseased muscle and its surrounding environment. 
Embryonic mesoangioblasts (MABs) are a mesodermal stem cell population 
primarily found during development in embryonic vessels, which express CD34, 
stem cell antigen 1 (Sca-1), and Flk-1 (Cossu and Bianco 2003). However, a 
similar population of ‘adult MABs’ has also been isolated from adult tissue of 
mouse, dog and human (Tonlorenze et al. 2007). Adult MABs also express 
pericyte markers neural/glial antigen 2 (NG2) and alkaline phosphatase (AP) 
(Dellavalle et al. 2007) and are a candidate for cellular therapies due to their 
ability to migrate extensively in the muscle bed, crossing vascular walls whilst 
also self-renewing. Indeed, when injected through the femoral artery of DMD 
(Duchenne’s muscular dystrophy) dogs, Sampaolesi et al. (2006) reported a 
significant amelioration and preservation of motility.  
Pericytes are vessel associated cells located in postnatal micro-vasulature, that 
express AP, NG2 and Beta-type platelet-derived growth factor receptor (PDGFRβ) 
(Dellavalle et al. 2011). Their main function is to create, maintain and re-model 
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blood vessels, although they have also been shown to integrate into skeletal 
muscle of mice (Dellavalle et al. 2011).  
Side Population (SP) muscle stem cells are identified by their exclusion of 
Hoechst 33342 and give rise to dystrophin positive myofires when injected 
intravenously into mice with a mutation of the dystrophin gene (MDX mice) 
(Gussoni et al. 1999). Residing in the muscle interstitium with close proximity of 
the endothelium, subsets of SP cells have been shown to express Sca-1, CD34 and 
Pax7 (Judson et al. 2013), although there is some controversy over the use of 
Hoechst 33342 dye exclusion as a defining parameter (Kallestad and McLoon 
2010).  
Fibro-adipogenic precursors (FAPs) are interstitial cells, which are lineage 
negative, Sca-1
+
, CD34
+
 and display both adipocyte and fibroblast differentiation 
potential in vitro (Joe et al. 2010). Uezumi et al (2010) further described this FAP 
population as PDGFRα+ with both groups further demonstrating adipogenic 
differentiation in vivo (Joe et al. 2010; Uezumi et al. 2010). 
Similarly to FAPs, skeletal muscle fibroblasts, which are positive for TE-7 and 
PDGFRα and negative for CD56, form adipocytes when cultured in adipocyte 
differentiation medium or with fatty acids (Agley et al. 2013). 
Finally, in 2010, a population of muscle-resident PW1
+
/Pax7
-
  interstitial cells 
(PICs) was identified in the mouse which are bi-potent, efficiently contributing to 
smooth and skeletal muscle regeneration in vivo, whilst also generating SCs and 
replenishing the PIC population (Mitchell et al. 2010). Since their discovery in 
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mice, PICs have also been described in hind-limb muscle of pigs (Lewis et al. 
2014). 
Many of the described muscle stem-progenitor cell populations share a similar 
phenotype, expressing the same markers and are isolated using similar techniques, 
therefore it may be expected that there is some overlap between these cell types. 
1.5.3 PICs 
Apart from their ability to effectively contribute to skeletal muscle regeneration, 
and their compatibility with a systemic delivery (Mitchell et al. 2010), PICs have 
not yet been characterized in detail. How they fit in and compare with other 
muscle stem cell populations is unclear and therefore they are of much interest. 
Their main defining characteristics are their location within the muscle 
interstitium and their expression of PW1. 
PW1, or paternally expressed gene 3 (peg3), encodes a large Kruppel-type zinc 
finger transcription factor with a proline-rich domain which is widely expressed 
during fetal development and later persists in adult neurons and skeletal muscle 
(Kuroiwa et al. 1996, Relaix et al. 1996).  PW1 knockout mice are 20% smaller at 
birth and go on to develop impaired maternal behaviour due to a reduction in 
oxytocin neurons in the hypothalamus, indicating that PW1 is involved with 
modulation of mammalian growth and behaviour (Li et al. 1999). 
PW1 is expressed in both PICs and quiescent SCs (93% of SC’s at 2 week 
postnatal) although it is not known if activated SCs continue to express PW1 
(Mitchell et al. 2010; Lewis et al. 2014). Utilising PW1- reporter transgenic mice, 
PW1 expression has also been described in multiple adult stem cell niches 
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throughout the body including the gut, skin, cental nervous system (CNS) and 
early HSCs (Besson et al. 2011). Therefore, it has been implicated as a possible 
marker for stem-progenitor cell populations throughout the adult mammalian 
body.  
PICs and SCs are distinguishable by both location and molecular markers (Table 
1.3); SCs express Pax7 and are located under the basal lamina (Mauro. 1961), 
whilst PICs do not express Pax7 and are located in the interstitium (Mitchell. et al 
2010, Lewis et al. 2014). PICs are also positive for stem cell antigen -1 (Sca-1), 
whilst both SC’s and PICs are negative for CD45 and positive for CD34. 
Furthermore, in contrast to satellite cells which only give rise to myofibres, PICs 
have bi-potent differential potential giving rise to both striated and smooth muscle 
(Mitchell et al 2010; Lewis et al. 2014). 
 
Table 1.3  Marker expression and location of PICs vs quiescent SCs. 
  PIC SC 
PW1 + + 
CD45 - - 
Pax7 - + 
Sca-1 + - 
CD34 + + 
Location Interstitial  Under Basal Lamina 
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Upon CD45
-
/CD34
+
 isolation by flow assisted cell sorting (FACS) murine PICs 
can be further split into 2 distinct PIC populations based on their level of Sca-1 
expression. Sca-1
MED
 PICs from 1 week old mice
 
demonstrate higher myogenic 
differential potential in vitro (fusion index = 40%) than their Sca-1
HIGH
 
counterparts (fusion index = 25%), however the Sca-1
MED
 PIC population declines 
rapidly (from ~9% of lineage negative cells) during early postnatal development 
and is no longer detectable at 5 weeks of age. In contrast the Sca-1
HIGH
 PICs 
persist into adulthood (7 weeks) increasing from ~18% to ~28% of all lineage 
negative cells (Pannérec et al. 2013). Importantly both young and adult Sca-1
HIGH
 
populations have a similar gene profile (Pannérec et al. 2013). These data suggest 
that the   Sca-1
MED
 fraction may be integral for the rapid growth needed in post-
natal development, whilst the Sca-1
HIGH 
PICs persist to maintain the muscle 
throughout adulthood.  
Importantly, Mitchell et al. (2010) demonstrated, by using Pax3
Cre
 mice crossed 
with Rosa
lacZ
 mice, that PICs are not derived from a Pax3 lineage and therefore 
are not derived from satellite cells. They do however go on to express Pax3 on 
entry into the skeletal muscle lineage suggesting they are upstream of SC’s in 
lineage differentiation. Indeed, PICs isolated from Rosa
lacZ
 mice and injected into 
focally injured tibialis anterior of nude mice were not only found to participate as 
efficiently as SC’s in myofibre formation, but also gave rise to Pax7+ SCs as well 
as replenishing the PIC population (Mitchell et al. 2010). 
Transcriptome and gene ontology analyses of PICs and SCs from 1 week old mice 
show that both cell types have distinct transcriptome signatures, with SC specific 
genes belonging primarily to the skeletal muscle lineage whilst PICs express 
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genes from multiple cell fates (Pannérec et al. 2013).  In agreement with these 
differences in transcriptomes, Lewis et al. (2014) found that PICs isolated from 2 
month old pig hind limb skeletal muscle (pPICs) expressed the three pluripotency 
markers, Oct3/4, Sox2, and Nanog alongside the stem/progenitor marker c-kit by 
both quantitative real-time polymerase chain reaction (qRT-PCR) and 
immunocytochemistry (ICC). When propagated in culture they maintained a 
stable phenotype and normal karyotype over 40 passages and were clonogenic 
throughout, thus indicating that they can be maintained in a primitive state in 
culture. Moreover, in addition to giving rise to skeletal and smooth muscle, pPICs 
were also capable of differentiation in vitro into other mesodermal cell types 
including endothelial and cardiomyocyte-like cells when cultured in lineage 
specific growth media. Furthermore, a subpopulation of PDGFRα+ PICs displays 
adipogenic properties (Pannérec et al. 2013).   
1.6 Cardiac Muscle 
Cardiac muscle is made up of striated cardiomyocytes and like skeletal muscle 
this striation is due to MHC and actin filaments. However unlike skeletal muscle 
which exhibit linear striations, cardiomyocyte filaments can have a more 
‘branched’ appearance and arrange themselves differently. The two MHC 
isoforms found within cardiac muscle are α-MHC and β-MHC, which display 
different shortening velocities and isometric forces (Malmqvist et al. 2004).  
1.6.1 Cardiac Muscle Regeneration 
The adult heart was, until recently, thought to be a post mitotic organ without any 
regenerative capability, with the belief that all cardiomyocytes were formed 
during fetal and early post-natal development (Nadal-Ginard 1978; Chien and 
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Olson 2002), and all cardiomyocytes within the heart being the same age as the 
individual (Oh et al. 2001). Any increase in size with growth was attributed to 
hypertrophy of the existing myocytes (Soonpaa and Field 1998; Hunter and Chien 
1999; Laflamme and Murry 2011). However, myocytes undergoing mitosis have 
been found in the hearts of rats (Overy and Priest 1966), mice (Anversa and 
Kajstura 1998) and humans (Kajstura et al. 1998). Moreover, it has since been 
reported using carbon dating techniques that human cardiomyocytes renew with a 
gradual decrease in annual turnover from 1% at the age of 25 to 0.45% at 75 with 
less than 50% of cardiomyocytes being replaced over a lifetime (Bergmann et al. 
2009).  
Mature cardiomyocytes are terminally differentiated, although there are a number 
of reports that claim ventricular cardiomyocytes can re-enter the cell cycle and 
divide by mitosis (Anversa and Kajstura 1998; Senyo et al. 2013). Myocyte 
replacement was originally attributed to a stem cell population (Beltrami et al. 
2003), this theory has since been confirmed by utilizing cell fate mapping 
demonstrating that newly formed myocytes are not derived from existing 
cardiomyocytes (Hsieh et al. 2007; Ellison et al. 2013) and are indeed formed by a 
resident stem cell population (Ellison et al. 2013, Koudstall et al. 2013). 
1.6.2 Cardiac stem-progenitor cells populations 
To date there have been numerous cardiac stem-progenitor cell populations 
identified in the mammalian heart (Ellison et al. 2014). These include c-kit 
positive, Sca-1 positive, cardiac side population, cardiosphere-derived and 
epicardial-derived cells (Table 1.4). 
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Table 1.4  Phenotype and properties of CSC populations (Adapted from 
Ellison et al. 2014) 
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c-kit+ cardiac stem/progenitor cells 
The first endogenous small cell population with the phenotype, behaviour and 
regenerative potential of bona fide cardiac stem and progenitor cells was 
discovered within adult rat myocardium in 2003 by the group of Anversa and 
Nadal-Ginard (Beltrami et al. 2003). Subsequent populations have since been 
reported in the mouse (Fransioli et al. 2008), dog (Linke et al. 2005), pig (Ellison 
et al. 2011) and human (Torella et al. 2006a, 2006b). These endogenous cardiac 
stem cells (eCSCs) express the stem cell markers c-kit and Sca-1 and are lineage 
negative being negative for surface markers CD45, CD34 and CD31 (Beltrami et 
al. 2003); c-kit is a tyrosine kinase receptor which regulates cell fate (Roskoski 
2005). eCSCs are found at a ratio of between ~1:1000 cardiomyocytes with 
significantly more located in the left and right atria’s than the left and right 
ventricle (Arsalan et al. 2012; Ellison et al. 2011). They can be successfully 
expanded in vitro (Beltrami et al. 2003) and are clonogenic, self-renewing and 
multipotent (Torella et al. 2007), capable of generating the three major cell types 
of the myocardium : myocytes, smooth muscle and endothelial vascular cells 
(Figure 1.4) (Nadal-Ginard et al. 2003; Ellison et al. 2007). Furthermore, they 
form cardiospheres in suspension which, after directed myogenic differentiation in 
defined culture medium, attach and differentiate into beating myocytes (Smith et 
al. 2014). When injected into the heart following a myocardial infarction (MI) 
they display significant regenerative potential, giving rise to new myocytes and 
vasculature and restoring cardiac function (Beltrami et al. 2003). 
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Figure 1.4  Schematic representation of eCSCs differentiation into the 
three cardiac lineages (Ellison et al. 2007). 
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Sca-1+ cardiac stem/progenitor cells 
Sca-1
 
positive cardiac stem/progenitor cells are resident non-myocyte cells that 
express stem cell antigen 1 (Sca-1) and have been identified in adult murine hearts 
(Oh et al. 2003). They are small, round cells  approximately  2-3µm  wide ,with a 
high nucleus to cytoplasm ratio (Samal et al. 2012) and express early cardiac 
specific factors such as Gata-4 and MEF2C (Oh et al.2003; Matsurra et al. 2004).  
Similar to c-kit
+
 eCSCs they are self-renewing (Matsuura et al. 2004; Ye et al. 
2012) and capable of myocyte formation both in vitro (Oh et al. 2003; Ye et 
al.2012, Matsuura et al. 2004; Takamiya et al. 2011, Chong et al. 2011, Wang et 
al. 2006), and in vivo, showing homing to injured myocardium and formation of 
new cardiomyocytes (Oh et al. 2003). Furthermore, 4 weeks post MI, animals 
injected intramyocardially with Sca-1
+
 eCSCs exhibit increased cardiac function 
and increased wall thickness of the infarcted area (Takamiya et al. 2011). 
Interestingly, Sca-1
+
 eCSCs have demonstrated  differentiation into non-cardiac 
lineages in vitro and in vivo (Takamiya et al.2011; Chong et al. 2011), with Sca-
1
HIGH
 eCSCs demonstrating a  broader differentiation potential over Sca-1
LOW
 
eCSCs, with the former being capable of osteogenic, chondrogenic, smooth 
muscle, endothelial and cardiac differentiation in vitro (Takamiya et al. 2011). As 
the homology of Sca-1 has not yet been confirmed in any other mammalian 
species other than the mouse, it is difficult to directly translate this research to 
human biology.   
Side population cells 
Cardiac side population cells (cSPs), which efflux Hoechst 33342, account for ~1% 
of total cardiac cells in the mouse heart (Hierlihy et al. 2002) and have 
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subsequently been isolated (Asakura et al. 2002). They express Sca-1 and low 
levels of c-kit, but are negative for CD34 and CD45 (Martin et al. 2004). 75% of 
cSPs are positive for the endothelial markers CD31, whilst the CD31 negative 
fraction displays the most cardiomyogenic potential (Wang et al. 2006). These 
CD31 negative cSPs express Sca-1 and the cardiac-specific markers Nkx2.5 and 
GATA4 and are capable of cardiogenic differentiation in vitro undergoing 
spontaneous contraction (Pfister et al.2005; Oyama et al. 2007). 
Cardiosphere-derived cells 
Messina et al. (2004) described the isolation of cardiosphere-derived cells (CDCs) 
from postnatal cardiac tissue that migrate and grow as clusters or ‘cardiospheres’. 
CDCs are clonogenic, self-renewing and differentiate into cardiomyocyte, 
endothelial and smooth muscle lineages (Beltrami et al. 2003; Messina et al. 2004; 
Davis et al. 2009). CDCs represent a mixed population with some cells expressing 
c-kit (Beltrami et al. 2003), mesenchymal markers CD105 and CD90 and a small 
population expressing endothelial markers CD34 and CD31 (Messina et al. 2004; 
Smith et al. 2007; Carr et al. 2011). It is thought that the growth of different 
cardiac stem-progenitor cell populations in cardiospheres mimics the stem cell 
niche (Ellison et al. 2014) with CDCs demonstrating a higher oxidative stress 
resistance over monolayer cultured cells (Bartosh et al. 2008) and a 2-fold 
increase in stem cell markers Nanog and Sox2 (Li et al. 2010). When injected 
intramyocardial into mice following MI, cardiosphere treated mice showed a 
significant increase in left ventricular ejection fraction after 3 weeks whilst 
monolayer cells did not (Li et al. 2010). 
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Epicardial-derived cells 
Epicardial-derived cells (EPDCs) have a fibroblastic appearance in culture and 
adhere to plastic dishes (van Tuyn et al. 2007). Human EPDCs express CD44, 
CD90, CD105 and GATA4 but are negative for Isl-1 (van Tuyn et al. 2007). 
When injected into infarcted mouse hearts they improve cardiac function and 
differentiate into endothelial and smooth muscle cells, however they do not make 
cardiomyocytes (Winter et al. 2007, 2009). Limana et al. (2007) identified a c-
kit
+
/CD45
-
 stem cell population in the adult epicardium, however, in contrast to 
previously described EPDCs, they are non-adherent. When injected into the 
mouse MI model, they proliferate and migrate towards the site of injury where 
they differentiate into myocardial and vascular cells significantly reducing left 
ventricular remodelling (Limana et al. 2007). Sca-1
+
 cardiac-derived colony 
forming units (cCFU’s) as described by Chong et al. (2011) are also derived from 
the epicardium. 
Isl-1+ cells 
Finally, a population of resident progenitor cells in the heart expressing the 
marker Islet-1 (Isl-1) was identified in rodent and human postnatal myocardium 
(Laugwitz et al. 2005). Isl-1 expression is involved in the direction of primitive 
cardiac progenitors to specific lineages (Bondue et al. 2011). The role of Isl-1 in 
development has been clearly documented (Moretti et al. 2006) however there is 
some doubt as to the role Isl-1 cells play in adult life.  Isl-1 positive cells found in 
the heart of adult (11-13 weeks) rats are positive for cardiac troponin I (cTnI) 
suggesting they are commited to cardiomyogenic differentiation (Genead et al. 
2010). 
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While these cardiac stem-progentior cell populations are described individually, 
there is in fact significant overlap and co-expression with each other, with the 
main differences being due to the isolation techniques used. This raises the 
possibility that these cell types may constitute a single stem-progenitor cell, 
displaying different phenotypes with lineage sequence (Ellison et al. 2014). 
It should be noted that bone marrow derived stem cells (BMDCs), 
although initially thought to give rise to new myocytes and vasculature 
in a mouse MI model (Orlic et al. 2001) have not been found to directly 
form cardiac tissue (Murry et al. 2004; Balsam et al. 2004). 1.7 Skeletal 
Muscle Vs Cardiac Muscle 
Although both striated muscles composed of myosin and actin filaments, cardiac 
and skeletal muscles contain several distinct differences (Table. 1.5) 
Firstly, both muscle types are comprised of different isoforms of MHC (although 
MHC1 and β-MHC are products of the same gene), and are controlled via 
different nervous pathways with skeletal muscle being controlled voluntarily 
whilst cardiac muscle is controlled autonomously. Furthermore skeletal muscle is 
composed of multi-nucleated myocytes in comparison to single or bi-nucleated 
cardiomyocytes. 
Skeletal muscle shows a much higher growth and regenerative capacity than 
cardiac muscle, with an average turnover of ~1-2% of myonuclei per week 
(Schmalbruch and Lewis. 2000) compared to a 50% turnover of cardiomyocytes 
over an individual’s lifetime (Bergmann et al. 2009). This regenerative capacity is 
apparent in the ability for muscle to adapt and change with damage caused by 
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exercise and mechanical stresses (Morton et al. 2009), such as in body builders 
and athletes. Although the heart has also shown some adaptation to exercise 
(Waring et al. 2012), regeneration of new myocytes are much more subtle. 
In agreement with differences in regenerative capacity of the two muscle types, 
the presence and frequency of endogenous stem/progenitor cell populations (SCs 
and eCSCs) is also dramatically different. SCs are found at a frequency of 1 SC 
for every 2-7 myonuclei (Peault et al. 2007) dependant on the type of muscle, 
whereas eCSCs are extremely rare at only 1 per ~1000 cardiomyocytes (Torella et 
al. 2007). This raises the question: is the regenerative capacity of a muscle limited 
by the frequency of stem/progenitor cells? 
Finally, the embryological origin of these two muscle types is different with 
skeletal muscle derived from the somites of the paraxial mesoderm, whilst cardiac 
tissue one of the earliest tissues formed from the lateral plate mesoderm. 
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Table 1.5  Skeletal Muscle vs Cardiac Muscle and their Regenerative 
capacity. 
 Skeletal Muscle Cardiac Muscle 
Myosin Isoforms 
MHCI, MHC IIa, 
MHC IIb 
α-MHC, β-MHC 
Nervous System  Somatic Autonomous 
Nuclei Multinucleated Single/Binulcleated 
Myocyte Turnover 
1-2% of myonuclei  
Per week 
50% over lifetime 
Regenerative Capacity High Very Low 
Regeneration Mediator Satellite cells eCSC 
Stem Cell Frequency  2-7% of myonuclei ~1 eCSC:1000 myocytes 
Embryological origin  Paraxial mesoderm Lateral plate mesoderm 
 
The roles that these two muscles play within the body and subsequent 
consequences of damage to the two tissues are markedly distinct from each other, 
with the homeostasis of the heart being imperative to survival. As the heart is a 
critical organ in sustaining life, it could be expected that it should have a superior 
regenerative capacity; however this is clearly not the case.  There are a number of 
reasons why the heart might not need to possess this, with the first being that in 
individuals with an active lifestyle and good diet, injuries and disease simply do 
not, or are very unlikely to occur, whereas skeletal muscle is constantly put under 
stress and subject to injury.  With more people leading unhealthy lifestyles and 
surviving to an older age, the need to find cures for heart conditions is a relatively 
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new problem in human evolution. Having a low turnover of cells may in fact be 
beneficial to the heart as with less cycling cells the probability of developing 
cancer is low. Indeed, primary angiosarcomas are one of the rarest forms of cancer, 
and most tumours reported in the heart are secondary tumours that originated in 
another tissue (Cancer Research UK). 
If PW1 marks ‘muscle stem cells’, and Sca-1 is a marker shared between PW1+ 
PICs and eCSCs, then it may be expected that it should also be a marker 
expressed in eCSCs. PW1 has previously been detected in embryonic and early 
postnatal cardiac tissue (Besson et al. 2011), however what population of cells this 
actually marks has not been determined. Therefore, do PICs and eCSCs, both 
being muscle-resident stem cells, belong to the same ASC population? 
1.8 Aims and Objectives 
The main aims of this study are: 
1. Quantify PW1 expression in skeletal muscle of postnatal and aged mice. 
2. Successfully isolate murine PICs and characterise their phenotype in vitro. 
3. Test PICs for stem cell properties, i.e. multipotency and self-renewal in 
vitro and in vivo. 
4. Determine the presence of ‘PIC like’ cells in cardiac tissue, and their 
overlap with previously described CSCs. 
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2. METHODS 
2.1 Animals  
C57BL/6 Mice derived from a conventional colony at Liverpool John Moores 
University were housed under controlled conditions of 19-23°C and 45-55% 
relative humidity with water and food (containing 22% protein) available ad 
libitum.  
All regulated animal procedures were carried out under the Home Office project 
licence PPL70/8273 and personal licence I0916B98D. 
2.2 Tissue collection and processing  
Animals were sacrificed at 3 day (2.6 ± 0.1 g), 10 day (5.4 ± 0.2 g), 21 day (7.8 ± 
0.4 g) and 2 years (35.7 ± 1.2 g) of age via CO2 asphyxiation or cervical 
dislocation. Immediately after sacrifice skeletal hind limb muscle and whole 
hearts were dissected and fixed in formalin for 24 hours before tissue processing.  
After 24 hour formalin fixation, tissue was cut transversely (skeletal muscle) or 
longitudinally (cardiac) and processed in a tissue processor (Leica, Nussloch, 
Germany; TO 1020) on the following cycle: 
1. Formalin – 1 hour 
2. Formalin – 1 hour 
3. Alcohol 70% – 1 hour 30 minutes 
4. Alcohol 80% – 1 hour 30 minutes 
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5. Alcohol 96% – 1 hour 30 minutes 
6. Alcohol 100% – 1 hour 
7. Alcohol 100% – 1 hour 
8. Alcohol 100% – 1 hour 
9. Xylene – 1 hour 30 minutes 
10. Xylene – 1 hour 30 minutes 
11. Paraffin – 2 hours 
12. Paraffin – 2 hours 
After processing, tissue samples were embedded in paraffin wax blocks using an 
embedding station (Leica; EG 1160A) after which 5 μm tissue sections were cut 
using a microtome (Leica; RM 2235) and mounted on polysine
TM
  microscope 
slides (Menzel-Gläser, Braunschweig, Germany) using a waterbath. 
2.3 Immunohistochemistry  
Immunohistochemistry is the process of detecting antigens in cells/tissues using 
primary (target antigen) and secondary (fluorochrome) antibodies (Figure 2.1). 
It is based on the principle that primary antibodies bind to specific antigens on the 
protein of interest. Primary antibodies are synthesised in animals by repeat 
immunization with the antigen of interest, the animals immune response then 
produces antibodies (B lymphocytes) against the antigen which are harvested and 
purified; most primary antibodies are now available commercially. When 
introduced to the tissue, the primary antibodies bind to the specific epitopes where 
they come in contact with them. The primary antibodies also contain isotype 
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specific antigens from the host animal in which they were made (e.g. Mouse IgG) 
and it is to these epitopes that secondary antibodies, made via the same process, 
which have been conjugated to fluorescent tags, are able to bind. Due to the nature 
in which the secondary antibody is made it is good practice to perform a blocking 
step with serum from the host of the secondary antibody (most commonly goat or 
donkey), prior to staining to prevent non-specific binding of the fluorescently 
tagged antibody. The more protein expressed by a cell/tissue the more primary 
and secondary antibody attachment and the greater the fluorescent signal will be.  
 
 
Figure 2.1  Schematic to show antibody binding and immunofluorescence 
on cell/tissue proteins.  
 
METHODS 
42 
 
Deparaffinisation and rehydration was achieved by incubation at 70°C for 30 
minutes, followed by immersion in the following: 
1. Xylene – 2 x 5 minutes 
2. 96% ethanol – 1 x 4 minutes, 1 x 3 minutes 
3. 90% ethanol – 3 minutes 
4. 80% ethanol – 3 minutes 
5. H20 – 4 minutes 
Antigen retrieval was achieved using pre-heated citric acid buffer (0.35 g/L citric 
acid monohydrate, Sigma, St Louis, USA; 2.4 g/L Citric acid trisodium, Sigma; 
pH 6) and heating on full power for 10 minutes in a microwave. Slides were 
allowed to cool to room temperature (RT) for ~45 minutes then rinsed in distilled 
water for 1 minute followed by 5 x 2 minute washes in PBS (Sigma). 
A hydrophobic barrier was created around each tissue section using an ImmEdge
™
 
Pen (Vector) before blocking with 10% donkey serum (Sigma) in PBS for 30 
minutes at RT. Directly after blocking, the donkey serum was discarded and the 
first primary antibody applied for either 1 hour at 37°C or overnight at 4°C (see 
sections 3.2, 4.2, 5.2, 6.2) and washed in PBS for 5 x 2 minutes. The relevant 
secondary antibody was then applied (1/100 dilution) for 1 hour at 37°C followed 
by 5 x 2 minute washes in PBS.  
Nuclei were counterstained with DNA binding dye, 4, 6-diamidino-2-
phenylindole (DAPI) (1:1000, Sigma) for 15 minutes at RT, followed by 6 x 2 
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minutes PBS washes before mounting in Vectashield™ mounting medium 
(Vector laboratories).   
All quantification was conducted at x40 magnification on a fluorescence 
microscope (Nikon, Surrey, UK;  E1000M Eclipse) and representative Z stack 
micrographs imaged on a confocal microscope (Zeiss, Cambridge, UK; LSM 710) 
2.3.1 Haematoxylin and eosin staining 
After deparaffinisation and rehydration, slides were immersed in haematoxylin 
(Sigma) for 3 minutes at RT and rinsed with running water for 5 minutes. Slides 
were counterstained with eosin (Sigma) for 5 minutes at RT and rinsed in running 
water for 5 minutes before air-drying for 1 hour at 37°C. Slides were cleared in 
Xylene for 5 minutes at RT before mounting with Distyrene Plasticizer Xylene 
(DPX; Sigma). 
2.3.2 DAB staining 
To determine which tumour cells arose from GFP
+
 PICs and were not a result of 
the ESC’s, paraffin embedded tumour tissue sections were prepared and stained 
for green fluorescent protein (GFP) (Abcam, Cambridge, UK; 1 hour at 37°C) as 
previously described (see section 2.3), after the GFP primary antibody and 5 x 2 
min wash in PBS, endogenous peroxidase activity was blocked using 1 part H2O2: 
3 parts PBS for 15 minutes at RT. After 5 x 2min washes in PBS donkey-anti-
Rabbit HRP (Santa Cruz, Texas, USA) was applied for 1 hour at 37°and 
SigmaFast DAB (3,3'-diaminobenzidine; Sigma) tablets were used to visualise the 
GFP (5 minutes at RT). Slides were washed in PBS (5 x 2 minutes), allowed to 
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dry (1 hour at 37°C) and cleared in xylene (5 minutes) before mounting and cover 
slipping using DPX (Sigma). 
2.4 Immunocytochemistry  
Cells grown on chamber slides were fixed with 4% formaldehyde (TAAB 
laboratory and microscopy, Berkshire, UK) for 20 minutes at room temperature 
and rinsed in PBS for 5 x 2 minutes before staining. For ICC of cytospin 
preparations: 200 μl of 50,000 cells/ml cell suspension per spot (2 spots per slide), 
were spun down onto polysine
TM
 (Menzel-Gläser) using a Cytospin 4 centrifige 
and Shandon EZ double cytofunnels (Thermo Scientific, Massachusetts, USA), 
slides were then rapidly fixed with Shandon cellfix spray (Thermo Scientific) and 
allowed to air dry. The fixative was removed by soaking the slides in 95% ethanol 
for 15 minutes, followed by 5 x 2 minutes washes in PBS. For staining of nuclei 
proteins, cells were permeabilised with 0.1% triton for 10 minutes at RT and 
washed for 5 x 2 minutes in 0.1% Tween PBS. 
Cells were blocked with 10% donkey serum in 0.1% Tween PBS for 30 minutes 
at RT. Directly after blocking, the donkey serum was discarded and the first 
primary antibody applied for 1 hour at 37°C and washed in PBS for 5 x 2 minutes. 
The relevant secondary antibody was then applied (1/100 dilution) for 1 hour at 
37°C followed by 5 x 2 minute washes in PBS. Nuclei were counterstained with 
DAPI, rinsed in PBS for 6 x 2 minutes before mounting with vectashield™ 
(Vector laboratories).  
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All quantification was conducted at x 40 magnification on a fluorescence 
microscope (Nikon; E1000M Eclipse) and representative Z stack micrographs 
imaged on a confocal microscope (Zeiss; LSM 710) 
2.5 Cell Isolation 
2.5.1 Isolation of PICs from murine skeletal muscle  
Skeletal muscle hind limb was dissected and rinsed in basic buffer (Table 2.1). 
The tissue was minced extensively with scissors and then stirred at 37°C for 30 
minutes in digestion buffer (Table 2.1). Following digestion, the preparation was 
centrifuged at 300 g for 1 minute (brake 3). The supernatant, containing the small 
cells, was filtered (40 μM) and the pellet discarded. The cell suspension was then 
topped up to 30 ml with incubation buffer (Table 2.1) and spun at 1500 rpm for 7 
minutes (brake 7) after which the supernatant was discarded and the pellet re-
suspended in 1ml incubation medium (Table 2.1). The small cell population was 
then sorted for the PIC cell population using Magnetic Activated Cell Sorting 
(MACS) as per standard protocol (Miltenyi, Bergisch Gladbach, Germany). 
Briefly, using direct mouse CD45 microbeads (Miltenyi) the CD45
+
 cells were 
depleted from the cell preparation, leaving the CD45
-
 fraction, from this, the Sca-
1
+
 cells were then enriched using an indirect (FITC) mouse Sca-1 microbead kit 
(Miltenyi).  
2.5.2 Isolation of Sca-1
+
 CSCs from murine hearts  
6 week old mice were given an injection of 200 U heparin (MP biomedicals) 15 
minutes prior to euthanasia with 50 μl of pentobarbitone. Hearts were then 
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dissected and the aorta cannulated as described in Smith et al. (2014). Cannulated 
hearts were retrograde coronary perfused (11.6 ml/minute) on an adapted 
lagendorff system with basic buffer (Table 2.1) until all blood was removed (~5 
minutes), followed by digestion buffer (Table 2.1) for 12 minutes and incubation 
buffer (Table 2.1) for 5 minutes.   Digested hearts were then placed in incubation 
buffer (Table 2.1) and minced extensively before centrifugation at 300 g for 1 
minute (brake 3).  Further filtration, centrifugation and MACs sorting for CD45
-
 
cells and Sca-1
+
 cells were as described for PIC isolation (section 2.4.1) 
Table 2.1  Cell Isolation Media 
Media Components 
Basic 
Buffer 
MEM (Sigma), 2.93 mM Hepes (Sigma), 2.05 mM Glutamine 
(Sigma), 9.99 mM Taurine (Sigma), pH 7.3 
Digestion 
Buffer 
Basic Buffer (as above), 7 mg/ml Collagenase II (Worthington, 
Lakewood, USA) 
Incubation 
Buffer 
Basic Buffer (as above), 0.5% BSA (Sigma), pH 7.3 
Incubation 
Medium 
PBS (Life Technologies, Carlsbad, USA), 0.5% BSA (Sigma), 2 
μM EDTA (Life Technologies) 
 
2.6 Cell culture  
Cells were cultured on 1.5% gelatin (Sigma) coated dishes in growth medium 
(Table 2.2). Cultures were incubated at 37°C in 5% CO2 and passaged 1 in 3 when 
they reached ~80% confluency using 0.25% trypsin-EDTA solution (Sigma). 
Once cells were detached, trypsin activity was quenched with passage medium 
(Table 2.2) before centrifugation (300 g for 3 minutes). The supernatant was 
aspirated and the cell pellet suspended in fresh growth media, for re-plating in a 
new dish at ~ 20,000 cells per cm
2
. 
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Mouse ESC’s (Gifted from Agi Grigoriadis, Kings College London) were 
cultured on 1% gelatin coated dishes in ESC growth medium (Table 2.2). 
Table 2.2  Cell Culture Media 
Media Components 
Growth 
Medium 
 45% DMEM/F12 Ham (Sigma), 1 X ITS (Life Technologies), 45% 
Neurobasal Medium (Life Technologies), 0.5% Glutamax (Life 
Technologies), 1 X B27 (Life Technologies),1 X N2 (Life 
Technologies), 20 ng/ml EGF (Peprotech, Rocky Hill, USA), 10 ng/ml 
bFGF (Peprotech), 10% ESCQ-FBS (Life Technologies), 10 ng/ml 
LIF (Millipore, Darmstadt, Germany), 1% PenStrep (Life 
Technologies), 0.1% Fungizone (Life Technologies), 0.1% 
Gentamicin (Sigma) 
Passage 
Medium 
 DMEM (Life Technologies), 10% FBS (Life Technologies), 1% 
PenStrep (Life Technologies), 0.1% Fungizone (Life Technologies), 
0.1% Gentamicin (Sigma) 
ESC 
Growth 
Medium 
10% FBS (Hyclone, Utah, USA), 1mM sodium pyruvate (Sigma), 
MEM non-essential amino acids (Life Technologies), 50 mM β-
mercaptoethanol (Sigma), 1000 U/ml GSK-inhibitor (Stemgent, 
Cambridge, USA) 1000 U/ml MEK-inhibitor (Stemgent) 1000 U/ml 
LIF (Millipore). 
 
2.6.1 Clonogenicity  
Clonogenicity was determined using a clonogenicity assay in which, through 
serial dilution, a single cell was deposited into a well of a 96-well plate (~ 50 cells 
seeded per plate). The number of wells which formed single-cell derived colonies 
by 14 days was quantified, and expressed as a percentage of the total number of 
single cells deposited (n=3 per assay).  
2.6.2 Population Doubling  
Doubling time is a measure of proliferation, giving the average time it takes for a 
cell to replicate. The population doubling time was calculated at every 5th passage 
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(n=3 per time point) using the following formula, where: t= time in culture, x= 
starting population, y= final population.  
Doubling time = t * 
log(2)
log(
𝑦
𝑥
)
 
2.6.3 Cardiosphere formation  
To generate cardiospheres; C9 PICs (P5) were treated with 100 nM Oxytocin in 
normal growth media for 72 hours prior. LIF and Oxytocin were then removed 
from the medium and cells re-plated in bacteriological dishes for a further 72 
hours. 
2.6.4 Directed Differentiation  
C9 PICS (P5) were plated at 2 x 10
4
 cells/cm
2
 in dishes as described (Table 2.3) 
and cultured in specific differentiation media listed in Table 2.4. 
Table 2.3  Directed Differentiation: Dishes and Coatings 
Differentiation Dish Coating Dishes 
Myogenic  1.5% Gelatin (Sigma) 3 x 10cm dish, 1 x 4 well 
glass chamber slide 
Cardiomyogenic 1 μg/ml Laminin (Sigma) 3 x 10cm dish, 1 x 4 well 
glass chamber slide 
Adipogenic 1.5% Gelatin (Sigma) 1 x 4 well glass chamber slide 
Endothelial 10 μg/ml Fibronectin (Sigma) 3 x 10cm dish, 1 x 4 well 
glass chamber slide 
Hepatic 10 μg/ml Fibronectin (Sigma) 4 x 10cm dish, 1 x 4 well 
glass chamber slide 
Neuronal 1 μg/ml Laminin (Sigma) 3 x 10cm dish, 1 x 4 well 
glass chamber slide 
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Table 2.4  Directed Differentiation Media 
Media Medium Components Duration  
Myogenic  
Medium 
High Glucose (4.5 g/L) DMEM(Life 
Technologies), 2% Horse serum (Life 
Technologies), 1% PenStrep (Life Technologies).  
5 days 
Cardiomyogenic 
Medium 
Days 1-4; α-MEM (Sigma), 1 µM dexamethasone 
(Sigma), 50 μg/ml ascorbic acid (Sigma), 10 mM 
β-glycerophosphate (Sigma) and 2% FBS (Life 
Technologies) 5 ng/ml TGF-β1 (Peprotech), 10 
ng/ml BMP2 (Peprotech), and 10 ng/ml BMP4 
(R&D Systems, Minneapolis, USA).   
Day 5-14; α-MEM (Sigma), 1 µM dexamethasone 
(Sigma), 50 μg/ml ascorbic acid (Sigma), 10 mM 
β-glycerophosphate (Sigma) and 2% FBS (Life 
Technologies), 150 ng/ml Dkk-1 (R&D Systems) 
14 days 
Adipogenic 
Medium 
Low glucose (1g/L) DMEM (Sigma), 10% FBS 
(Invitrogen), 50μM Hydrocortisone (Sigma), 1μM 
Dexamethazone) (Sigma). 
14 days 
Endothelial 
Medium 
DMEM (Invitrogen), 10 ng/ml VEGF (Peprotech), 
1% PenStrep (Invitrogen). 
7 days 
Hepatic 
medium 
Low glucose DMEM (Sigma), 25% F12K media 
(Invitrogen), 20ng/ml HGF (Peprotech), 10 ng/ml 
Oncostatin (Peprotech), 1x ITS (Invitrogen), 5 
mM Nicotinamide (Sigma), 2.5% FBS 
(Invitrogen), 1% PenStrep (Invitrogen). 
14 days 
Neuronal 
Medium 
medium (low glucose DMEM, 10% horse serum, 
300 ng/ml Retinoic acid) 
14 days 
 
2.6.5 GFP transduction 
C9 PICs (P10) were transduced with the construct for green fluorescent protein 
(GFP) via lentiviral transduction: 10
6 
293T cells (Clontech, California, USA) at 70% 
confluency were treated with 5 µg Delta 8.9 plasmid, 10 µg GFP plasmid, 2 µg 
VSV-g plasmid (pre-prepared plasmids gifted from Daniele Torella, Magna 
Graecia University, Italy) and 30 µl Lipofectamine2000 (Life Technologies) in 6 
ml of OptiMEM-I (Life Technologies) for 4 hours. A further 5 ml of OptiMEM-I 
containing 10% FBS (Life Technologies) and 1% PenStrep (Life technologies) 
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was then added.  After 24 hours the media was changed for normal 293T growth 
media and left for a further 24 hours, after which the lentiviral supernatant was 
collected. PICs were transduced for 24 hours using a 1: 5 ratio of; lentiviral 
supernatant: PIC media containing 8 µg/ml of Polybrene (Sigma). The tranduction 
efficiency was checked by flow cytometry. 
2.7 Flow Cytometry  
Cells were blocked with 10% donkey serum in incubation medium (Table. 2.1) 
immediately before incubation with the primary antibody. For nuclear expression 
of PW1, cells were permeabilised with BD fixation/permeabilisation kit (BD, 
New Jersey, USA) as per manufacturer’s instructions prior to the blocking step. 
All antibodies were incubated at 4°C for 15 minutes and washed in incubation 
buffer after incubation. Flow cytometry was conducted on a BD FACS Calibur 
and 10,000 events recorded for each analysis. Results were plotted and analysed 
using Flowing Software (Turku Centre for Biotechnology). Isotype controls were 
used to determine expression.  
The FACS Calibur is a 4 colour flow cytometer and contains two lasers; a 15mW 
air-cooled argon-ion laser with an excitation of 488 nm and a 9mW red diode 
laser with an excitation of 635 nm. It also contains four filters: FL1= 530/30, 
FL2= 585/42, FL3= 650LP and FL4= APC- 661nm.  
2.8 Quantitative RT-PCR (qRT-PCR)  
Total mRNA was obtained from cell pellets using the QIAshredders and RNeasy 
mini kit (Qiagen, Venlo, Netherlands) with a DNase step (Qiagen) to remove any 
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residual DNA, as per manufacturers instructions. Briefly, cell pellets were lysed 
with RLT buffer containing 1% β-mercaptoethanol before transfer to a 
QIAShredder tube and spun at top speed for 2 minutes. 70% ethanol was added to 
the flow through and transferred into an RNeasy column. This was then spun 
at  >8000 g for  15 seconds. The flow through was discarded and the column 
washed with RW1 buffer and spun (>8000 g for 15 seconds, flow through 
discarded) immediately followed by a 15 minute incubation with DNase. 
Following this, the column was once again washed with RW1 buffer, spun (>8000 
g for 15 seconds) and the flow through discarded. The column was then washed 
twice with RPE buffer and the flow through discarded (1
st
 wash spun  at >8000 g 
for 15 seconds, and the second spin for 2 min’s). Finally the RNeasy column filter 
was placed inside a new collection tube, 30 μl of RNase free water added to the 
filter and spun at >8000 g for 1 minute.  
Final mRNA concentration (ng/μl) and quality (260/280 and 260/230 ratio) of the 
resulting flow though was measured using a Nanodrop 2000 (Thermo scientific). 
 cDNA was synthesised via reverse transcription, using a Taqman reverse 
transcription (RT)  kit (Life technologies). Each reaction contained 10ng/μl RNA, 
10μl of 10xRT Buffer, 22μl of MgCl2 (25mM), 20μl dNTP mix (2.5mM), 5μl 
Random hexamers (50μM), 2μl RNase inhibitor (20U/l), 2.5μl Multiscribe RT 
enzyme (50U/μl) and DNase/RNase free H2O. The reaction was performed on a 
Biorad i-cycler (Bio-rad, Hercules, USA), on the following program:  
1. 25°C - 10 minutes 
2. 48°C   - 30 minutes 
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3. 95°C  - 5 minutes  
qRT-PCR was peformed on a Biorad  i-cycler with a MyIQ detection system, 
using IQ SYBR Green supermix (Bio-rad). The PCR-reaction included 1μl of 
template cDNA and 500nM of forward and reverse primers with the following 
program: 
1. 95°C – 5 minutes 
2. 40 cycles of: 
a. 95°C – 15 seconds 
b. 60°C – 30 seconds 
c. 72°C – 30 seconds  
Florescence was detected as the end of each amplification cycle (step 2c). 
Melt curve analysis was performed on all reactions,  at 0.5°C  increments between 
55-95°C, to detect any genomic DNA contamination, primer dimers and/or non-
specific amplification. 
Data were analysed using BioRad IQ software, and  the transcript copy number 
estimated  by normalising results to the housekeeping gene (HKG) GAPDH, using 
the following equation where Ct= cycle threshold.  
Copy number of target = 2500*1.93^(HKi - target Ct)  
Where 2500 is an empirical estimation of the number of HKG transcripts, 1.93 
reflects a typical reaction amplification efficiency of 93%, and HKi is the 
geometric mean Ct of the HKG (Aguilar et al. 2007). 
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Fold change of differentiated cells over undifferentiated cells was calculated as 
below:  
Fold Change = 
Differentiated copy number
Undifferentiated copy number
 
All primers were designed using NCBI Primer-BLAST software , with melting 
temperatures of 60ºC and primer lengths of ~20. All reactions were performed in 
triplicate.  
2.9 Surgery 
12 week old C57BL/6 were anaesthetised via inhalation of isoflurane and 
immediately given antibiotics (0.5ml Betamox LA) and pain relief (5mg/kg 
Carprieve) subcutaneously and Visotears used on the eyes to prevent drying. 
Animals were placed on a heat mat throughout surgery and recovery. Hair was 
removed prior to incision using clippers and Nair™ hair removal cream (3 
minutes), before disinfection with Hibiscrub. A small (~10mm) incision was made 
midline on the mouse right hand side just under the ribcage, followed by a slightly 
smaller incision (~7mm) in the peritoneum directly underneath. The kidney was 
then gently exposed using small non-toothed forceps to hold it in place. A small 
incision was made to the kidney capsule using a 27 gauge needle without piercing 
the kidney itself: The kidney capsule was kept moist with PBS containing 0.05% 
gentamicin throughout. A small space was then made between the kidney and its 
capsule using a fine pipette tip containing the cell mix. The cell mix was 
deposited slowly, forming a gel like ball as the matrigel solidified, and the entry 
site cauterized to prevent leakage. The peritoneum and skin were individually 
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closed using 5-0 Vicryl sutures and the animal allowed to recover. 10 out of 12 
animals operated on survived (1 did not recover, 1 died 24 hours post-surgery). 
Animals were sacrificed 4 weeks post-surgery and assessed for tumour formation. 
Tumours were removed and fixed and processed for immunostaining as 
previously described (see section 2.2). 
2.10 Statistical Analysis  
Data is presented as Mean ±SD. Significance between 2 groups was determined 
using an independent T-test. For analysis of more than 2 groups, One-Way 
ANOVA was performed with tukey post hoc method to locate the differences. 
Significance was reported when p<0.05. 
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RESULTS 
3. PIC location and distribution  
3.1 Introduction 
Growth velocity is highest in early postnatal development than at any subsequent 
stage with a rapid growth and maturation of skeletal muscle occurring during this 
time (Lui and Baron. 2011). To enable this growth, it has previously been shown 
that there is an abundance of SCs present at birth, which sharply decline in 
frequency to adult levels (Suzuki et al. 2010), after which point there is a gradual 
decline with age (Neal et al. 2012) and in age-related sarcopenia (Shefer et al. 
2010). 
PICs are identified by their expression of PW1 and interstitial location (see Table 
1.3) and are found at a similar frequency to SCs with ~22, ~13 and ~16 PICs per 
100 fibres compared to 19, 14 and 11 SCs at birth, 7,  and 14 days  respectively 
(Mitchell et al. 2010). Similarly, our group found a 1:1 ratio of PICs: SCs in the 
hind-limb muscle of 2 month old pigs (Lewis et al. 2014). The abundance of PICs 
declines in aged mice (18 months) to <1 per 100 fibres (Formicola et al. 2014) 
with the PIC: SC ratio decreasing to  ~1:3.  
This study determined PW1 expression, PIC and SC abundance in murine hind-
limb up to 21 days post-natal development, which is when SC abundance per 
muscle fibre falls to adult levels in mice (Cardasis and Cooper 1975). Formicola 
et al. (2014) previously looked at PIC and SC abundance in 18 month old mice; 
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however mice can live for 2 years or more. Therefore, to properly encapsulate the 
abundance of PICs and SCs in aged muscle their presence in 2 year old mice was 
also investigated. 
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3.2 Methods 
3.2.1 Quantitative Immunohistochemistry  
Skeletal muscle sections of 3, 10, 21 day and 2 year old mice (n=3 per age group) 
were stained as described in (see Section 2.3) for antibodies listed in Table 3.1. 
Total nuclei, PW1
+
 nuclei, PW1
+
 interstitial nuclei and total muscle fibres were 
counted (3, 10 and 21 days: n=10 fields of view per animal, 2 years: n=20 fields 
of view per animal). Muscle fibres were identified by a fully intact basal lamina, 
delineated by laminin, PW1 staining was seen in nuclei. PW1
+
 cells located in the 
interstitium were counted as PICs, whilst PW1
+
 cells located under the basal 
lamina of the muscle fibres were counted as satellite cells. Standard deviation was 
calculated from the mean of each animal per group (n=3). 
Table 3.1  Antibodies used on paraffin embedded skeletal muscle tissue 
sections. 
Primary Antibody Dilution Incubation 
 
Secondary Antibody 
 
PW1 
(Gifted by David Sassoon, 
Inserm, Paris) 
1:3000 
Overnight at 
4°C 
 
Alexa Fluor 488  
Donkey anti-Rabbit, 
(Stratech) 
 
 
Laminin 
(Sigma) 
 
1:50 
1 Hour at 
37°C 
 
Alexa Fluor 594 
Donkey anti-Chicken (Stratech) 
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3.3 Results 
Expression of PW1 in hind-limb skeletal muscle cross sections was assessed by 
immunohistochemistry (IHC) at 3, 10 and 21 days and 2 years. PW1 was seen as 
nuclear staining, co-expressed with DAPI (Figure 3.1). 
PW1 expression was quantified as a percentage of total nuclei in all locations of 
the hind limb muscle, inclusive of SCs and PICs.  At 3 days ~9% of nuclei were 
positive for PW1, this abundance decreased ~1.5 fold between 3 and 10 days, with 
subsequent decreases of ~1.5 fold between 10-21 days and ~3 fold between 
21days and 2 years. This equated to a ~6 fold reduction in PW1 expression from 3 
days to 2 years, with PW1 expressed in less than ~1.5% of nuclei in aged animals 
(Figure 3.2). 
The number of PW1
+
 nuclei per muscle fibre was calculated: Muscle fibres were 
identified as delineated by laminin staining.  Similar to PW1 abundance, there was 
a ~11 fold decrease in the number of PW1
+
 nuclei/muscle fibre (cross-sectional 
area), between 3 days and 2 years; Specifically, a ~2 fold decrease between 3-10 
days, ~1.5 fold decrease between 10- 21 days and ~4 fold decrease between 21 
days and 2 years (Figure 3.3).  These data translated to a reduction from 1 PW1
+
 
nuclei: 3 fibres at 3 days, to 1 PIC: 31 fibres at 2 years (Figure 3.4).  
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Figure 3.1  Identification of PW1 in murine hind-limb muscle. 10 day old 
mouse paraffin embedded hind limb muscle, stained by IHC for PW1 (red) and 
laminin (green). Nuclei are stained in blue by DAPI. Scale = 50µm. 
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Figure 3.2  Total PW1 abundance in hind-limb muscle from postnatal to 
ageing. PW1 expression as a percentage of total nuclei (inclusive of PICs and SCs) 
in 3, 10 and 21 day, and 2 year old mice. Data is mean ±SD, n=3 per group. * 
denotes significant differences (p<0.05) vs 10 day, 21 day and 2 year, ** denotes 
significant differences (p<0.05) vs 21 day and 2 year, † denotes significant 
differences (p<0.05) vs 2 year. 
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Figure 3.3  The number of PW1 nuclei per muscle fibre from postnatal to 
ageing. The number of PW1
+
 nuclei (inclusive of PICs and SCs) per cross 
sectional muscle fibre in 3, 10, and 21 day and 2 year old mice. Data is mean ±SD, 
n=3 per group. * denotes significant differences (p<0.05) vs 10 day, 21 day and 2 
year, ** denotes significant differences (p<0.05) vs 21 day and 2 year, † denotes 
significant differences (p<0.05) vs 2 year. 
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Figure 3.4 The ratio of PW1 nuclei: Muscle fibre from postnatal to ageing. 
The ratio of PW1
+
 nuclei: muscle fibre (cross-sectional area) in hind limb skeletal 
muscle of 3, 10 and 21 day, and 2 year old mice. Data is mean, n=3 per group. 
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Cells positive for nuclear PW1 staining were identified as being either: 
A) PIC – located within interstitial spaces  
or 
B) SC – located directly under the basal lamina of muscle fibres, with at least 
one side free of laminin (Figure 3.5).  
To account for activated satellite cells that may have moved into interstitial spaces 
Pax7 staining was utilized to further distinguish between PICs and SC’s, however 
no interstitial cells expressing both Pax7 and PW1 were found.  
At 3 days ~5% of total nuclei were identified as PW1
+
 PICs, this reduced ~ 12 
fold by 2 years to ~0.5% (Figure 3.6).  PICs represented ~57% of PW1
+
 nuclei 
assessed between 3 and 21 days, however this number dropped to ~30% in 2 year 
old animals (Figure 3.7). 
Similar to total PW1 expression, there was a progressive decrease with age (~21 
fold between 3 days and 2 years) in the number of PICs per muscle fibre (Figure 
3.8). This equated to a total reduction from 1 PIC: 5 muscle fibres at 3 days, to 1 
PIC: 104 fibres at 2 years of age (Figure 3.9). 
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Figure 3.5 The identification of PICs and SCs in murine hind limb muscle. 
10 day old mouse hind limb muscle stained for PW1 (red), laminin (green) and 
DAPI (blue), showing A. PW1
+
 interstitial PIC and B. PW1
+
 satellite cell under 
the basal lamina. Scale = 10µm. 
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Figure 3.6  PIC abundance in hind-limb muscle from postnatal to ageing.  
The percentage of total nuclei identified as interstitial PICs in 3, 10 and 21 day, 
and 2 year old mice. Data is mean ±SD, n=3 per group. * denotes significant 
differences (p<0.05) vs 10 day, 21 day and 2 year, ** denotes significant 
differences (p<0.05) vs 21 day and 2 year, † denotes significant differences 
(p<0.05) vs 2 year. 
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Figure 3.7 Percentage of PICs in the PW1
+
 cell fraction from postnatal to 
ageing.  The percentage of PW1
+
 nuclei identified as interstitial PICs in hind limb 
skeletal muscle in 3, 10 and 21 day, and 2 year old mice. Data is mean ±SD, n=3 
per group. * denotes significant differences (p<0.05) vs 3, 10 and 21 day. 
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Figure 3.8  The number of PICs per muscle fibre from postnatal to ageing. 
The number of interstitial PICs per muscle fibre in hind limb skeletal muscle of 3, 
10, and 21 day, and 2 year old mice. Data is mean ±SD, n=3 per group. * denotes 
significant differences (p<0.05) vs 10 day, 21 day and 2 year, ** denotes 
significant differences (p<0.05) vs 21 day and 2 year, † denotes significant 
differences (p<0.05) vs 2 year. 
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Figure 3.9 The ratio of PIC: Muscle fibre from postnatal to ageing. The 
ratio of interstitial PIC: muscle fibre (cross-sectional area) in hind limb skeletal 
muscle of 3, 10 and 21 day, and 2 year old mice. Data is mean, n=3 per group. 
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The abundance of SC’s followed a similar trend with age as PICs: SCs reduced 
from ~4% of all nuclei at 3 days, to ~1% by 2 years (Figure 3.10).  However, they  
showed an inverse trend in the percentage of PW1
+
 nuclei that they represented 
being 43% of the PW1
+
 nuclei between 3-21 days, rising to ~70% in aged mice 
(Figure 3.11).  
Again, similar to PICs, the number of SCs per muscle fibre decreased ~6 fold 
between 3 days and 2 years (Figure 3.12). This equated to a total reduction from 1 
SC: 7 muscle fibres at 3 days, to 1 SC: 44 fibres at 2 years of age (Figure 3.13). 
Overall, the ratio of PICs: SCs remained constant (~13:10) during the first 3 
weeks of postnatal development, however this dropped to ~4:10 in 2 year old 
mice (Figure 3.14). 
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Figure 3.10 SC abundance in hind-limb muscle between from postnatal to 
ageing.  The percentage of total nuclei identified as SCs under the basal lamina in 
3, 10 and 21 day, and 2 year old mice. Data is mean ±SD, n=3 per group. * 
denotes significant differences (p<0.05) vs 10 day, 21 day and 2 year, ** denotes 
significant differences (p<0.05) vs 21 day and 2 year, † denotes significant 
differences (p<0.05) vs 2 year. 
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Figure 3.11 Percentage of SCs in the PW1
+
 fraction between 3 days and 2 
years.  The percentage of PW1
+
 nuclei identified as SCs under the basal lamina in 
hind limb skeletal muscle in 3, 10 and 21 day, and 2 year old mice. Data is mean 
±SD, n=3 per group. * denotes significant differences (p<0.05) vs 3, 10 and 21 
day. 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
3 Day 10 Day 21 Day 2 year
%
 S
C
s 
o
f 
P
W
1
+  
n
u
cl
e
i * 
PIC LOCATION AND DISTRIBUTION 
 
72 
 
 
 
 
 
 
 
Figure 3.12  The number of SCs per muscle fibre between 3 days and 2 
years. The number of SCs under the basal lamina per muscle fibre in hind limb 
skeletal muscle of 3, 10, and 21 day, and 2 year old mice. Data is mean ±SD, n=3 
per group. * denotes significant differences (p<0.05) vs 10 day, 21 day and 2 year, 
** denotes significant differences (p<0.05) vs 21 day and 2 year, † denotes 
significant differences (p<0.05) vs 2 year. 
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Figure 3.13 The ratio of SC: Muscle fibre between 3 days and 2 years. The 
ratio of SC: muscle fibre (cross-sectional area) in hind limb skeletal muscle of 3, 
10 and 21 day, and 2 year old mice. Data is mean, n=3 per group. 
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Figure 3.14 PIC to SC ratio between 3 days and 2 years. The ratio of PICs: 
SCs in hind limb skeletal muscle in 3, 10 and 21 day and 2 year old mice. Data is 
mean, n=3 per group. 
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3.3 Discussion 
The main findings that emanated from this study are: 
1. There was a decrease in PW1 expression in skeletal muscle over the 2 year 
lifespan of the mouse. 
2. The number of PICs and SCs per muscle fibre decreased with age. 
3. The ratio of PICs: SC’s remained constant during the first 3 weeks of 
postnatal development. 
4. The PIC: SC ratio declined in aged animals. 
3.3.1 PW1 abundance in skeletal muscle 
The abundance of PW1 expression in hind-limb tissue, and its decrease with age, 
was in agreement to that previously reported (~1.5 fold between 0-14 days) during 
early postnatal development (Mitchell et al. 2010).  Jones et al. (2014) described a 
similar decrease of PW1 transcripts in skeletal muscle of mice between 0-21 days. 
Transcripts further decreased from 21- 42 days; however there was no difference 
between 42-70 days suggesting PW1 expression stabilises at adult levels. 
In aged animals (2 Years), PW1 protein expression decreased further; a similar 
decline (~3.6 fold) was recently reported between 7 weeks and 18 months 
(Formicola et al. 2014). This decrease was due to a reduction in the abundance of 
both PICs and SCs: It was noted that SCs demonstrated a visually weaker PW1 
signal than PICs, suggesting there may be a difference in PW1 protein expression 
between the two cell populations, although this was not quantified.  
PIC LOCATION AND DISTRIBUTION 
 
76 
 
3.3.2 Reduction in PIC abundance with age 
PICs declined in abundance from 3 days to 2 years. This trend was previously 
shown in mice between 0-14 days (Mitchell et al. 2010) and 7 weeks to 18 months 
(Formicola et al. 2014). The mechanism behind this change in abundance is 
unknown, however chronological and replicative aging may account for the 
reduction of cells in the stem cell pool (Rando 2006).  
3.3.3 Reduction in SC abundance with age 
It is well documented that SCs decline with age: Formicola et al. (2014) reported 
a ~2.5 fold reduction in the number of SCs per muscle fibre, in young and old 
mice (7 weeks to 18 months) with other groups showing similar results: ~2.5 fold 
decrease between 3.5 and 27 months (Day et al. 2010); ~ 3 fold decrease between 
3.5 and 16 months (Shefer et al. 2010). Furthermore, Neal et al. (2012) found a 
greater reduction (~6 fold) between juvenile (2 weeks) and aged mice (2.5 years), 
which is in agreement with this study. It is thought that SCs become less efficient 
at proliferation and myotube formation with age due to the aging of their 
environment, rather than intrinsic aging of the SCs themselves (Carlson and 
Faulkner 1989, Conboy et al. 2005). 
3.3.4 PICs vs SCs 
The present study found that SCs and PICs were found at a ratio of ~1:1 
throughout the first 3 weeks of postnatal life in the mouse, with a similar ratio 
documented in 0, 7, 14 day and 7 week old mice (Mitchell et al 2010; Formicola 
et al. 2014) and 2 month old pigs (Lewis et al. 2014).  
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However,  the PIC: SC ratio changed in aged animals to ~1:3, as previously 
described in 18 month old mice (Formicola et al. 2014), demonstrating that PICs 
decline at a faster rate than SC’s in old age; the exact time point this occurs, and 
the mechanism behind this change is unknown.  
This steady ratio during early post-natal development suggests that it may be the 
decrease in the PIC population that is directly affecting the SC cell pool.  Indeed, 
PICs have been shown to give rise to SCs (Mitchell et al. 2010); however, 
pericytes have also been shown to contribute to the SC pool (Cappellari and 
Cossu. 2013), which may account for a lesser reduction in SCs than PICs in 2 year 
aged mice. 
The link between SCs and PICs is apparent, however, it has not yet been fully 
explored. To further elucidate how these two cell types are linked, their 
abundance in relation to each other should be studied throughout adulthood. Thus 
providing us with a clear picture as to when the ratio of PICs: SC cells changes; 
Do PICs slowly decline at a slightly faster rate than SCs?  Or is there a sudden 
drop in PIC abundance at a specific time point? 
Furthermore, Pax7 germline knockout mice have an increased abundance of PICs, 
and a lesser number of SCs, with a ~3:1 ratio of PIC: SC (Mitchell et al. 2010). 
Whether this occurs as PICs are less efficient at generating SCs without Pax7, or 
whether the PIC population is elevated by another mechanism to counteract the 
SC depletion has not yet been determined. However, the reduced capacity for 
muscle regeneration seen in Pax7 germline knockout mice (Oustanina et al. 2004) 
would indicate that it may be the former.  
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Lineage tracing studies would help identify and describe this link between PICs 
and SCs, however to do this we would first need to identify a PIC exclusive 
marker to enable labelling of the PIC population solely.  
If the decline in PICs is directly responsible for the subsequent decline in SCs 
with age, can PICs be replenished? And would this counteract the effects of 
sarcopenia? 
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4. PICs are self-renewing and clonogenic in vitro 
4.1 Introduction 
The phenotype and behaviour of murine PICs in vitro is not yet well documented. 
Previous studies have identified the phenotype and regenerative capacities of PICs 
in vivo, such as their expression of PW1/Sca-1 and CD34 and ability to contribute 
to the regeneration of skeletal muscle following an injury (Mitchell et al. 2010, 
Pannérec et al. 2013).  Our group was the first to demonstrate that porcine PICs 
(pPICs) maintain a stable phenotype and karyotype over long term cell culture, 
and express stemness markers, however as no Sca-1 homologue has been 
identified in pig,  pPICs were not selected by positive expression of Sca-1, but 
CD34 instead (Lewis et al. 2014). 
Isolating adult stem cells (ASCs) from solid tissues can be achieved by enzymatic 
digestion, which requires an initial mechanical breakdown of the tissue into 
smaller pieces prior to treatment. Enzymatic digestion breaks down tissues using 
proteolytic enzymes such as trypsin and collagenase, releasing small cells held 
within the tissue compartment. The use of such enzymes has been well 
documented as far back as 1974 in isolating myogenic cells from adult rat muscle 
(Bischoff. 1974) and has since been used to isolate cells from a variety of tissues. 
Mitchell et al. (2014) first isolated PICs using 0.15%/g Pronase before 
purification, whilst subsequent  studies used 2 µg/ml collagenase A, 2.4U/ml 
dispase I and 10ng/ml DNase I (Pannérec et al. 2013) or 100 mg/ml collagenase A 
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and 3mg/ml of dispase I (Lewis et al. 2014). Cells obtained by this method can be 
further purified using an enrichment protocol. 
Affinity based separation methods utilize known surface markers of target stem 
cell populations, applying antibodies to label them with either magnetic or 
fluorescent tags. Fluorescence activated cell sorting (FACS) labels target cells 
with antigen specific fluorescent tags, and sorts them based on fluorescent signal 
and light scattering by flow cytometry. Similarly, Magnetic activated cell sorting 
(MACS) labels cells with an antibody coated magnetic bead. When passed 
through a magnetic field, any magnetically labelled cells are captured, and 
unwanted cells discarded. MACS purity is ~75% and allows for a higher output 
and faster separation of ~10
11 
cells/hour compared to 10
7
 cells/hour using FACS 
(Zhu et al. 2013).Furthermore, MACS sorting is less stressful on the cells than 
FACS with improved cell viability post-sorting (Li et al. 2013). PICs have 
previously been isolated by FACS (Mitchell et al. 2010, Pannérec et al. 2013) for 
negative expression of CD45 and TER119 and positive expression of Sca-1 and 
CD34.
  
Our group isolated pPICs via MACS for CD34 positive expression and 
CD45 negative expression (Lewis et al. 2014). 
Ordinarily, ASCs are cultured at 37°C in 5% CO2 to mimic conditions within the 
mammalian body. Cell culture treated flasks/plates are coated with a substrate 
such as gelatin to aid cell attachment prior to plating in growth media. Growth 
media are specific for each ASC cell type, and traditionally contain media 
supplements and growth factors known to encourage proliferation and/or maintain 
pluripotency.  A number of ASC populations isolated from either skeletal or 
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cardiac muscle have been cultured in vitro long term including eCSCs, which 
have a PD of ~22 hours and can proliferate over 65 passages (Ellison et al. 2011).  
It has not yet been shown that murine PICs can be propagated and maintained in 
culture, or if they express stem cell properties. For the first time, this study 
characterises the phenotype and in vitro characteristics of murine PICs to answer 
the following: 
a) Can they be propagated in culture long term? 
b) Do they display stem cell characteristics of self-renewal and clonogenicity?  
 
SELF-RENEWAL AND CLONOGENICITY OF PICS IN VITRO 
 
82 
 
4.2 Methods 
PICs were isolated and cultured as described (see Sections 2.5.1 and 2.6) and their 
phenotype confirmed and further characterised by immunocytochemistry, flow 
cytometry and qRT-PCR.  
4.2.2 Immunocytochemistry of cytospin slides 
Immunocytochemistry was conducted as per methods (Section 2.4). Antibodies 
used and their applications are listed in table 4.1. 
Table 4.1  Antibodies used in immunocytochemistry of cytospin slides. 
Primary 
Antibody 
Dilution Incubation Secondary Antibody 
Sca-1 
(Abcam) 
1/50 1 hour at 37° 
Alexa Fluor 488  
Donkey anti-Rat 
(Stratech) 
PW1 
(Gifted by David 
Sassoon, Inserm, 
Paris) 
1/3000 1 hour at 37° 
Cy 3 
Donkey anti-Rabbit 
(Stratech) 
Sox2 
(Santa Cruz) 
 
1/50 1 hour at 37° 
Dylight 488  
Donkey anti-Goat 
(Stratech) 
Nanog 
(Abcam) 
1/50 1 hour at 37° 
Alexa Fluor 488  
Donkey anti-Rabbit 
(Stratech) 
Oct3/4 
(Santa Cruz) 
 
1/50 1 hour at 37° 
FITC 
Donkey anti-Mouse IgG 
(Stratech) 
Pax7 
(DSHB) 
 
1/50 1 hour at 37° 
FITC 
Donkey anti-Mouse IgG 
(Stratech) 
CD45 
(Santa Cruz) 
1/50 1 hour at 37° 
Alexa Fluor 594 Donkey anti-Rat 
(Stratech) 
 
 
4.2.3 Flow Cytometry  
Flow cytometry was conducted as per methods (Section 2.7), using antibodies and 
relevant controls described in Table 4.2. 
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Table 4.2  Antibodies used in Flow Cytometry 
Antibody Conjugate/ 
Secondary 
Control Dilution Incubation 
PW1 
Inserm, Paris 
Alexa Fluor 488 
Donkey anti-Rabbit 
Stratech 
Alexa Fluor 488  
Donkey anti-Rabbit 
Stratech 
1/20 
15 minutes at 
4°C 
Sca-1 
Miltenyi 
 
FITC conjugated 
FITC Mouse IgG 
Isotype control 
Miltenyi 
1/20 
15 minutes at 
4°C 
Albumin 
Abcam 
 
FITC Conjugated 
FITC Rat IgG 
Isotype control 
Abcam 
1/20 
15 minutes at 
4°C 
CD45 
Biolegend 
 
FITC Conjugated 
FITC Mouse IgG 
Isotype control 
Abcam 
1/20 
15 minutes at 
4°C 
Pdgfrβ 
Abcam 
 
PE Conjugated 
PE Mouse IgG  
Isotype Control 
Abcam 
1/20 
15 minutes at 
4°C 
CXCR4 
Abcam 
 
Alexa Fluor 488 
Donkey anti-Rat 
Stratech 
Alexa Fluor 488 
Donkey anti-Rat 
Stratech 
1/20 
15 minutes at 
4°C 
NG2 
Santa Cruz 
 
Alexa Fluor 488 
anti-Rabbit 
Stratech 
Alexa Fluor 488 
Donkey anti-Rabbit 
Stratech 
1/20 
15 minutes at 
4°C 
Pdgfrα 
Santa Cruz 
 
Dylight 488  
Donkey anti-Goat 
Stratech 
Dylight 488  
Donkey anti-Goat 
Stratech 
1/20 
15 minutes at 
4°C 
CD146 
RnD 
 
FITC Donkey anti-
Mouse IgG 
Stratech 
FITC Donkey anti-
Mouse IgG 
Stratech 
1/20 
15 minutes at 
4°C 
c-kit 
Santa Cruz 
 
Alexa Fluor 488 
Donkey anti-Rabbit 
Stratech 
Alexa Fluor 488 
Donkey anti-Rabbit 
Stratech 
1/20 
15 minutes at 
4°C 
CD34 
eBioscience 
FITC Conjugated 
FITC Rat IgG isotype 
Control 
Abcam 
1/20 
15 minutes at 
4°C 
CD31 
Miltenyi 
 
PE Conjugated 
PE Rat IgG Isotype 
Control 
Miltenyi 
1/20 
15 minutes at 
4°C 
CD31 
eBioscience 
FITC Conjugated 
FITC Rat IgG isotype 
Control 
Abcam 
1/20 
15 minutes at 
4°C 
Pax7 
DSHB 
FITC Donkey anti-
Mouse IgG 
Stratech 
FITC Donkey anti-
Mouse IgG 
Stratech 
1/20 
15 minutes at 
4°C 
c-kit 
Miltenyi 
PE Conjugated 
PE Rat IgG isotype 
Control 
Miltenyi 
1/20 
15 minutes at 
4°C 
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4.2.4 qRT-PCR 
qRT-PCR was conducted as per methods (Section 2.8), using primers listed in 
Table 4.3. 
Table 4.3  Primer sequences  
Gene Accession Number Forward Reverse 
Sox2 NM_011443.3 CACAACTCGGAGATCAGCAA CTCCGGGAAGCGTGTACTTA 
Oct3/4 NM_013633.2 CCAATCAGCTTGGGCTAGAG CTGGGAAAGGTGTCCCTGTA 
Nanog NM_028016.2 TACCTCAGCCTCCAGCAGAT GTGCTGAGCCCTTCTGAATC 
PW1 NM_008817.2 TTTTGGTGAGTTGCTTGCAG ACGTTCTTGGGCATAACTGG 
CD34 NM_133654.3 GGGTAGCTCTCTGCCTGATG TCTCTGAGATGGCTGGTGTG 
SCA1 NM_001271446.1 CCATCAATTACCTGCCCCTA AAGGTCTGCAGGAGGACTGA 
CD45 NM_011210.3 CCTGCTCCTCAAACTTCGAC GACACCTCTGTCGCCTTAGC 
CD146 NM_023061.2 GAGCTCATCTCCCCTCACAG TCCTGACCACTACCCAAAGG 
GAPDH NM_008084.2 ACCCAGAAGACTGTGGATGG CACATTGGGGGTAGGAACAC 
β-actin NM_007393.3 AGCCATGTACGTAGCCATCC TCTCAGCTGTGGTGGTGAAG 
 
4.2.5 Self-renewal 
To determine self-renewal, C9 PICs were cultured (see Section 2.6) for 20 
passages, with their clonogenicity (see Section 2.6.1) and population doubling 
time (see Section 2.6.2) calculated every 5
th
 passage. Furthermore, their 
morphology was observed and phenotype assessed throughout their time in 
culture by qRT-PCR (at P1, P10 and P20) and FC (at P2 and P20). 
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4.2 Results 
4.2.1 Isolation and Characterisation of CD45
-
 /Sca-1
+
 PICs  
Murine hind limb muscle obtained from both legs of 21 day old mice was 
enzymatically digested before the CD45
-
/Sca1
+
 fraction was obtained through 
MACS technology (See section 4.2.1), ~ 800,000 CD45
-
/Sca-1
+
 cells were 
obtained per mouse.  
Isolated cells were plated in 35mm dishes in one of 2 medias: Promocell complete 
skeletal muscle media or a defined stem cell growth media, as optimised by our 
laboratory for the expansion of eCSCs. After 6 days cells cultured in Promocell 
media had a >50% decrease in number since plating, whilst in contrast, the cells 
plated in defined stem cell growth media had increased 10-fold to ~1.5x10
5
 cells 
per dish (Figure 4.1). 
CD45
-
/Sca-1
+
 cells cultured in growth media contained a high number of small, 
round and bright cells with a very high nucleus to cytoplasmic ratio, which 
adhered to the culture dish whilst those cultured in Promocell media did not show 
any small rounded, bright cells and appeared flattened  (Figure 4.2). 
Our defined growth medium was chosen for all subsequent culture due to the 
growth rate and morphology of the cells observed. There was an initial visual 
increase in the abundance of small, round, bright cells observed between P0 and 
P3 (Figure 4.3) which maintained for the duration of time in culture. These small 
cells detached quickly when trypsinised with very little cell death occurring at 
each passage.  
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Figure 4.1 PIC population growth in Promocell vs Growth media. Cell 
count at initial plating (D0) and after 6 days (D6) of culture in PIC and Promocell 
growth medias (n=1 culture dish). 
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Figure 4.2  Cell Morphology in Promocell vs Growth Media. Transmitted 
light microscope observation of CD45
-
/Sca-1
+
 cells isolated from 21 day old mice 
after 6 days in culture with A. Promocell media and B. growth media. Scale 
=200µm. 
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Figure 4.3 Cell morphology at P3. Transmitted light microscope observation 
of CD45
-
/Sca-1
+
 cells isolated from 21 day old mice and cultured to P3. Scale 
=200µm. 
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Immunocytochemistry (ICC) of cytospin slides (Figure 4.4), and FC analysis 
(Figure 4.5)  of P3 cells from 21 day old mice,  confirmed the isolated cells were 
CD45
-
/Sca-1
+
. In agreement with PIC phenotype, cells were also confirmed as 
being Pax-7
- 
and PW1
+
, and are thereafter referred to as ‘PICs’.  
To further elucidate the phenotype of PICs, an array of markers previously 
described in PIC populations (Figure 4.6) and other muscle related cells (Figure 
4.7) was carried out at P4.  Results showed PICs did not express endothelial 
markers CD31 or CD146, nor pericyte markers NG2 and PDGFRβ (< 3%), but 
did express PDGFRα (19%), CD34 (51%) and CXCR4 (59%) as expected based 
on previous studies (Lewis et al. 2014). 
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Figure 4.4  Confirmation of PIC isolation by ICC.  Protein expression of 
CD45
-
/Sca-1
+
 cells by ICC at P3: showing negativity for CD45 (red) (A), 
positivity for Sca-1 (green) (B) and PW1 (red) (C), and negativity for Pax-7 
(green) (D). Nuclei visualised with DAPI (blue). Scale =50µm. 
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Figure 4.5 Confirmation of PIC isolation by FC. FC analysis of CD45
-
/Sca-
1
+
 cells at P3: showing positivity for PW1 (A) and Sca-1 (B), and negativity for 
CD45 (C) and Pax-7 (D). 
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Figure 4.6 Flow Cytometry analyses for known PIC markers. FC analysis 
of PICs at P4 for surface marker expression CD34 (A), PDGFRα (B), CXCR4 (C) 
and c-kit (D). 
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Figure 4.7. Flow Cytometry analysis for non-PIC markers. FC analysis of 
PICs at P4 for surface marker expression of CD31 (A), CD146 (B), NG2 (C) and 
PDGFRβ (D).  
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Next, PICs were assessed for markers of stemness and pluripotency (Sox2, Oct3/4 
and Nanog), ICC revealed nuclear staining for all 3 of these markers in > 98% of 
cells at P3 (Figure 4.8). 
In addition, gene transcription was assessed by qRT-PCR; PICs expressed 
transcripts for the PIC markers PW1, Sca-1 and CD34 whilst being negative for 
CD45 (Transcript copy number < 1).  Furthermore, they expressed all three 
transcripts for Sox2 , Oct3/4 and Nanog. PW1 was the most highly expressed with 
a CT (19.9) similar to that of GAPDH (19.8) (see appendix for all CT values). 
Nanog displayed the highest transcript number out of the pluripotency genes 
being 12 times higher than Sox2 and 2 times higher than Oct3/4 (Figure 4.9). 
The levels of transcripts was compared to that of mouse ESCs, which exhibited 
higher levels of the pluripotency markers, comparable levels of Sca-1 and a lesser 
amount of PW1 than seen in PICs (Figure 4.9). 
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Figure 4.8  Pluripotency marker expression in PICs. Expression at P3 of 
pluripotency markers Sox2 (A), Oct3/4 (B) and Nanog (C) as shown in green. 
Nuclei are stained blue by DAPI.  Scale =50µm.  
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Figure 4.9  PIC transcript profile. Transcript analysis by qRT-PCR of PICs 
at P3 (blue) and mouse ESCs (red). Bars represent the transcript copy number 
normalised to GAPDH. Error bars represent the standard deviation of the mean, 
n=triplicate.   
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4.2.2 Single cell derived clonal cell lines from PICs 
Clonogenicity assays were conducted at P5 to allow cells to recover from the 
isolation protocol, and also to activate their proliferation, as described by Smith et 
al. (2014) when isolating and cloning CSCs. Isolated PICs were deposited as a 
single cell/well by serial dilution into 96 well cloning plates (n=3). 34 ±11% of 
single cells (PICs) went on to form clonal populations of small rounded cells, 
which formed aggregates at high density (Figure 4.10). The 12 fastest growing 
and morphologically ‘best’ looking (comprised of small, rounded bright cells) cell 
lines were chosen for further propagation, these were labelled C1 – C12. Of the 
initial 12 clone lines selected, seven (C1, C2, C3, C4, C5, C9 and C12) continued 
to exhibit good morphology (Figure 4.11) and population growth over 3 passages, 
and were used for further analysis.  
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Figure 4.10 Single cell-derived PIC clones. Transmitted light microscope 
observation of a single PIC (top, scale =100µm), and subsequent clonal 
population after 12 days cultured in a 96 well plate (bottom, scale =500µm).  
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Figure 4.11 PIC Clone morphology. Transmitted light microscope 
observation of clonal PIC populations (C1-C12). Scale =200µm. 
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The PW1 expression of each clonal line was evaluated at P2 post-cloning by ICC, 
with all 7 clonal cell lines being positive for PW1 (Figure 4.12). When quantified 
by flow cytometry all clones had >90% expression of PW1. C9 and C12 had the 
highest expression (99%) of PW1, whilst C1 and C3 had the lowest expression at 
94% and 95% respectively (Figure 4.13). 
Sca-1 was also expressed in all clonal lines (Figure 4.14) with the lowest being C3 
(65%) and the highest C12 (97%).  
Transcript profiles of the 7 clonal PIC cell lines was assessed by qRT-PCR and 
compared to un-cloned ‘bulk’ cultured PICs. Levels of PIC specific transcripts 
(PW1, Sca-1 and CD34) remained high in all clones (Figure 4.15) with the 
exception of C1 which had a marked decrease in Sca-1 and CD34. Although bulk 
cultured PICs had a higher copy number PW1, Sca-1 and CD34 than any of the 
clonal cell lines, Clone 9 had the highest expression for both PW1 and Sca-1 with 
values closest to that of bulk PICs.  
Transcript levels of pluripotency genes (Sox, Oct3/4 and Nanog) appeared lower 
in all clonal cell lines than in bulk PICs (statistical analysis not performed as 
results are a triplicate of n=1 for all groups).  Levels of Nanog and Oct3/4 were 
largely comparable between all clonal PICs, however Sox2 detection was 
negligible in all lines except C9 (Figure 4.16).  
Therefore, C9 was selected for further investigation due its comparable 
transcriptome profile to that of bulk PICs; moreover, it displayed high expression 
of Sca-1 and the highest expression of Nanog, Oct/3/4, Sox2 and PW1, than all 
other clones. 
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Figure 4.12 PW1 expression in clones by ICC. Expression of PW1 (red) by 
immunocytochemistry in clonal PIC populations, Nuclei visualised with DAPI 
(blue). Scale=50µm. 
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Figure 4.13 PW1 expression in PIC clones by FC. PW1 expression in clonal 
PIC populations. 
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Figure 4.14 Sca-1 expression in PIC clones by FC. Sca-1 expression in clonal 
PIC populations. 
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Figure 4.15 Transcription of PIC markers in clonal vs bulk PICs. Transcript 
analysis by qRT-PCR of PW1. Sca-1 and CD34 in clonal PICs, compared to bulk 
PICs. Bars represent the transcript copy number normalised to GAPDH. Error 
bars represent the standard deviation of the mean, n=triplicate. 
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Figure 4.16 Transcription of pluripotency genes in clonal vs bulk PICs. 
Transcript analysis by qRT-PCR of Sox2, Oct3/4 and Nanog in clonal PICs 
compared to bulk PICs. Bars represent the transcript copy number normalised to 
GAPDH. Error bars represent the standard deviation of the mean, n=triplicate.   
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4.2.3 Maintaining a clonal cell line. 
The morphology of C9 PICs remained consistently small, round and bright 
(Figure 4.17) with a stable doubling time of 16±3 hours over 20 passages (Figure 
4.18). C9 PICs were passaged every 48 hours which equated to ~64 population 
doublings over 20 passages. C9 PICs were able to produce single-cell derived 
sub-clones with an efficiency of 91±2%, assessed at every 5
th
 passage (Figure 
4.19). Furthermore, they maintained a stable expression of Sca-1 (Figure 4.20) 
and PW1 (Figure 4.21) by FC analysis at P2, P10 and P20. 
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Figure 4.17 C9 morphology over time in culture. Transmitted light 
microscope observation of C9 PICs at P1 (A), P10 (B) and P20 (C). Scale 
=200µm. 
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Figure 4.18 C9 Population doubling time. Doubling time of C9 PICs between 
P1 and P20. Data is mean ±SD, n=3. 
 
 
Figure 4.19 C9 Clonogenicity.  Clonogenicity of C9 PICs at 5 passage 
intervals between P5 and P20. Data is mean ±SD, n=3. 
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Figure 4.20 Sca-1 expression of C9 over time in culture. FC analysis 
showing expression of Sca-1 in C9 PICs at P2 (A), P10 (B) and P20 (C).  
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Figure 4.21 PW1 expression of C9 over time in culture. FC analysis showing 
expression of PW1 in C9 PICs at P2 (A), P10 (B) and P20 (C).  
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To further show the stability of C9 PICs in culture, FACs analysis for surface 
markers previously screened for in bulk PICs was conducted at P2 and P20.  
When compared to bulk PICs; CD34 and CXCR4 expression had increased by ~6% 
and ~20% respectively, whilst C9 PICs no longer expressed PDGFRα. There were 
no notable changes of more than 5% between, P2 and P20 for PIC markers CD34 
(Figure 4.22), PDGFRα (Figure 4.23), CXCR4 (Figure 4.24) and c-kit (Figure 
4.25). Furthermore C9 PICs remained negative for CD31 (Figure 4.26), CD146 
(Figure 4.27), PDGFRβ (Figure 4.28) and NG2 (Figure 4.29).  
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Figure 4.22 CD34 expression over time in culture.  Expression of CD34 in 
C9 PICs by FC at P2 (A) and P20 (B). 
 
 
Figure 4.23 PDGFRα expression over time in culture. Expression of 
PDGFRα in C9 PICs by FC at P2 (A) and P20 (B). 
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Figure 4.24 CXCR4 expression over time in culture. Expression of CXCR4 
in C9 PICs by FC at P2 (A) and P20 (B). 
 
 
Figure 4.25 c-kit expression over time in culture. Expression of c-kit in C9 
PICs by FC at P2 (A) and P20 (B). 
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Figure 4.26 CD31 expression over time in culture. Expression of CD31 in C9 
PICs by FC at P2 (A) and P20 (B). 
 
 
Figure 4.27 CD146 expression over time in culture. Expression of CD146 in 
C9 PICs at P2 (A) and P20 (B). 
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Figure 4.28 PDGFRβ expression over time in culture. Expression of 
PDGFRβ in C9 PICs by FC at P2 (A) and P20 (B). 
 
 
Figure 4.29 NG2 expression over time in culture. Expression of NG2 in C9 
PICs by FC at P2 (A) and P20 (B). 
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The stability of the transcriptome profile of C9 PICs was assessed by qRT-PCR at 
P1, P10 and P20. PW1, Sca-1, CD34, Oct3/4 and Nanog were all expressed 
throughout the 20 passages, with slight fluctuations in transcript levels at each 
passage.  Sox2 however had dropped below a copy of number of 1 by P10 
indicating the transcript was no longer present (Figure 4.30). 
 
 
  
Figure 4.30 C9 Transcription profile over time in culture. Transcriptome 
analysis by qRT-PCR of C9 PICs at P1, P10 and P20. Bars represent the transcript 
copy number normalised to GAPDH. Error bars represent the standard deviation 
of the mean, n=triplicate.  
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Sub clones of C9 PICs generated at P10 (C9A, C9B, C9C) were found to have a 
similar morphology to that of C9 PICs from which they originated (Figure 4.31), 
and were propagated for further investigation. 
Sub-clones had a Sca-1 expression of 95±1% by FC at P2 (Figure 4.32) and a 
PW1 expression of 99±0% (Figure 4.33). There was no change in Sca-1 (Figure 
4.34) or PW1 (Figure 4.35) between bulk, clonal and sub-clonal PICs. 
The transcriptome profile of C9A, C9B and C9C was analysed by qRT-PCR at P2 
post cloning: CD34, and PW1 expression was similar in C9 and sub-clones whilst, 
supporting the FC data, Sca-1 was increased in sub-clones over the original C9 
population. The pluripotency genes Sox2 and Oct3/4 were not detectable in sub-
clones and levels of Nanog were greatly reduced (Figure 4.36). 
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Figure 4.31 C9 Sub-clone Morphology. Morphology of sub-clones at P1, 
generated from C9 at P10: C9A (A), C9B (B), and C9C (C). Scale = 200um. 
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Figure 4.32 Sca-1 expression in C9 sub-clones. Expression of Sca-1 by FC at 
P2 of C9A (A), C9B (B), and C9C (C). 
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Figure 4.33 PW1 expression in C9 sub-clones. Expression of PW1 by FC at 
P2 of C9A (A), C9B (B), and C9C (C). 
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Figure 4.34 Sca-1 expression in bulk vs. clonal vs. subclonal PICs. Sca-1 
expression by FC in bulk, clonal and sub-clonal PICs. Bars represent the mean for 
each group. Error bars represent the standard deviation of the mean, bulk n=1, 
clones, n=7, sub-clones n=3.  
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Figure 4.35 PW1 expression in bulk PICs vs clones vs sub-clones. PW1 
expression by FC in bulk, clonal and sub-clonal PICs. Bars represent the mean for 
each group. Error bars represent the standard deviation of the mean, bulk n=1, 
clones, n=7, sub-clones n=3.  
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Figure 4.36 Transcription profile of C9 PIC sub-clones vs C9 PICs. 
Transcriptome analysis by qRT-PCR analysis of sub-clones (C9A-C) compared to 
original C9 PICs. Bars represent the transcript copy number normalised to 
GAPDH. Error bars represent the standard deviation of the mean, n=triplicate. 
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When all data were merged to form one group for clones, one group for subclones 
and bulk PICs, there seemed to be a reduction in transcript levels for all 3 
pluripotency genes with each cloning stage, with only Nanog remaining above a 
copy number of 1 in all groups. PIC markers PW1, CD34 and Sca-1 were present 
in all PIC populations and whilst there was some fluctuation between groups, no 
obvious trend was observed (Figure 4.37). 
 
 
 
Figure 4.37 Transcription profile of bulk PICs vs clones vs sub-clones. 
Transcriptome analysis by qRT-PCR of bulk (n=1 in triplicate), clones (n=7) and 
sub-clones (n=3). Bars represent the transcript copy number normalised to 
GAPDH. Error bars represent the standard deviation of the mean. 
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4.4 Discussion 
The main findings of this study are: 
1. PICs were successfully isolated from murine hind-limb tissue. 
2. PICs can be propagated in culture for long periods whilst maintaining a 
stable phenotype. 
3. PICs are clonogenic and self-renewing in vitro. 
4. PICs express markers of pluripotency. 
4.4.1 Isolation and characterisation of PICs 
The confirmation of isolated PICs as CD45
-
/Sca-1
+
/Pax7
-
/PW1
+
 by FC analysis 
and ICC, whilst being morphologically small, round and bright, is consistent with 
that previously described (Mitchell et al. 2010; Pannérec et al. 2013; Lewis et al. 
2014). PICs in this study were not sorted for CD34
+
 expression, unlike in previous 
studies (Mitchell et al 2010; Pannérec et al 2013; Lewis et al 2014) as MACs 
sorting does not allow for 2 positive sorts. In line with this, FC analysis confirmed 
they contained a mix of CD34
-
 and CD34
+
 cells. 
A low percentage of bulk PICs expressed PDGFRα, this is in contrast to that 
described previously in murine PICs  and pPICS (33%) (Pannérec et al. 2013; 
Lewis et al. 2014), which both contain PDGFRα+ and PDGFRα- cells. 
Furthermore, C9 PICs didn’t express PDGFRα which suggests the process of 
cloning selected for a PDGFRα- population. In light of this, C9 PICs are distinct 
from the FAP population described as CD45
-
/Sca-1
+
/CD34
+
/ PDGFRα+ (Uezumi 
et al. 2010; Joe et al. 2010; Pannérec et al. 2013), whilst in vitro characteristics of 
SELF-RENEWAL AND CLONOGENICITY OF PICS IN VITRO 
 
126 
 
previously described PICs have contained a subset of FAPs (Mitchell et al. 2010; 
Pannérec et al. 2013; Lewis et al. 2014)(Figure 4.38). 
 
 
Figure 4.38 Overlap of previously described PIC populations. 
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The protein expression of CXCR4 in this study was similar to levels reported in 
pPICs (59% vs 55%) (Lewis et al. 2914). CXCR4 (C-X-C chemokine receptor 
type 4), is a receptor for SDF-1 (stromal-derived-factor-1) and is implicated in the 
homing of multiple ASC populations including: HSC’s (Sharma et al. 2011), 
adipose derived stem cells (Stuermer et al. 2015), MSC’s (Shi et al. 2007) and 
eCSCs (Ellison et al. 2013). PICs also express the gene for CXCR4 but at a lower 
intensity than SC’s (Pannérec et al 2013). Interestingly, C9 PICs showed 
increased positivity for CXCR4 over their un-cloned bulk counterparts, suggesting 
that the process of cloning selected for a CXCR4
+ 
population. It is not known if 
this was true for all clone lines, however an increase in CXCR4 has been shown to 
increase clonogenicity of neuroblastoma cell lines in vitro (Liberman et al. 2012).  
In agreement with Lewis et al. (2014) PICs are not of haematopoietic or 
endothelial lineage, being negative for CD45 and CD31 and furthermore they are 
distinct from pericytes and adult MABs as they did not express NG2, PDGFRβ or 
CD146. 
4.4.2 PICs can be propagated in vitro 
Previously, Mitchell et al (2010) had reported differentiation of freshly isolated 
PICs with time in culture with 30% of cells expressing MyoD and Pax7 after 4 
days suggesting they had undergone differentiation; however PICs were cultured 
for 3-4 days in BIOAMF-2 media, which is specifically optimized for primary 
culture of human amniotic fluid cells and is not designed to maintain self-renewal.  
This study is the first to show that murine PICS can be propagated and maintained 
in long term culture. The media used in this study is one optimised by our group 
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and has previously been used to culture pPICS (Lewis et al. 2014) and eCSCs 
(Ellison et al. 2013). Indeed, we previously demonstrated pPICs were capable of 
maintaining a stable phenotype and karyotype over 40 passages (Lewis et al. 
2010). The importance of using the correct growth media was further reinforced 
in this study by the growth senescence of PICs when placed in promocell growth 
media. 
Clonal PIC cell lines displayed a similar morphology and phenotype to both bulk 
PICs, and each other, as did their sub-clonal counterparts.  A clonal population 
was chosen for assessment over time in culture to ensure that results were 
characteristic of PICs and were not an artefact of a mixed cell population. C9 was 
subsequently chosen for further analysis due to it being the most similar to the 
transcription profile of non-cloned ‘bulk’ cells, and the phenotype of PICs in 
general.  
The ability to propagate PICs in vitro culture is in contrast to that seen in SCs 
which rapidly lose their self-renewal properties and under-go differentiation 
(Cosgrove et al. 2009). SCs were not isolated during this study. 
4.4.3 PICs are self-renewing and clonogenic  
When propagated in culture PICs displayed characteristics of stem cells: 
clonogenicity and self-renewal.  
PICs demonstrated an ability to form single-cell derived clonal populations; their 
clonal efficiency of ~34% was less than reported in pPICS (53%) (Lewis et al. 
2014), but is within the range previously reported for other adult stem cell 
populations such as porcine skin stem cells (23% - Dyce et al. 2004). Moreover, 
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C9 PICs retained a subsequent clonogenicity of ~91%, substantiating their 
clonogenic properties, and self-renewal ability. This is the first study propagate 
and compare clones, and subsequently sub-clone PICs. 
C9 PICs exhibited a stable PD over 20 passages, demonstrating each generation is 
as proliferative as its predecessor. A shorter PD is indicative of a higher rate of 
proliferation: The PD of murine ESCs is ~10-14 hours (Pauklin et al. 2011), 
porcine iPSCs derived from fetal fibroblasts have a PD of ~17hours (Ezashi et al. 
2009), whilst pPICS have a PD of ~22 hours (Lewis et al. 2014).  
The doubling time of PICs isolated from the mouse (~16 hours) was shorter than 
that reported in pPICs, which could be because a) Murine PICs are more 
proliferative than pPICs or b) The pPIC population was not a clonal cell line, not 
sorted for Sca-1, and therefore heterogeneous. 
In heterogeneous populations, different cell types divide at different rates, 
therefore affecting the overall doubling time. In contrast C9 PICs were derived 
from a single cell, thus all cells would display a similar rate of proliferation. 
The total number of population doublings over 20 passages was calculated to be 
~64, far surpassing hayflicks limit of 14-28 doublings for cells of murine origin, 
as well as also extending beyond the 40-60 doublings initially reported as the 
maximum in human cells (Hayflick. 1973). 
Importantly, in addition to maintaining their PD, C9 PICs also retained their 
morphology and phenotype over time in culture, displaying comparable levels of 
PW1 and Sca-1 at P2 and P20. Sca-1 and PW1 are both genes associated with 
ASC populations and stemness (Holmes and Stanford 2007; Besson et al. 2011).  
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4.4.4 PICs express markers of pluripotency  
This is the first study to describe the presence of pluripotency markers in murine 
PICS. The levels of pluripotency gene transcripts were lower in PICs than in 
ESCs as expected, although they were still substantial. It was noted that there was 
a decrease in transcript levels of all 3 pluripotency genes, over time in culture. 
Whether the pluripotent potential of the cells differed with time was not tested.  
Despite these discrepancies, the growth kinetics and morphology did not change. 
This therefore suggests they could be artefacts of the in vitro environment rather 
than an inability of the PICs to self-renew competently. In vivo PICs would 
naturally inhabit a 3D environment interacting with many other cell types. Whilst 
in vitro conditions are optimised to mimic the in vivo environment, ultimately cell 
culture cannot currently provide an identical niche to that in which they naturally 
reside within the body. 
Bulk PICs had the highest number of transcripts for pluripotency markers, 
however bulk PICs were not cultured long term. Therefore, it is not known if PICs 
self-renew more efficiently in a heterogeneous culture.  
In summary, for the first time these data suggest that murine PICs display 
properties of bona fide stem cells being clonogenic and self-renewing in vitro. 
Furthermore, similar to PICs isolated from the pig (Lewis et al. 2014), they 
expressed markers of pluripotency (Nanog, Oct3/4 and Sox2) which is the final 
attribute of a true stem cell. The pluripotent potential of PICs will be investigated 
in the next chapter.  
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5. PICs display multipotent potential 
5.1 Introduction 
Potency (bi-potent, multipotent or pluripotent) is the third measure of stemness 
and can be determined in vitro by inducing differentiation down specific cell 
lineages of the 3 germ layers, using defined culture media.  
Mitchell et al (2010) originally demonstrated that PICs were bi-potent, 
differentiating into both skeletal and smooth muscle in vitro after 24-36 hours in 
myogenic differentiation media (DMEM, 2% horse serum), with approximately 
30% of PICs expressing MHC, whilst the majority went on to express SMA. Our 
group found a similar ratio, with 76% of pPICs differentiating into smooth muscle 
vs. 24% into skeletal muscle (Lewis et al. 2014). Furthermore, Sca-1
Med
 PICs have 
a higher fusion index (40%) than that of Sca-1
High
 PICs (20%) in 1 week old mice. 
This fusion index of 20% in maintained in Sca-1
High
 PICs from adult (7 week old) 
mice (Sca-1
Med
 PICs do not persist into adulthood) (Pannérec et al. 2013). 
Most recently, our group demonstrated that skeletal muscle derived pPICs have 
cardiomyogenic potential, forming cardiospheres that upon further differentiation 
express cTnI and Cx43 (Lewis et al. 2014). Furthermore, pPIC generated 
cardiospheres showed they could also differentiate into endothelial and smooth 
muscle cells (Lewis et al. 2014), similar to eCSCs that can generate all 3 cardiac 
lineages (Ellison et al. 2013). 
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In addition to their myogenic potential, PICs also demonstrate an adipogenic 
differentiation potential of 60% in vitro (Pannérec et al 2013), with lipid droplet 
formation also seen in pPICs (Lewis et al. 2014).  
On further investigation, Pannérec et al (2013) reported that PDGFRα+ PICs were 
capable of adipogenic differentiation but did not display myogenic differentiation 
potential, whilst PDGFRα- PICs had myogenic potential but lacked adipogenic 
differentiation capability.  These findings are in agreement with previous data that 
PDGFRα+ cells in adult muscle interstitium are fibro-adipogenic progenitor (FAP) 
cells (Uezumi et al. 2010; Joe et al. 2010). 
Other muscle derived progenitors, including satellite cells, have previously been 
reported to undergo osteogenic differentiation in vitro (Asakura et al. 2001, Oishi 
et al 2013). Similarly to adipogenic differentiation, Oishi et al (2013) identified 
PDGFRα+ cells as having osteogenic differentiation capabilities, whilst CD56+ 
cells did not. 
All three of these cell types (myogenic, adipogenic and osteogenic) originate from 
the mesoderm layer and what has not yet been described is the ability of PICs to 
differentiate the trans- germ layer into cells types from the other two germ layers, 
the endoderm and the ectoderm. The endoderm gives rise to gastrointestinal and 
the respiratory tract as well as pancreatic beta cells and hepatocytes, whilst the 
third primary germ layer, the ectoderm, gives rise to cells of the nervous system, 
skin and teeth amongst others (Gao et al. 2013).  
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PICs express the pluripotency markers Oct3/4, Nanog and Sox2 (Figure 4.8; 
Lewis et al. 2014); therefore for the first time, this study will assess the trans-germ 
layer differentiation potential and potency of PICs both in vitro and in vivo. 
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5.2 Methods 
5.2.1 Directed Differentiation in vitro  
C9 PICs (P5) were plated in dishes and chamber slides as described (see Table 2.3) 
at ~20,000 cells per cm
2
. Undifferentiated C9 PICs (P5) were used as controls for 
all in vitro differentiation experiments. Chamber slides were stained by ICC, and 
cell pellets were analysed by qRT-PCR as previously described in the methods 
(Section 2.4 and 2.8 respectively). Antibodies and their applications are listed in 
Table 5.1; Primers are listed in Table 5.2. 
For ICC: the number of positive cells/nuclei was counted and expressed as a 
percentage of total nuclei (n=100 nuclei counted per marker) 
For qRT-PCR: Copy number normalised to GAPDH and βactin, and fold change 
over undifferentiated PICs was calculated as described (see Section 2.8). 
Myogenic differentiation 
Once cells achieved 80% confluency, normal growth media was changed for 
myogenic differentiation medium (Table 2.4). After 5 days chamber slides were 
fixed for ICC staining of MHC, α-sarc and SMA. Cell pellets made from the 
10cm dishes, were pooled and analysed by qRT-PCR for the same markers. 
Cardiomyogenic differentiation 
Cardiospheres were formed (see Section 2.6.3) prior to transfer to dishes for 
cardiomyogenic differentiation. After 14 days in cardiomyogenic differentiation 
medium (Table 2.4); chamber slides were fixed for ICC staining for Cx43, cTnI 
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and Desmin. Cell pellets made from the 10cm dishes, were pooled and analysed 
by qRT-PCR for Cx43, cTnI and α-sarc. 
Adipogenic differentiation 
After 14 days in adipogenic differentiation media (Table 2.4) cells were fixed for 
histological Oil Red O staining: Fixed chamber slides were immersed in 
Propanediol (Sigma) for 5 minutes at RT followed by Oil red O (Sigma) for 8 
minutes at 60°C.  This was again rinsed in Propanediol for a further 5 minutes, 
followed by running water for 5 minutes. Cells were then counter stained using 
Haematoxylin (Sigma) for 3 minutes at RT and rinsed in running water for 5 
minutes before mounting with vectashield™ (Vector laboratories).  
Endothelial differentiation 
After 7 days in endothelial differentiation medium (Table 2.4); chamber slides 
were fixed for ICC staining of CD31, Cd34, CD146 and vWF. Cell pellets made 
from the 10cm dishes, were pooled and analysed by qRT-PCR for the same 
markers. 
Hepatic differentiation 
After 14 days in hepatic differentiation medium (Table 2.4); chamber slides were 
fixed for ICC staining of CK18, CK19, HNF1α and Albumin. 1 x 10cm dish was 
used for flow cytometry (see Section 2.7) to detect Albumin Expression (Abcam; 
1:20 dilution). Cell pellets made from 3 x 10cm dishes, were pooled and analysed 
by qRT-PCR for the same markers. 
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Neurogenic differentiation 
After 14 days in hepatic differentiation medium (Table 2.4); chamber slides were 
fixed for ICC staining of ChAT, β-3 tubulin, GFAP and γ-Enolase. Cell pellets 
made from 3 x 10cm dishes, were pooled and analysed by qRT-PCR for the same 
markers. 
Table 5.1  Directed Differentiation: Immunocytochemistry Antibodies  
Primary Antibody Dilution Incubation Secondary Antibody 
α-sarc 
(Sigma) 
1/50 1 hour at 37° 
Dylight 594  
Donkey anti-Mouse IgM (Stratech) 
MHC 
(Sigma) 
1/50 1 hour at 37° 
Cy3  
Donkey anti-Mouse IgG (Stratech) 
SMA 
(Sigma) 
1/500 1 hour at 37° 
Cy3  
Donkey anti-Mouse IgG (Stratech) 
Cx43 
(Cell Signalling) 
1/50 1 hour at 37° Alexa Fluor 488  
Donkey anti-Rabbit (Stratech)  
cTnI 
(Santa Cruz) 
1/50 1 hour at 37° Alexa Fluor 488  
Donkey anti-Rabbit (Stratech) 
Desmin 
(Santa Cruz) 
1/50 1 hour at 37° FITC  
Donkey anti-Mouse IgG (Stratech) 
CD31 
Santa Cruz 
1/50 1 hour at 37° Dylight 488  
Donkey anti-Goat (Stratech) 
vWF 
Millipore 
1/50 1 hour at 37° Alexa Fluor 488  
Donkey anti-Rabbit (Stratech) 
CD34 
Santa Cruz 
1/50 1 hour at 37° Dylight 488  
Donkey anti-Goat (Stratech) 
CD146 
RnD 
1/50 1 hour at 37° FITC  
Donkey anti-Mouse IgG (Stratech) 
CK18 
Abcam 
1/50 1 hour at 37° FITC  
Donkey anti-Mouse IgG (Stratech) 
CK19 
Santa Cruz 
1/50 1 hour at 37° Dylight 488  
Donkey anti-Goat (Stratech) 
HNF-1α 
Santa Cruz 
1/50 1 hour at 37° Alexa Fluor 488  
Donkey anti-Rabbit (Stratech) 
Albumin 
Abcam 
1/50 1 hour at 37° FITC conjugated 
ChAT 
Abcam 
1/50 1 hour at 37° 
Alexa Fluor 488  
Donkey anti-Rabbit (Stratech) 
GFAP 
Dako 
1/50 1 hour at 37° 
Alexa Fluor 488 
Donkey anti-Rabbit (Stratech) 
β3-Tubulin 
Abcam 
1/50 1 hour at 37° 
FITC  
Donkey anti-Mouse IgG (Stratech) 
γ-Enolase 
Santa Cruz 
1/50 1 hour at 37° 
Dylight 488  
Donkey anti-Goat (Stratech) 
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Table 5.2  Directed Differentiation: Primer sequences  
Gene Accession Number Forward Reverse 
α-sarc NM_009606.2|  AAGTGCGACATCGACATCAG AAGTGCGACATCGACATCAG 
MHC NM_001039545.2 CCAAGCTGACCAAGGAGAAG CCAAGCTGACCAAGGAGAAG 
SMA NM_007392.3 GCTGTCCCTCTATGCCTCTG GAAGGAATAGCCACGCTCAG 
Cx43 NM_010288.3 GTGGCCTGCTGAGAACCTAC GAGCGAGAGACACCAAGGAC 
cTrI NM_009406.3 GAAGCAGGAGATGGAACGAG TTAAACTTGCCACGGAGGTC 
CD31 NM_001032378.1 GCCTCACCAAGAGAACGGAAGGC TGGGCCTTCGGCATGGAACG 
vWF NM_011708.4 TGCCCTTGTGTGTGCACGGG GTACCCTGGCTGCTGCACCG 
CD146 NM_023061.2 GAGCTCATCTCCCCTCACAG TCCTGACCACTACCCAAAGG 
Ck18 NM_010664.2 CGAGGCACTCAAGGAAGAAC CTTGGTGGTGACAACTGTGG 
Ck19 NM_008471.2 CTCGGATTGAGGAGCTGAAC TCACGCTCTGGATCTGTGAC 
Albumin NM_009654.3 GACAAGGAAAGCTGCCTGAC TTCTGCAAAGTCAGCATTGG 
HNF1α NM_009327.3 ACTTGCAGCAGCACAACAT GAATTGCTGAGCCACCTCTC 
β-3-tubulin NM_023279.2 CATGGACAGTGTTCGGTCTG TGCAGGCAGTCACAATTCTC 
ChAt NM_009891.2 GTAACAGCCCAGGAGAGCAG AGGTGTTGCATGCACTGAAG 
ENO2 NM_013509.2 TCTATCGCCACATTGCTCAG AGGGTGTGGTACACCTCTGC 
GFAP NM_001131020.1 CACGAACGAGTCCCTAGAGC ATGGTGATGCGGTTTTCTTC 
GAPDH NM_008084.2 ACCCAGAAGACTGTGGATGG CACATTGGGGGTAGGAACAC 
β-actin NM_007393.3 AGCCATGTACGTAGCCATCC TCTCAGCTGTGGTGGTGAAG 
 
5.2.2 Teratoma assay  
Cells were injected in 10μl of 70% Matrigel (Sigma) with PBS under the kidney 
capsule of mice for tumour formation (see Section 2.9). PICs were labelled with 
GFP as per methods (Section 2.6.5). Groups were as follows: 
Group A – SHAM - no cells (n=2). 
Group B – 1 x 106 GFP PICs (n=3). 
Group C – 5 x 105 GFP PICs/ 5 x 105 ESCs (n=3). 
Group D – 1 x 106 ESCs (n=2). 
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Teratomas’ were stained as previously described (see Section 2.3) for lineage 
specific antibodies (Table 5.3). 
Table 5.3  Table of antibodies used in IHC of teratomas  
Primary Antibody Dilution Incubation Secondary Antibody 
GFP 
(Abcam) 
1/50 1 hour at 37° 
Alexa Fluor 488  
Donkey anti-Rabbit (Stratech) 
β-3-Tubulin 
(Abcam) 
1/50 1 hour at 37° 
Cy3  
Donkey anti-Mouse IgG 
(Stratech) 
Desmin 
(Santa Cruz) 
1/50 1 hour at 37° 
Cy3  
Donkey anti-Mouse IgG 
(Stratech) 
αFP 
( Life Technologies) 
1/50 1 hour at 37° 
Cy3  
Donkey anti-Mouse IgG 
(Stratech) 
SMA 
(Sigma) 
1/500 1 hour at 37° 
Cy3  
Donkey anti-Mouse IgG 
(Stratech) 
GFP 
(Abcam) 
1/50 1 hour at 37° 
HRP 
Donkey anti-Rabbit (Santa Cruz) 
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5.2 Results 
5.2.1 Myogenic differentiation 
Clonal PICs (C9 P10) were placed in myogenic differentiation media: Transmitted 
light observations revealed the formation of elongated myotubes after 24 hours in 
culture, which continued to grow and align themselves to form fibres with 
neighbouring myotubes for the first 5 days in culture (Figure 5.1). At this point 
muscle fibres were observed to spontaneously twitch in vitro without any external 
stimulus (see video). Further culture past day 5 resulted in gradual degeneration of 
fibre structures and cell detachment, probably due to over confluence. 
Cells were fixed at Day 5 for immunofluorescent (IF) staining to determine the 
fibre type using antibodies against myosin heavy chain (MHC) and alpha-
sarcomeric actin (α sarc) for striated skeletal muscle, and smooth muscle actin 
(SMA) to detect smooth muscle.  Confocal microscopy of stained fibres showed 
that ~80% of fibres expressed proteins for MHC and α-sarc whilst ~20% 
expressed proteins for SMA (Figure 5.2). It should be noted that SMA is also 
expressed in undifferentiated skeletal myoblasts, however the morphology was 
consistent with smooth muscle cells.  
qRT-PCR analysis of fibres at day 5 for  the corresponding genes for MHC, α-sarc 
and SMA found all 3 were highly expressed (Figure 5.3). The fold change in these 
transcripts (over un-differentiated cells) was calculated, and all showed increases 
over undifferentiated cells (Figure 5.4). 
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Figure 5.1 Cell morphology after myogenic differentiation. Transmitted 
light microscope observations after myogenic differentiation of C9 PICs at day 1, 
4 and 5. Scale = 200µm. 
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Figure 5.2 Myogenic protein expression. IF staining of cells after 5 days of 
directed myogenic differentiation, for MHC (A); red, α-sarc (B); red and SMA 
(C); red. Nuclei were counterstained with DAPI (blue). Scale = 50µm. 
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Figure 5.3 Myogenic transcript expression. Transcript analysis by qRT-PCR 
for muscle markers MHC, α-sarc and SMA after 5 days of directed myogenic 
differentiation of C9 PICs. Bars represent the transcript copy number normalised 
to GAPDH. Error bars represent the standard deviation of the mean, n=triplicate. 
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Figure 5.4  Fold change increase in myogenic marker transcripts. The fold 
change increase in transcript copy number of MHC, α-sarc and SMA after 5 days 
of directed myogenic differentiation of C9 PICs. Bars represent the fold change 
over undifferentiated PICs.  Error bars represent the standard deviation of the 
mean, n=triplicate. 
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To demonstrate cardiomyogenic differentiation potential, firstly cardiospheres 
were generated (see section 2.6.3) from PICs (Figure 5.5). After 14 days of 
cardiomyogenic differentiation, a small number of cells expressed cardiac gap 
junction protein connexin 43 (Cx43), cardiomyocyte marker cardiac troponin I 
(cTnI) and desmin (Figure 5.6). Furthermore, transcripts were detected for Cx43, 
cTnI and α-sarc (Figure 5.7), with an increase in all three transcripts over 
undifferentiated cells (Figure 5.8); however cardiospheres were not seen to beat. 
 
 
Figure 5.5 Cell morphology after cardiosphere formation. Transmitted 
light microscope observations of C9 PICs after cardiosphere formation and 14 
days of cardiomyogenic differentiation. Scale = 200µm. 
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Figure 5.6 Cardiomyogenic protein expression. IF staining of C9 PICs after 
14 days of directed cardiogenic differentiation for cardiac markers Cx43 (A); 
green, cTnI (B); green and Desmin (C); green. Nuclei were counterstained with 
DAPI (blue). Scale = 50µm. 
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Figure 5.7 Cardiomyogenic transcript expression. Transcript analysis of C9 
PICs by qRT-PCR for cardiac markers Cx43, cTnI and α-sarc after 14 days of 
directed cardiomyogenic differentiation. Bars represent the transcript copy 
number normalised to GAPDH. Error bars represent the standard deviation of the 
mean, n=triplicate. 
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Figure 5.8 Fold change increase in cardiomyogenic marker transcripts. 
The fold change in transcript copy number of Cx43, cTnI and α-sarc after 14 days 
of directed cardiomyogenic differentiation of C9 PICs. Bars represent the fold 
change over undifferentiated PICs.  Error bars represent the standard deviation of 
the mean, n=triplicate.  
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5.2.2 Differentiation into other Mesoderm cell types 
To demonstrate an ability to form non-myogenic cells from the mesoderm layer, 
PICs were placed in either adipogenic or endothelial differentiation. 
After 14 days of directed adipogenic differentiation, cells were fixed and stained 
with Oil red O, revealing the formation of lipid droplets (Figure 5.9), however 
true mature adipocyte morphology was not seen. 
 
 
Figure 5.9 Lipid formation following adipogenic differentiation. 
Transmitted light microscope observation of Oil red O staining (red) to detect 
lipid droplets after 14 days of directed adipogenic differentiation. Nuclei are 
counterstained with haemotoxilin (blue). Inset is a x 2 zoom of the cell identified 
by an arrow. 
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After culture in endothelial differentiation media (see section 2.11.4) for 7 days 
PICs formed vessel like structures (Figure 5.10), which when imaged after IF 
staining were found to express proteins for CD31 (98%), vWF (98%), CD34 (99%) 
and CD146 (97%) (Figure 5.11). Transcripts for all four of these markers were 
found by qRT-PCR in differentiated cells (Figure 5.12), however fold changes 
over undifferentiated cells were quite small (Figure 5.13).  
 
 
Figure 5.10 Cell morphology after endothelial differentiation. Transmitted 
light microscope observations after 7 days of endothelial differentiation. Scale = 
100µm. 
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Figure 5.11 Endothelial protein expression. IF staining of C9 PICs after 7 
days of directed endothelial differentiation for surface markers CD31 (A); green, 
CD34 (B); green, vWF (C); green and CD146 (D); green. Nuclei were 
counterstained with DAPI (blue). Scale = 50µm. 
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Figure 5.12 Endothelial transcript expression. Transcript analysis by qRT-
PCR for endothelial markers CD31, vWF, CD146 and CD34 after 7 days of 
directed endothelial differentiation of C9 PICs. Bars represent the transcript copy 
number normalised to GAPDH. Error bars represent the standard deviation of the 
mean, n=triplicate. 
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Figure 5.13 Fold change increase in endothelial marker transcripts. The 
fold change increase in transcript copy number of CD31, vWF, CD146 and CD34 
after 7 days of directed endothelial differentiation of C9 PICs. Bars represent the 
fold change over undifferentiated PICs.  Error bars represent the standard 
deviation of the mean, n=triplicate. 
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5.2.3 Differentiation into hepatic cells of the Endoderm 
To demonstrate cross-lineage differentiation into cell types of the endoderm 
lineage, C9 PICs were placed in hepatic differentiation media for 14 days, after 
which they displayed a change in morphology, however this was not consistent 
with a true hepatic morphology (Figure 5.14). IF Staining showed a small number 
of cells expressed proteins for cytokeratin’s 18 (CK18) (5%) and 19 (CK19) (6%), 
whilst most cells expressed albumin (92%) and hepatic nuclear factor 1-alpha 
(HNF1α) (85%) (Figure 5.15). Furthermore, albumin expression was also 
confirmed by FC (Figure 5.16). It should be noted that HNF1α staining was seen 
in the cytoplasm, and not in the nucleus as expected. Transcript levels of all four 
markers increased slightly after differentiation (Figure 5.17; Figure 5.18).  
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Figure 5.14 Cell morphology after hepatic differentiation. Transmitted light 
microscope observations after 14 days of hepatic differentiation. Scale = 200µm. 
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Figure 5.15 Hepatic protein expression. IF staining of C9 PICs after 14 days 
of directed hepatic differentiation for surface markers CK18 (A); green, CK19 (B); 
green, HNF1α (C);green and Albumin (D); green. Nuclei were counterstained 
with DAPI (blue). Scale = 50µm. 
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Figure 5.16 Albumin expression. FC analysis for albumin after 14 days of 
hepatic differentiation of C9 PICs. Control is undifferentiated C9 PICs. 
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Figure 5.17 Hepatic transcript expression. Transcript analysis by qRT-PCR 
for endothelial markers CK18, CK19, Albumin and HNF1α after 14 days of 
directed hepatic differentiation of C9 PICs. Bars represent the transcript copy 
number normalised to GAPDH. Error bars represent the standard deviation of the 
mean, n=triplicate. 
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Figure 5.18 Fold change increase in hepatic marker transcripts. The fold 
change in transcript copy number of CK18, CK19, Albumin and HNF1α, after 14 
days of directed hepatic differentiation of C9 PICs. Bars represent the fold change 
over undifferentiated PICs.  Error bars represent the standard deviation of the 
mean, n=triplicate. 
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5.2.4 Differentiation into neuronal cells of the Ectoderm  
Finally neurogenic differentiation was selected to determine differentiation 
potential of PICs into cell types of the ectoderm lineage.  
After 14 days of directed neurogenic differentiation a small number of cells 
became spindle shaped with dendritic projections as seen in neuronal cell types 
(Figure 5.19) and were shown to express proteins for choline acetyltransferase 
(ChAT) (54%) , glial fibrillary acidic protein (GFAP)( 96%), class III beta tubulin 
(β-3-tubulin) (98%) and gamma-Enolase (γ-Enolase) (69%) (Figure 5.20). During 
the fixation process, dendritic cells morphology changed as seen in Figure 5.20. 
qRT-PCR revealed high levels of transcripts for these markers (Figure 5.21) and  
moderate (<2) fold changes over undifferentiated controls (Figure 5.22). 
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Figure 5.19 Cell morphology after neuronal differentiation. Transmitted 
light microscope observations after 14 days of neuronal differentiation of C9 PICs. 
Scale = 100µm 
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Figure 5.20 Neuronal protein expression. IF staining of cells of C9 PICs after 
14 days of directed neuronal differentiation for surface markers ChAT (A); green, 
β-3-tubulin (B); green, GFAP (C); green and ENO2 (D); green. Nuclei were 
counterstained with DAPI (blue). Scale = 50µm. 
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Figure 5.21 Neuronal transcript expression. Transcript analysis by qRT-PCR 
for eneuronal markers β-3-tubulin, ChAT, ENO2 and GFAP, after 14 days of 
directed neuronal differentiation of C9 PICs. Bars represent the transcript copy 
number normalised to GAPDH. Error bars represent the standard deviation of the 
mean, n=triplicate. 
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Figure 5.22 Fold change increase in neuronal marker transcripts. The fold 
change in transcript copy number of β-3-tubulin, ChAT, ENO2 and GFAP after 
14 days of directed neuronal differentiation of C9 PICs. Bars represent the fold 
change over undifferentiated PICs.  Error bars represent the standard deviation of 
the mean, n=triplicate. 
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Whilst calculating fold changes in transcripts, a transcript profile of 
undifferentiated PICS revealed that they expressed transcripts for genes associated 
with multiple cell fates (Figure 5.23) with the highest being for myogenic and 
neuronal lineages. 
 
 
 
Figure 5.23 Multi-lineage transcript expression of PICs. Transcript analysis 
by qRT-PCR for: myogenic, cardiomyogenic, endothelial, hepatic, and neuronal 
genes of C9 PICs. Bars represent the transcript copy number normalised to 
GAPDH. Error bars represent the standard deviation of the mean, n=triplicate. 
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5.2.5 Multipotency of PICs in vivo.  
To test whether PICs displayed a similar multipotency in an in vivo environment, 
PICs were transplanted under the kidney capsule alongside ESC’s in a tumour 
formation assay (see section 2.14). To distinguish between cells that arose from 
ESC’s or PICs, C9 PICs (P10) were transduced with a GFP construct prior to 
injection (see section 2.14.1).   
Post-transduction, GFP
+
 PICs demonstrated normal PIC morphology and their 
GFP expression was confirmed by FC at P2-post transduction (Figure 5.24; Figure 
5.25).  Furthermore, GFP
+
 PICs (P8) retained a similar transcript profile to their 
non-GFP
+
 counterparts (Figure 5.26). GFP
+ 
PICs were propagated for 8 passages 
to obtain enough cells to perform the assay. Mouse ESC’s were cultured feeder-
free prior to transplantation to prevent MEF contamination (Figure 5.27). 
Mice injected with PBS (no cells), and those injected with only GFP
+
 PICs did not 
form a tumour demonstrating that PICs are not tumorigenic. In contrast mice 
injected with ESC’s, and those injected with a mix of ESCs and GFP PICs 
displayed hair loss, and tumour formation (Figure 5.28). Tumours contained a 
variety of cells with different morphologies (Figure 5.29). 
Upon staining, ESC-only derived tumours did not contain any GFP whilst 
tumours formed from co-cultures of ESC’s and GFP+ PICS did (Figure 5.30). 
GFP was co-localised with cells from all 3 germ layers (Figure 5.31, denoted by 
arrows), however the majority of GFP
+
 cells expressed mesodermal markers (not 
quantified). 
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Figure 5.24 GFP
+
 PIC morphology. Transmitted light microscope observation 
(A), fluorescence (B) and merged image (C) of GFP
+
 transfected C9 PICs. Scale = 
200µm. 
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Figure 5.25 GFP expression of transfected PICs. FC analysis of GFP 
expression in transfected C9 PICs.  
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Figure 5.26 Transcription profile of GFP transfected PICs. Transcript 
analysis by qRT-PCR of GFP
+
 PICs (P8) vs. C9 PICs (P10). Bars represent the 
transcript copy number normalised to GAPDH. Error bars represent the standard 
deviation of the mean, n=triplicate.   
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Figure 5.27 ESC morphology. Transmitted light microscope observations of 
ESCs colonies prior to transplantation. Scale = 100µm 
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Figure 5.28 Teratoma formation in mice.  Hair loss and teratomas viewed on 
the kidney of mice after 4 weeks. No teratomas found in SHAM (n=2) or PIC only 
(n=3) treated animals. Hair loss and teratoma formation seen in PIC/ESC (n=3) 
and ESC only (n=2) treated animals. 
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Figure 5.29 Tumour morphology. Variety of morphologies seen in teratomas; 
visualised by haematoxylin and eosin staining.  Scale = 200μm (top left) and 
20μm in all other images. 
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Figure 5.30 GFP staining of teratomas. No GFP was detected in teratomas 
generated in ESC only treated mice by DAB (A) or IHC (B); green. GFP was 
detected by DAB staining (C) and IHC (D); green in tumours from GFP
+
 
PIC/ESC treated mice. Nuclei were counterstained with DAPI (blue), scale = 
100μm. 
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Figure 5.31 Teratomas from PIC/ESC treated mice display GFP
+
 cells 
from the 3 germ layers. GFP staining (green) by IHC co-expressed (arrows) with 
αFP (A); red, β3-tubulin (B); red, DESMIN (C); red and SMA (D); red. Nuclei 
were counterstained with DAPI (blue), scale = 50μm. Arrows indicate co-
localisation with GFP. 
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5.3 Discussion 
The main findings to emerge from this study are: 
1. For the first time, it is shown that single-cell derived PICs can generate 
both skeletal and smooth muscle in vitro, and display differentiation 
potential into cardiomyocytes. 
2. PICs can be driven to express proteins and transcripts of multiple cell 
types from the mesoderm. 
3. PICs display multipotent potential expressing proteins and transcripts from 
cells of the 3 germ layers in vitro and in vivo, but are primarily driven 
towards a mesodermal and specifically skeletal muscle lineage.  
4. PICs are not tumorigenic. 
5.3.1 PICs can generate skeletal, cardiac and smooth muscle  
Mitchell et al (2010) previously described PICs giving rise to new muscle fibres 
in vivo, which was the cell fate of the majority of PICs placed in myogenic 
differentiation media this study. The ratio of skeletal/smooth muscle of 80/20 is 
directly opposite to that found in the previous studies by Mitchell et al. (2010), 
Pannérec et al. (2013) and Lewis et al. (2014), whom all reported that PICs 
predominantly formed smooth muscle in vitro with a fusion index of only 20-30%  
skeletal muscle.  
Both Mitchell et al. (2010) and Pannérec et al. (2013) assessed myogenic 
differentiation after 24-48 hours, once the formation of muscle fibres was 
observed. This study, in line with Lewis et al. (2014) assessed myogenic 
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differentiation after 5 days, however the ratio of skeletal to smooth muscle in 
pPICs was similar to that previously reported in the mouse, and therefore the time 
point of assessment for differentiation would not seem to cause the change in ratio.  
Furthermore, myogenic differentiation of pPICs at P3 and P40 yielded similar 
results and therefore implies that time in culture before differentiation is not a 
factor (Lewis et al. 2014).  
All three previous studies (Mitchell et al.2010; Pannérec et al. 2013; Lewis et al. 
2014) used heterogeneous populations whilst this study used a clonal cell line, this 
study is therefore the first to demonstrate that a single PIC is capable of 
generating both types of muscle. This may also account for the difference in ratio 
with the clonal cell line used displaying an affinity towards skeletal muscle, whilst 
the previously described heterogenous populations harbour cells that form both. 
Aside from the differences in ratio, all studies are in agreement that PICs are 
capable of forming both skeletal and smooth muscle. Importantly, the observation 
of twitching fibres at 5 days of differentiation indicates some functionality of the 
muscle fibres and not just phenotypic and biochemical expression. 
Lewis et al. (2014) demonstrated directed differentiation into a cardiac muscle 
type, with the formation of cardiospheres and cardiomyogenic differentiation. In 
agreement with this, C9 PICs were able to form cardiosphere like aggregates, in 
which a small number were positive for cardiac specific markers (Cx43, cTnI). 
Cx43 is a cardiac gap junction protein, whilst cTnI binds exclusively to actin 
filaments in cardiomyocytes, both of these proteins were found post-
differentiation with an increase in transcription over un-differentiated cells, in 
agreement with Lewis et al. (2014). However, cardiospheres in this study were not 
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seen to beat, and the low expression of Cx43 would suggest sufficient gap 
junctions had not formed between cells. Therefore, whilst these data indicate that 
PICs can form cardiomyocyte-like cells, what is not shown is whether they are 
capable of full maturation and functionality of bona fide cardiomyocytes.  This 
lack of maturity could be a result of non-optimal culture conditions, or it may be 
that while PICs can be manipulated to start expressing proteins and transcripts 
associated with cardiomyocytes, intrinsic processes prevent them from full 
differentiation and maturation. 
5.3.2 PICs display differentiation potential into multiple mesodermal cell 
types. 
It was previously shown that PICs have adipogenic differentiation potential 
(Pannérec et al. 2013; Lewis et al. 2014), however previous differentiation was 
solely reported in PDGFRα+ PICs; Sca-1+/PDGFRα+ cells in skeletal muscle have 
been described as adipogenic progenitors (Uezumi et al. 2010). This study used 
clonal PICs, which were negative for PDGFRα by FC analysis, and found that 
while intracellular lipid droplets were observed, cells did not adopt full adipocyte 
morphology. Adipogenic differentiation of pPICs also failed to differentiate fully 
(Lewis et al. 2014) using the same protocol, however ~33% of pPICs expressed 
PDGFRα.  Similarly, PDGFRα+ bone marrow derived cells possess adipogenic 
differentiation potential whilst their PDGFRα- counterparts do not (Rostovskaya 
and Anastassiadis 2012).  
It should be noted that previous studies used different differentiation medias; 
Pannérec et al. (2013) used DMEM, 20% FBS, 0.25µM dexamethasone, 0.5mM 
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isobutylmethylxanthine, 1µg/ml insulin and  5µM troglitazone for 5 days, whilst 
this study and Lewis et al. (2014) used low-glucose DMEM (1 g/l), 10% FBS, 1 
mM dexamethasone, 50 mM hydrocortisone for 7 days. Therefore it may be that 
the protocol was not sufficient to drive full differentiation.   
Further to myogenic and cardiomyogenic differentiation, Lewis et al. (2014) also 
demonstrated endothelial differentiation of cardiospheres derived from pPICs; this 
present study is the first to show direct endothelial differentiation potential. 
However, full differentiation and maturity was not displayed. 
These data suggest that PICs are capable of expressing proteins and transcripts 
from multiple cell types of mesodermal tissues, further work would be needed to 
determine whether they are capable of full differentiation.   
Promisingly other similar skeletal muscle derived stem cells (Sca1
+
/CD45
-
/c-kit
+
) 
have been shown to contribute to all 3 major blood lineages, 3 months post-
transplant after bone marrow irradiation (Jackson et al. 1999). 
A similar ability is also seen in embryonic mesoangioblasts which are capable of 
generating endothelial cells, adipocytes, smooth muscle, osteoblasts, cartilage, 
myotubes and cardiomyocytes in vitro and/or  in vivo (Minasi et al. 2002). 
5.3.3 PICs have multipotent potential in vitro and in vivo  
For the first time, this study demonstrated that PICs can cross the germ layer 
barrier in vitro and contribute to the formation of cell types from all three lineages 
in vivo.  However, whilst these assays suggest a broad differentiation potential 
with up regulation of lineage specific markers for all 3 germ layers, they do not 
demonstrate any functionality of PIC derived cells. In both differentiation assays 
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PICs showed an affinity towards the mesodermal lineage, with higher transcript 
levels and fold changes in vivo, and more GFP
+
 PICs co-expressing mesodermal 
proteins, than endodermal or ectodermal ones in vivo. Furthermore, in vitro 
differentiation resulted in immature cells suggesting that either PICs are not 
capable of full differentiation due to intrinsic processes, or a more efficient 
differentiation protocol is needed to drive full maturation. 
The ability to cross the germ-layer barrier is rare but not unknown in ASC 
populations;  In 2007, Beltrami et al. demonstrated that Oct3/4
+
/Nanog
+
/REX1
+
 
human multipotent adult stem cells (hMASCs), isolated from the liver, heart and 
bone marrow, were capable of cross-lineage differentiation in vitro, each 
demonstrating differentiation into neuron (ectoderm), osteoblast (mesoderm) and 
hepatocyte (endoderm) like cells.  
Similarly, murine PDGFRα+ cardiac resident cCFU stem cells are capable of 
hepatic, endoderm and neuronal differentiation in vitro. Furthermore, when GFP 
labelled cCFUs cells were transplanted alongside unlabelled ESCs under the 
kidney capsule of a mouse, resulting teratomas contained GFP expressing cells 
from all 3 germ layer lineages (Chong et al. 2011).  
Furthermore, Muscle-derived stem cells, obtained via pre-plating, have previously 
been shown to differentiate into hepatocyte-like cells when co-cultured with 
hepatocytes, expressing albumin and HNF1α (Bellayr et al. 2010). When injected 
into liver tissue following partial hepatectomy, they engraft and persist >3 months 
post transplantation (Bellayr et al. 2010). 
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The functionality of cells generated in vitro is hard to determine, and behaviour in 
vitro does not necessarily encapsulate the behaviour of their in vivo counterparts. 
Importantly, Dil labelled adult neural stem cells have shown transdermal 
differentiation, contributing to the formation of chimeric chick and mouse 
embryos, and to cell formation of all 3 germ layers (Clarke et al. 2000). This 
suggests that some ASC populations are capable of generating functional cells of 
multiple lineages.  
In agreement with this study; Pannérec et al. (2013) previously reported that PICs 
express genes for multiple cell fates: PW1 is most widely expressed in skeletal 
muscle and the CNS in postnatal tissue (Besson et al. 2011), interestingly PICs 
demonstrated the highest transcripts for genes associated with these two lineages. 
This raises the question; Are PW1 cells in skeletal muscle the same population as 
found in the CNS? If so, it may be that PICs are primed for multiple cell fates 
dependent of their niche.  
5.3.4 PICs are not tumorigenic 
PICs did not form teratomas in vivo suggesting they have multipotent potential, 
but are not pluripotent, as also seen in PDGFRα+ cardiac resident MSC-like stem 
cells (Chong et al. 2011). Importantly, the inability of PICs to form teratomas 
independently means they are good candidates to be used in cellular therapies.  
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6. PW1 Expression in the Heart 
6.1 Introduction 
PW1 has previously been described as being expressed in the heart during 
embryological development. The heart is the first mesodermal derivative to down 
regulate PW1 between 8-10 days post coitum (p.c), however PW1 is later 
expressed in the atria by 16 days p.c (Relaix et al. 1996; Besson et al. 2011). 
Furthermore, PW1 mRNA has been detected in postnatal mouse hearts, with a 
decrease between 1-4 weeks of age (Finkielstain et al. 2009). 
PW1 expression has previously been shown to overlap with multiple adult stem 
cell populations including Lrg5
+
 intestinal stem cells, spermatogonia, Runx2
+
 
osteogenic progenitors, Sox9
+ 
chondrogenic progenitors, CNS stem cells, HSCs 
and  Epidermal stem cells (Besson et al. 2011). In line with this it would be 
expected that PW1 could also be expressed in adult cardiac stem cell populations: 
Yaniz-Galende et al. (2014) reported that 1.5±1.4 % of murine cardiac cells 
express PW1, located mainly in the epicardium and myocardial interstitium. 
When PW1
+
 cells were isolated from mice 52±22% co-expressed Sca-1 and 
43±14% co-expressed PDGFRα, whilst only ~6±5% expressed c-kit. Furthermore, 
after MI there is a 3 fold increase in the number of PW1
+
 cells.   
This study will quantify overall PW1 expression in cardiac tissue during postnatal 
development and in aged tissue. Furthermore, isolated Sca-1
+
 CSCs will be tested 
for PW1 expression.  
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6.2 Methods 
6.2.1 Quantitative Immunohistochemistry  
Cardiac sections of 3, 10, 21 day and 2 year old mice (n=3 per age group) were 
stained as described in methods (Section 2.3), for antibodies listed in Table 6.1. 
Total nuclei, PW1
+
 nuclei and total cardiomyocytes were counted (n=60 fields of 
view per animal in all groups, 20 per region: endocardium, epicardium and mid-
wall). Cardiomyocytes were identified as having a fully intact cell membrane and 
central nuclei; PW1 staining was nuclear. Standard deviation was calculated from 
the mean of each animal per group (n=3 per group). 
Table 6.1  Antibodies used on paraffin embedded cardiac tissue sections. 
Primary Antibody Dilution Incubation Secondary Antibody 
PW1 
(Gifted by David 
Sassoon, Inserm, Paris) 
1:3000 
Overnight at 
4°C 
Alexa Fluor 488  
Donkey anti-Rabbit (Stratech) 
Laminin 
(Sigma) 
 
1:50 
1 Hour at 
37°C 
Alexa Fluor 594 
Donkey anti-Chicken (Stratech) 
 
CSCs were isolated and cultured as described (see Sections 2.5.2 and 2.6) and 
their phenotype confirmed by immunocytochemistry, flow cytometry and qRT-
PCR.  
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6.2.2 Immunocytochemistry 
Immunocytochemistry was conducted as per methods (Section 2.8) for antibodies 
and their applications listed in table 4.1. The number of positive cells/nuclei was 
quantified as a percentage of total nuclei (n=100 cells per marker). 
Table 6.2  Antibodies used in immunocytochemistry of cytospin slides. 
Primary Antibody Dilution Incubation Secondary Antibody 
Sca-1 
(Abcam) 
1/50 1 hour at 37° 
Alexa Fluor 488 
 Donkey anti-Rat (Stratech) 
PW1 
(Gifted by David 
Sassoon, Inserm, Paris) 
1/3000 1 hour at 37° 
Cy 3  
Donkey anti-Rabbit (Stratech) 
CD45 
(Santa Cruz) 
1/50 1 hour at 37° 
Alexa Fluor 594  
Donkey anti-Rat (Stratech) 
c-kit 
(RnD Systems) 
1/50 1 hour at 37° 
Alexa Fluor 488  
Donkey anti-Rabbit (Stratech) 
LRG5 
(Santa Cruz) 
1/50 1 hour at 37° 
Alexa Fluor 488  
Donkey anti-Goat (Stratech) 
 
6.2.3 Flow Cytometry  
Flow cytometry was conducted as per methods (Section 2.6) using antibodies and 
relevant controls described in Table 6.3. 
Table 6.3  Antibodies used in Flow Cytometry 
Antibody Conjugate/ 
Secondary 
Control Dilution Incubation 
PW1 
(Gifted by David 
Sassoon, Inserm, 
Paris) 
Alexa Fluor 488 
Donkey anti-Rabbit 
(Stratech) 
Alexa Fluor 488  
Donkey anti-Rabbit 
(Stratech) 
1/20 
15 minutes at 
4°C 
CD31 
(eBioscience) 
FITC Conjugated 
FITC Rat IgG isotype 
Control 
(Abcam) 
1/20 
15 minutes at 
4°C 
Pdgfrα 
(Santa Cruz) 
 
Dylight 488  
Donkey anti-Goat 
(Stratech) 
Dylight 488  
Donkey anti-Goat 
(Stratech) 
1/20 
15 minutes at 
4°C 
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6.2.4 qRT-PCR 
qRT-PCR was conducted as per methods (Section 2.8) using the primers listed in 
Table 6.4. 
Table 6.4  Primer sequences  
Gene Accession Number Forward Reverse 
Sox2 NM_011443.3 CACAACTCGGAGATCAGCAA CTCCGGGAAGCGTGTACTTA 
Oct3/4 NM_013633.2 CCAATCAGCTTGGGCTAGAG CTGGGAAAGGTGTCCCTGTA 
Nanog NM_028016.2 TACCTCAGCCTCCAGCAGAT GTGCTGAGCCCTTCTGAATC 
c-kit NM_021099.3 TTATCCTTTAGGCCGTGTGG TGTGGCCCCTTAAGTACCTG 
PW1 NM_008817.2 TTTTGGTGAGTTGCTTGCAG ACGTTCTTGGGCATAACTGG 
CD34 NM_133654.3 GGGTAGCTCTCTGCCTGATG TCTCTGAGATGGCTGGTGTG 
SCA1 NM_001271446.1 CCATCAATTACCTGCCCCTA AAGGTCTGCAGGAGGACTGA 
CD45 NM_011210.3 CCTGCTCCTCAAACTTCGAC GACACCTCTGTCGCCTTAGC 
CD31 NM_001032378.1 GCCTCACCAAGAGAACGGAAGGC TGGGCCTTCGGCATGGAACG 
GAPDH NM_008084.2 ACCCAGAAGACTGTGGATGG CACATTGGGGGTAGGAACAC 
 
 
 
PW1 EXPRESSION IN THE HEART 
 
184 
 
6.2 Results 
6.2.1 PW1 Expression and Distribution in Cardiac Tissue 
First the nuclei expression of PW1 in cardiac longitudinal cross sections was 
assessed at 3, 10 and 21 days and 2 years; PW1
+
 cells were observed in interstitial 
spaces, no cardiomyocyte nuclei expressed PW1 (Figure 6.1). 
The abundance of PW1 expression decreased (p<0.05) during the first 3 weeks 
postnatal, there was no further decrease in aged mice (Figure 6.2). PW1
+
 cells 
were predominantly found in the epicardium in all ages (Figure 6.3). 
In line with this, numbers of PW1
+
 cells per 10
4
 cardiomyocytes reduced between 
3-21 days (Figure 6.4) with greater PW1
+
 cells per cardiomyocyte in epicardial 
regions (Figure 6.5).  
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Figure 6.1 Identification of PW1 in murine cardiac tissue. 10 day old 
mouse epicardium (A), mid-wall (B) and endocardium (C); stained for PW1 (red), 
laminin (green) and nuclei identified by DAPI (blue). Scale = 50µm.  
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Figure 6.2  PW1 abundance in cardiac tissue with age. PW1 expression as a 
percentage of total nuclei in 3, 10 and 21 day, and 2 year old mice. Data is mean 
±SD, n=3 per group. * denotes significant differences (p<0.05) vs 10, 21 day and 
2 year; ** denotes significant differences (p<0.05) vs 21 day and 2 year. 
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Figure 6.3  PW1 abundance in the three cardiac layers. PW1 expression as 
a percentage of total nuclei in 3, 10 and 21 day, and 2 year old mice for each layer: 
epicardium (Epi), endocardium (Endo) and mid-wall (Mid).  Data is Mean ±SD, 
n=3 per group. * denotes significant differences (p<0.05) vs. Endo and Mid for 
that time point.  
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Figure 6.4 The number of PW1 nuclei per 10
4
 cardiomyocytes between 3 
days and 2 years. The number of PW1
+
 nuclei per 10
4
 cardiomyocytes in 3, 10, 
and 21 day and 2 year old mice. Data is Mean ±SD, n=3 per group. * denotes 
significant differences (p<0.05) vs. 10 day, 21 day and 2 year; ** denotes 
significant differences (p<0.05) vs. 21 day and 2 year. 
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Figure 6.5  The number of PW1 nuclei per 10
4
 cardiomyocytes in the three 
cardiac layers. The number of PW1
+
 nuclei per 10
4
 cardiomyocytes in 3, 10 and 
21 day, and 2 year old mice in each layer: epicardium (Epi), endocardium (Endo) 
and mid-wall (Mid).  Data is mean ±SD, n=3 per group. * denotes significant 
differences (p<0.05) vs Endo and Mid for each time point.  
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6.2.2 Isolation of CD45
-
 /Sca-1
+
 cardiac stem cells (CSCs) 
Murine hearts from 21 day old mice were perfused and enzymatically digested. 
The CD45
-
/Sca-1
+
 fraction was obtained via MACS technology and propagated in 
culture (Figure 6.6) (see Methods 2.4.2). 
ICC of cytospin slides of P3 Sca-1
+
 CSCs confirmed they were CD45
-
/Sca-1
+
 and 
were negative for CD45, positive for Sca-1 and also positive for PW1 (Figure 6.7).  
Furthermore, this Sca-1
+
 cell population contained a subset of c-kit+ (7%) and 
LRG5
+
 (15%) cells (Figure 6.8).  
FC analysis quantified PW1 expression (83%) whilst determining the Sca-1
+
 
CSCs were also negative for CD31 and PDGFRα (Figure 6.9). 
The transcriptome profile of P3 Sca-1
+
 CSCs was assessed by qRT-PCR; They 
expressed Sca-1, PW1, CD34 and the pluripotency marker Nanog. Transcript 
levels of Sox2, Oct3/4 and c-kit were negligible (Figure 6.10). 
The clonogenicity of Sca-1
+
 CSCs assessed at P5 was 38±7% (Figure 6.11) and 
they maintained a stable population doubling time of 37±2 hours over 20 passages 
(Figure 6.12). 
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Figure 6.6  Isolated cell morphology. Transmitted light microscope 
observation of CD45
-
/Sca-1
+
 CSC’s isolated from 21 day old mice hearts at P0 (A) 
and P3 (B). Scale =200µm. 
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Figure 6.7  Phenotype by ICC. Expression of CD45
-
/Sca-1
+
 CSCs by ICC at 
P3: showing positivity for Sca-1 (green; A), PW1 (red; B) and negativity for 
CD45 (red; C). Nuclei visualised with DAPI (blue).  Scale =50µm.  
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Figure 6.8  Sca-1
+
 CSCs contain c-kit
+
 and LRG5
+
 fractions. Expression of 
CD45
-
/Sca-1
+
 CSCs by ICC at P3: showing positivity for c-kit (green; A) and 
LRG5 (green; B). Nuclei visualised with DAPI (blue).  Scale =100µm.  
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Figure 6.9  Phenotype by FC. Phenotyping of CD45
-
/Sca-1
+
 cells by FC at P3: 
showing positivity for PW1 (A) and negativity for CD31 (B) and PDGFRα (C). 
Control are cells stained with isotype controls. 
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Figure 6.10  Sca-1
+
/PW1
+
 CSC transcript profile. qRT-PCR of CSCs at P3. 
Bars represent the transcript copy number normalised to GAPDH. Error bars 
represent the standard deviation of the mean, n=triplicate.   
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Figure 6.11 Sca-1
+
/PW1
+
 CSCs are clonogenic. Transmitted light microscope 
observation of a clonal population after 14 days in a 96 well plate. Scale =200µm.  
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Figure 6.12 Sca-1
+
/PW1
+
 CSC population doubling time. Doubling time 
between P1 and P20. Data are the Mean ± SD, n=3. 
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6.3 Discussion 
The main findings that emanated from this study were: 
1. PW1 cells are present in the heart. 
2. PW1+ cells decreased for the first 3 weeks of postnatal development, and 
maintained their number at 2 years. 
3. PW1+ cells are mostly expressed in the epicardium. 
4. CD45-/Sca-1+ CSCs express PW1. 
6.3.1 PW1 expression in the heart 
The expression of PW1 in cardiac tissue and the decline in PW1 abundance over 
the first 3 weeks of postnatal development corroborated previous data; Indeed, 
Finkielstain et al. (2009) reported a ~5 fold decline in PW1 mRNA in mice 
between 1-4 weeks of age, with a lesser ~2 fold reduction seen in rats between 3-9 
weeks. Furthermore, the percentage of PW1
+
 nuclei in the present study was 
similar to that described by Yaniz-Galande et al. (2014). PW1 expression in 
cardiac tissue of aged animals had not previously been described.  Interestingly, 
unlike in skeletal muscle, in the present study PW1 expression was not reduced in 
aged animals. As PW1 marks stem cell populations, it would be expected that the 
abundance of PW1 would mirror the abundance of stem cells in aged tissue.  
6.3.2 PW1 marks CSC populations 
To date the abundance of most cardiac stem/progenitor cells, including Sca-1
+
 
CSCs in aged animals has not been quantified. However, the abundance of c-kit
+
 
CSCs has been shown to increase in aged hearts, with a ~2 fold increase between 
4 and 22 months old rats (Torella et al. 2004); In the present study there was no 
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difference between 21 days and 2 years, however it is possible that PW1 declines 
further than 21 days into adulthood before increasing in aged animals. Further 
time points during adult life would be needed to support this theory.   
Matsuura et al. (2004) reported that Sca-1
+
 cells are found at a frequency of 33 per 
10
4
 cardiomyocytes in 10-12 week old mice. The present study reported ~19 
PW1
+
 nuclei per 1 x 10
4
 cardiomyocytes, at both 21 days and 2 years. Tomita et al. 
(2005) described Sca-1
+
 SP cells in the heart which account for 3.5% of all cells at 
2 days of age. In this present study PW1 was seen in ~0.1% of cells at 3 days. 
These data suggest that not all Sca-1
+
 cells within the heart express PW1. In this 
present study,  PW1 was expressed in 83% of isolated CD45
-
/Sca-1
+
 cells, 
however this was after culture and therefore may not be representative of freshly 
isolated cells and the percentage found in vivo.  
In the present study, Sca-1
+
/PW1
+
 CSCs were low or negative for c-kit expression. 
Matsuura et al. (2004) reported that ~9% of Sca-1 cells from the heart co-express 
c-kit, and this also included CD45
+
 (40%) mast cells. In contrast ~45% of c-kit
+
 
CSCs express Sca-1 (Smith et al. 2014). It was not determined here whether the c-
kit
+
 CSCs express PW1. 
The majority of PW1
+
 cells were situated in epicardial regions; which are similar 
to that reported by Yaniz-Galende et al. (2014). These data support an epicardial 
origin, and could be similar to the previously described Sca-1
+
 cardiac derived 
cCFU population, which similar to PICs in this present study,  demonstrated multi 
lineage differentiation potential in vitro and in vivo (Chong et al. 2011), however 
isolated Sca-1
+
/PW1
+
 CSCs did not express PDGFRα.   
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These data suggests that PW1 does indeed mark a proportion of cardiac 
stem/progenitor cells. However, whether this proportion corresponds to an 
independent population, or is comprised of subsets from multiple populations 
remains to be determined (see Section 7). Indeed, it is known that PW1 marks 
skeletal mesoangioblasts, and may therefore also mark MABs of cardiac origin.  
Isolated Sca-1
+
/PW1
+
 CSCs maintained a stable doubling time over 20 passages 
and were clonogenic, which together with their phenotype suggest the cells 
demonstrated properties of cardiac stem/progenitor cells. Sca-1
+
 CSCs in the 
study by Wang et al. (2014) had a similar phenotype, with a comparable 
morphology and were stable in vitro over >50 passages. From these data it may be 
deduced that Sca-1
+
 /PW1
+ 
cells isolated here represent the same Sca-1
+
 cells as 
described by Wang et al. (2014); which were also shown to differentiate into the 
three cardiac lineages; cardiomyocyte, endothelial and smooth muscle cells in 
vitro. Furthermore, they were not tumourigenic when injected into SCID (severe 
combined immune deficiency) mice (Wang et al. 2014). 
In summary, these data suggest PW1 is not expressed by all cardiac derived 
stem/progenitor cells. However, its abundance mostly co-insides with cells from 
epicardium regions and it is highly expressed in CD45
-
/Sca-1
+
 CSCs.  
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7. DISCUSSION 
PW1
+
 PICs are found within interstitial spaces of skeletal muscle at a similar 
frequency to satellite cells, declining in abundance with age. Isolated PICs display 
stem cell properties of self-renewal, clonogenicity and multipotency in vitro; they 
can be propagated over long term culture whilst maintaining their phenotype, and 
are multipotent but not tumourigenic in vivo. PW1 also marks an epicardial 
derived Sca-1
+
 stem cell population in the heart. 
7.1 PW1 expression with ageing 
PW1 marks multiple stem cell populations found throughout the mammalian body 
(Besson et al. 2011) inclusive of PICs, SC’s and a subset of CSC’s. Most recently, 
PW1 has also been identified in mesoangioblasts from the mouse, dog and human 
(Bonfanti et al. 2015).  
Bonfanti et al. (2015) postulated that PW1 expression may be linked to stem cell 
competence, as PW1
-
 MABs displayed inhibited myogenic potential compared to 
their PW1
+
 counterparts. Furthermore, silencing PW1 inhibited the ability of 
MABs to cross the endothelium (Bonfanti et al. 2015). Moreover, PW1 has 
previously been implicated as a mediator of embryonic and post-natal growth 
(Finkielstain et al. 2009), and the decline in PW1 in both skeletal and cardiac 
muscle with age would seem to be linked to the decrease in growth velocity post-
natally.  
The decrease in PW1 expression in skeletal muscle of aged animals, seen as a 
decrease in both PICs and SC’s, was not mirrored in cardiac tissue. However, the 
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cellular turnover of these two muscles is vastly different; skeletal muscle 
demonstrates a higher rate of cell proliferation and regenerative capacity then 
cardiac tissue. Indeed, c-kit
+
 CSC’s are maintained within their niche, and 
increase in aged animals (Torella et al. 2004). However it is not yet conclusively 
determined if the c-kit
+
 CSC population also express PW1. . The present study 
showed low/negative c-kit expression in Sca-1
+
/PW1
+
 CSCs in the heart. Lewis et 
al. (2014) showed that 17% of PW1
+
 PICS isolated from porcine skeletal muscle 
and propogated in culture expressed c-kit. Further analysis of heart sections for 
PW1 and c-kit expressing cells are warranted. The mechanism behind why some 
ASC populations decrease in abundance with age, but others do not is not yet 
known; however, it may be linked to stem cell aging. Other ASC populations that 
have previously been shown to decline in abundance with age; include SP cells of 
the bone marrow (Garvin et al. 2007), keratinocytes (Blanpain and Fuchs 2009) 
and neuronal stem cells (Kuhn et al. 1996). 
The decline in PICs and SC abundance may be due to replicative aging, causing 
them to become senescent and drop out of the cell compartment. The remaining 
PICs and SC’s, may be chronologically aged; however, aged satellite cells have 
been shown to regain their function when transplanted into a ‘younger’ 
environment, suggesting that chronological aging processes may be reversible 
(Conboy et al. 2005). 
Chronologically aged cells such as CSCs which have undergone minimal 
replicative aging do not drop out of the compartment; thus their abundance is 
maintained. However, this does not mean they will have the same regenerative 
capacity as their younger counterparts. It should be noted that chronological and 
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replicative aging are not exclusive of each other, and many cells will be aged by 
both processes.  
In light of this, when deriving stem cell therapies the following question should be 
considered: Does the stimulation of endogenous ASCs to proliferate in vivo speed 
up the aging process? 
7.2 PICs vs. CSCs 
PICs and CSC’s share multiple characteristics and phenotypic properties. Indeed,  
both are negative for the hematopoietic marker CD45 and positive for  Sca-1, with 
sub-sets also expressing c-kit  (Lewis et al. 2014). PICs and CSCs have been 
shown to efficiently contribute to new skeletal or cardiomyocyte formation in vivo 
(Mitchell et al. 2010; Beltrami et al. 2003; Oh et al. 2004; Takamiya et al. 2011). 
The present study shows for the first time the self-renewing and clonogenic 
potential of PW1
+
/Sca-1
+
 PICs isolated from skeletal and cardiac muscle. Similar 
properties have been shown for Sca-1
+
 CSCs (Pfister et al. 2005; Tomita et al. 
2005; Chong et al. 2011). Furthermore, colony forming Sca-1
+
 cells isolated from 
12 week old mice hearts have shown osteogenic, chondrogenic, smooth muscle, 
endothelial and cardiac differentiation in vitro (Takamiya et al. 2011). Moreover, 
a subset of Sca-1
+
  cardiac CFU cells originated from the epicardium have shown 
similar multipotent differentiation potential as the PW1
+
 PICs in this study when 
transplanted in a teratoma formation assay (Chong et al. 2011).  Whether this 
multipotent potential results in functional regeneration of multiple tissues in vivo 
remains to be tested. Finally, the cardiac PW1
+
/Sca-1
+
 cells in the present study 
were located in the epicardium, which together with their multipotent 
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differentiation potential in vivo, suggests they are the same or a derivative cell of 
the Sca-1
+
 cCFU cells, described by Chong et al. (2011). 
The similarities between skeletal muscle and cardiac derived PW1
+
 cells raise the 
possibility that they are tissue specific counterparts of the same universal ASC 
population. 
7.3 The overlap of ASC populations within the body 
There are a plethora of purported ASC populations, many share similar 
phenotypes, differentiation potential, and reside within the same niche e.g. 
pericytes and PICs both form SC’s and subsequent myotubes (Cappellari and 
Cossu. 2013; Mitchell et al. 2010). It may be that these cell types describe sub-
sets of a single population, displaying various phenotypic markers dependent on 
their location and differentiation state. Indeed, this is apparent in the heart, which 
was previously thought to be post-mitotic; since the first discovery of CSCs a 
number of different cardiac progenitor cells have been described. If the heart did 
indeed contain multiple stem cell populations we would expect it to have a higher 
regenerative capacity than it demonstrates (Ellison et al. 2014). Further to this, 
some ASC’s such as SP cells and pericytes are found in multiple tissues and 
organs throughout the body suggesting they represent a ‘global’ cell population 
and are not tissue specific (Armulik et al. 2011; Unno et al. 2011; Asakura et al. 
2002; Preffer et al. 2002). Moreover, ASC’s from a variety of different tissues 
express similar markers such as  PW1 (Besson et al 2011; Mitchell et al. 2010; 
Bonfanti et al. 2015); Whether PW1 is independently expressed by multiple stem 
cell populations, or indicates that these ASC populations originate from the same 
lineage remains to be determined. The multipotent potential of purported ASC’s 
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varies, from progenitor cells such as SC’s, which are capable of limited 
differentiation into myotubes; to stem cells which are capable of generating 
several cell types within their germ layer (e.g pericytes of the mesoderm and 
PW1
+
 PICs in the present study). Interestingly, a small number of ASC 
populations have demonstrated broad developmental plasticity; generating cell 
types form multiple germ layers, such as neuronal stem cells (Clarke et al. 2000), 
cCFUs (Chong et al. 2011) and hMASCs (Beltrami et al. 2007).   
In the present study we showed that PW1
+
 PICs have the potential to give rise to 
cells from the 3 germ layers, both in vitro and in vivo. However, the number of 
PW1
+
 PICs that generated endo- and ecto-derm cells was minimal in the teratoma 
assay, and their functional competence was not validated. Further investigation 
into whether PICs can regenerate damaged tissue (such as brain and heart) in vivo 
is warranted. 
It could be hypothesized that the adult mammalian body harbors a small number 
of truly multipotent ASC’s that are responsible for the replenishment and 
homeostasis of germ layer specific ASCs (Figure 7.2). These germ-lineage 
specific ASC’s would in turn maintain tissue specific progenitor cell populations 
(e.g SC’s), to facilitate the regeneration of tissues with injury or age in a cascade 
effect. Thus a stem cells multipotent potential is greater the higher up the 
hierarchy they are (Figure 7.2). 
Whilst many ASC populations have been extensively characterized, there is not 
yet an exclusive marker of a truly multipotent ASC. If they do exist, these cells 
would represent a tiny percentage of all cells within the mammalian body; thus, 
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they have so far eluded detection and subsequent characterization. If an exclusive 
marker can be found, lineage tracing studies could then be used to track these 
cells and their progeny, testing this hypothesis (Figure 7.2). 
 
 
 
Figure 7.2 Schematic to show proposed hierarchy of ASC populations. 
Size of circle indicates level of potency. 
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7.4 PICs are candidates for a multipotent ASC population. 
The present study has demonstrated that’s PICs express genes for multiple cell 
fates and have true stem cell characteristics of self-renewal, clonogenicity and 
multipotency in vitro and in vivo. They are also present in the heart. They have 
been shown to restore muscle after injury (Mitchell et al. 2010), however their 
ability to contribute to functional and sufficient regeneration of other tissues is yet 
to be determined.  If PICs are found to be capable of such functional regeneration 
of other tissues, they would be representative of a truly multipotent ASC. 
7.5 PICs in regenerative medicine. 
PICs are candidates for stem cell therapy for regeneration of skeletal muscle, as 
demonstrated by Mitchell et al. (2010). Furthermore, as the present study has 
shown, their self-renewal, proliferation and phenotype preservation in culture 
allows large numbers to be propagated. These can be used in cellular therapies 
where large numbers are required for transplantation. Importantly, the present 
study also showed that PICs do not form teratomas allowing for safe 
transplantation. However, immunological responses following transplantation 
might need to be determined. 
Although normal homeostasis of skeletal muscle is generally efficient throughout 
adult life, PICs may be of use in treating age related diseases such as sarcopenia, 
or improving muscle regeneration and limiting fibrosis after major injury.  
7.5.1 Muscular dystrophies 
It has not yet been described if PICs are capable of functional repair of muscle in 
diseases such as DMD. However, it may be hypothesized that allogenic 
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transplantation of PICs from a healthy individual into a DMD patient would result 
in the formation of SC’s and myofibres that do not contain malfunctions in the 
dystrophin gene. Whether transplanted PICs and their progeny would temporarily 
ameliorate muscle wastage, or could persist to provide long-term regenerative 
benefits is unknown.  However, allogeneic transplantation of WT mesoangioblasts 
into α-sarcoglycan null mice (limb girdle muscular dystrophy model) has been 
shown to reconstitute skeletal muscle; with labelled cells and their progeny still 
present after 4 months (Sampaolesi et al. 2003). Furthermore, when transplanted 
into golden retrievers with muscular dystrophy, allogeneic WT mesoangioblasts 
resulted in the recovery of dystrophin expression, muscle morphology and 
function. However, 50% of dogs deteriorated after immunosuppression was 
stopped (Sampaolesi et al. 2006). An early phase I/II clinical trials is currently 
underway in Italy (EudraCT number: 2011-000176-33) to determine the safety of 
intra-arterial delivery of HLA-identical allogeneic mesoangioblasts in DMD 
patients. 
7.5.2 Regeneration of other tissues 
PICs are located in an easily accessible and abundant tissue within the body, with 
a higher concentration of cells per tissue than other rare populations, such as 
CSC’s in the heart. Therefore, if PICs are capable of both cardiac and skeletal 
muscle regeneration then they may provide a source of patient-specific stem-
progenitor cells in individuals with heart disease. 
Furthermore, if PICs are truly representatives of a bona fide multipotent ASC 
population, regenerating multiple tissues of different lineages, then they may also 
potentially be used to regenerate other organs or tissues, from which their tissue 
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specific ASC are either a) rare or b) inaccessible or c) senescent, such as the heart 
or brain.  
It is not known whether PICs would demonstrate an affinity to home to skeletal 
muscle, or whether transplanted PICs would home to other sites of injury 
throughout the body.  However, PICs express CXCR4, which is associated with 
homing: Indeed, c-kit
+
 CSCs, which display an affinity to home to the heart 
following injury, lose this ability when CXCR4 is knocked down, and are found 
in other tissues such as the spleen and lungs (Ellison et al. 2013). CXCR4 has also 
been implicated in the homing of other stem cells population after injury including 
renal stem cells of the kidney (Tögel et al. 2005) and MSCs in fracture repair 
(Yellowley 2013).  
Although these data are promising, there are many obstacles to be overcome to 
determine if PICs are amenable with multiple systemic cellular therapies.  
7.6 Limitations of the study. 
There are several limitations to this study: 
1) PICs were isolated from 21 day old mice. Thus, it is not known if the in 
vitro characteristics and multipotent potential are representative of PICs 
found in adult muscle (6-8 week old mice). 
2) C9 PICs were used for all in vitro assays to demonstrate the multipotent 
potential of a single PIC: therefore it is not known what percentage of the 
bulk PIC population demonstrates these characteristics and phenotype. 
3) PICs were not sorted for CD34 expression as previously described in the 
literature and this was due to the selection method used. MACS sorting 
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only allows for positive enrichment of one marker because after the first 
positive enrichment all cells would continue to be labelled with magnetic 
beads, preventing a second positive enrichment. MACS sorting was 
utilized because as FACS sorting was not available, but also because 
MACS sorting results in higher cell viability which is crucial for sorting 
rare cell populations (Li et al. 2013). 
 
This study would also benefit from the following additions: 
1) PW1 and PIC abundance in different ages throughout adulthood. 
2) Phenotyping of the multiple previously described CSC populations, to 
determine if PW1 is expressed in all CSC populations, or if not, which 
ones specifically. This work is now ongoing in the Ellison Laboratory.  
3) To extrapolate these data to humans, PICs should be isolated and 
characterized in human skeletal and cardiac muscle.
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8. CONCLUSIONS 
PW1 is expressed in PICs, SC’s and CSCs, declining in abundance during 
postnatal development. Furthermore, PICs decline at a faster rate than SC’s in 
skeletal muscle, whilst PW1 abundance in cardiac tissue is comparable between 
21 days and 2 years. 
Here, it is shown for the first time that murine PICs isolated from skeletal muscle 
display true stem cell properties of clonogenicity, self-renewal and express 
pluripotency markers Oct3/4, Sox2 and Nanog. They show a small capacity for 
multipotency displaying proteins and transcripts of cell types from all 3 germ 
layers both in vitro and in vivo, although the maturity and functionality of these 
cells was not assessed. However, most PICs display a strong preference towards 
the skeletal muscle lineage from which they originate. 
PICs maintain their phenotype and morphology over long-term culture, together 
with their clonogenicity, and without evidence of growth arrest or senescence. 
Furthermore, PICs are not tumorigenic. These data validate the ability of isolated 
PICs to undergo in vitro propagation in the prospect of generating large numbers 
of these cells to be used in cellular regenerative therapies. 
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9. FUTURE DIRECTIONS 
Following on from these findings, a number of questions are raised that warrant 
further investigation: 
• Do all SC’s originate from PICs? 
• Does PIC abundance increase following exercise or injury? 
• Do PICs isolated from aged mice have the same regenerative capability as their 
younger counterparts? 
 • Are PICs present, and in what abundance in diseased muscle? 
• Can PICs regenerate cardiac tissue following an MI? 
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11. APPENDIX 
Table 11.1 qRT-PCR CT values of bulk PICs  
Gene 
Bulk PICs 
Mean CT ± SD 
GAPDH 19.79 ± 0.15 
Sox2 28.75 ± 0.10 
Oct3/4 25.71 ± 0.81 
Nanog 24.96 ± 0.10 
PW1 19.92 ± 0.19 
CD34 27.20 ± 0.76 
Sca-1 25.82 ± 0.45 
CD45 34.73 ± 0.65 
CD146 24.13 ± 0.07 
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Table 11.2 qRT-PCR CT values of clonal PICs  
Gene 
C1 C2 C3 
Mean CT ± SD Mean CT ± SD Mean CT ± SD 
GAPDH 18.50 ± 0.06 17.26 ± 0.03 16.65 ± 0.2 
Sox2 33.85 ± 0.90 33.00 ± 0.24 33.39 ± 0.52 
Oct3/4 26.83 ± 0.13 24.63 ± 0.52 24.20 ± 0.23 
Nanog 25.52 ± 0.69 24.61 ± 0.21 24.89 ± 0.22 
PW1 23.45 ± 0.87 20.35 ± 0.5 20.78 ± 0.88 
CD34 32.42 ± 0.35 27.47 ± 0.49 27.88 ± 0.88 
Sca-1 30.07 ± 0.27 25.82 ± 0.45 25.70 ± 0.39 
Gene 
C4 C5 C12 
Mean CT ± SD Mean CT ± SD Mean CT ± SD 
GAPDH 16.25 ± 0.58 16.88  ± 0.06 17.95 ± 0.00 
Sox2 33.10 ± 0.28 33.50 ± 0.16 35.25 ±1.82 
Oct3/4 25.83  0.68 24.23 ± 0.58 26.04 ± 1.69 
Nanog 24.82  0.35 24.55 ± 0.17 24.83 ± 0.11 
PW1 19.85  0.10 19.55 ± 0.86 19.47 ± 0.58 
CD34 27.67  0.34 26.06  ± 0.19 26.91 ± 0.31 
Sca-1 24.49  0.36 24.45  ± 0.13 25.30 ± 0.10 
Gene 
C9 C9 P10 C9 P20 
Mean CT ± SD Mean CT ± SD Mean CT ± SD 
GAPDH 18.50  ± 0.06 19.28 ± 0.53 18.37 ± 0.07 
Sox2 29.12  ± 0.70 37.78 ± 0.12 33.07 ± 0.37 
Oct3/4 25.75  ± 0.54 23.27 ± 0.72 23.04 ± 0.62 
Nanog 25.15  ± 0.20 26.23 ± 0.17 27.20 ± 0.63 
PW1 19.55  ± 0.22 19.42 ± 0.28 20.44 ± 0.20 
CD34 28.40  ± 0.75 26.26 ± 0.47 25.22 ± 0.93 
Sca-1 25.34  ± 0.89 23.93 ± 0.22 24.55 ± 0.30 
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Table 11.3 qRT-PCR CT values of myogenic differentiation 
Gene 
Myogenic 
Gene 
Undifferentiated 
Mean CT ± SD Mean CT ± SD 
GAPDH 27.56 ± 0.61 GAPDH 19.28 ± 0.53 
β-actin 27.12 ± 0.90 n/a n/a 
MHC 29.42 ± 0.37 MHC 23.94 ± 0.23 
α-sarc 27.88 ± 0.13 a-sarc 24.24 ± 0.20 
SMA 27.14 ± 0.64 SMA 24.28 ± 0.10 
 
 
Table 11.4 qRT-PCR CT values of cardiomyogenic differentiation 
Gene 
Cardiomyogenic 
Gene 
Undifferentiated 
Mean CT ± SD Mean CT ± SD 
GAPDH 14.83 ± 0.25 GAPDH 16.98 ± 0.29 
β-actin 15.36 ± 0.19 Cx43 27.61 ± 0.47 
Cx43 21.97 ± 0.26 cTnI 27.61 ± 0.47 
α-sarc 12.73 ± 0.14 GAPDH 19.28 ± 0.53 
GAPDH 21.58 ± 0.84 a-sarc 24.24 ± 0.20 
β-actin 22.39 ± 0.37 n/a n/a 
cTnI 27.50 ± 0.75 n/a n/a 
 
 
Table 11.5 qRT-PCR CT values of endothlial differentiation 
Gene 
Endothelial 
Gene 
Undifferentiated 
Mean CT ± SD Mean CT ± SD 
GAPDH 19.26 ± 0.14 GAPDH 19.28 ± 0.53 
β-actin 23.26 ± 0.34 n/a n/a 
CD31 28.67 ± 0.72 CD31 26.37 ± 0.04 
vWF 27.67 ± 0.26 vWF 30.27 ± 3.76 
CD146 28.61 ± 1.01 CD146 25.79 ± 0.20 
CD34 26.90 ± 0.13 CD34 26.26 ± 0.47 
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Table 11.6 qRT-PCR CT values of hepatic differentiation 
Gene 
Hepatic 
Gene 
Undifferentiated 
Mean CT ± SD Mean CT ± SD 
GAPDH 24.19 ± 0.24 GAPDH 19.28 ± 0.53 
β-actin 23.24 ± 0.44 n/a n/a 
CK18 28.23 ± 1.21 CK18 25.57 ± 0.35 
CK19 29.21 ± 0.43 CK19 26.65 ± 0.39 
Albumin 26.29 ± 0.84 Albumin 25.16 ± 0.17 
HNF1α 25.86 ± 1.20 HNF1α 24.76 ± 0.59 
 
 
Table 11.7 qRT-PCR CT values of neuronal differentiation 
Gene 
Neuronal 
Gene 
Undifferentiated 
Mean CT ± SD Mean CT ± SD 
GAPDH 19.78 ± 0.74 GAPDH 19.28 ± 0.53 
β-actin 19.90 ± 0.27 n/a n/a 
β3-tubulin 24.08 ± 0.32 β3-tubulin 23.64 ± 0.16 
ChAT 25.26 ± 0.63 ChAT 24.74 ± 0.33 
ENO2 24.17 ± 0.04 ENO2 24.34 ± 0.40 
GFAP 24.92 ± 0.13 GFAP 23.76 ± 0.23 
 
 
Table 11.8 qRT-PCR CT values of GFP PICs 
Gene 
GFP PICs 
Average CT ± SD 
GAPDH 20.04 ± 0.33 
Sox2 33.32 ±0.59 
Oct3/4 36.10 ± 1.07 
Nanog 23.90 ± 0.48 
CD34 30.17 ± 0.42 
PW1 21.20 ± 0.33 
Sca-1 25.32 ± 0.54 
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Table 11.9 qRT-PCR CT values of CSCs 
Gene 
CSCs 
Average CT ± SD 
GAPDH 17.76 ± 0.37 
Sox2 33.19 ± 0.27 
Oct3/4 35.14 ± 0.40 
Nanog 27.79 ± 0.23 
c-kit 32.16 ± 0.75 
GAPDH 17.50 ± 0.08 
CD31 29.33 ± 1.26 
GAPDH 17.65 ± 0.54 
CD34 22.81 ± 0.05 
CD45 32.92 ± 0.07 
GAPDH 17.00 ± 0.08 
PW1 22.98 ± 0.19 
 
 
 
